C:\Users\drao\Documents\STN Express 8.4\Queries\09993647 (RCE 3).str





chain nodes :
13 14 15 16 17 18 20 21 22 23 25 26 27 28 29 30 31 38 41
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 32 33 34 35 36 37
chain bonds :
1-26 2-18 3-17 4-25 5-13 6-27 7-31 8-30 9-14 10-28 11-29 12-20 13-15 14-15 15-16
20-34 21-36 21-22 21-41 23-38
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37 33-34 34-35
35-36 36-37
exact/norm bonds :
5-13 9-14 12-20 13-15 14-15 15-16 20-34 21-22 21-41
exact bonds :
1-26 2-18 3-17 4-25 6-27 7-31 8-30 10-28 11-29 21-36 23-38
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37 33-34 34-35
35-36 36-37
isolated ring systems :
containing 1 : 7 : 32 :

G1:H,CH3

G2:NH2,[@1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS 41:CLASS

=>
Uploading C:\Users\drao\Documents\STN Express 8.4\Queries\09993647 (RCE 2).str



chain nodes :
13 14 15 16 17 18 20 21 22 23 25 26 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 33 34 35 36 37 38
chain bonds :
1-27 2-18 3-17 4-26 5-13 6-28 7-32 8-31 9-14 10-29 11-30 12-20 13-15
14-15 15-16 20-35 21-23 21-22 21-37 23-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 33-34 33-38
34-35 35-36 36-37 37-38
exact/norm bonds :
5-13 9-14 12-20 13-15 14-15 15-16 20-35 21-23 21-22 23-25
exact bonds :
1-27 2-18 3-17 4-26 6-28 7-32 8-31 10-29 11-30 21-37
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 33-34 33-38
34-35 35-36 36-37 37-38
isolated ring systems :
containing 1 : 7 : 33 :

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1:H,Me

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 21:41:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       83 TO ITERATE

100.0% PROCESSED       83 ITERATIONS                              27 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1114 TO     2206
PROJECTED ANSWERS:             229 TO      851

L2            27 SEA SSS SAM L1

=> =>
Uploading C:\Users\drao\Documents\STN Express 8.4\Queries\09993647 (RCE 3).str
```



```
chain nodes :
13  14  15  16  17  18  20  21  22  23  25  26  27  28  29  30  31  38  41
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  32  33  34  35  36  37
chain bonds :
1-26  2-18  3-17  4-25  5-13  6-27  7-31  8-30  9-14  10-28  11-29  12-20  13-15
14-15  15-16  20-34  21-36  21-22  21-41  23-38
ring bonds :
```

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37
33-34 34-35 35-36 36-37
exact/norm bonds :
5-13 9-14 12-20 13-15 14-15 15-16 20-34 21-22 21-41
exact bonds :
1-26 2-18 3-17 4-25 6-27 7-31 8-30 10-28 11-29 21-36 23-38
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37
33-34 34-35 35-36 36-37
isolated ring systems :
containing 1 : 7 : 32 :

G1:H,CH3

G2:NH2,[@1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:CLASS 41:CLASS

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1:H,Me
G2:NH2,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam

```
SAMPLE SEARCH INITIATED 21:44:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       55 TO ITERATE

100.0% PROCESSED       55 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          656 TO     1544
PROJECTED ANSWERS:               2 TO      124

L4            2 SEA SSS SAM L3

=> => s l3 sss ful
FULL SEARCH INITIATED 21:45:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1074 TO ITERATE

100.0% PROCESSED     1074 ITERATIONS                               82 ANSWERS
SEARCH TIME: 00.00.01

L5           82 SEA SSS FUL L3

=> => s l5
L6         1704 L5

=> s riedl/in
L7            0 RIEDL/IN

=> s dumas
L8         1281 DUMAS

=> s riedl
L9           47 RIEDL

=> s khire
L10           1 KHIRE

=> s lowinger
L11           1 LOWINGER

=> s scott
L12        3875 SCOTT

=> s smith
L13       15656 SMITH

=> s wood
L14      202638 WOOD

=> s natero
L15           0 NATERO

=> s l7 or l8 or l9 or l10 or l11 or l12 or l13 or l14
L16      223268 L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14

=> s l6 and l16
L17           0 L6 AND L16
```

```
=> s bayer
L18       8417 BAYER

=> s l6 and l18
L19         11 L6 AND L18

=> d l19 1-11 bib,ab,hitstr
```

L19 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2010:317457 CAPLUS
DN 153:471241
TI Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (Sorafenib Hepatocarcinoma Assessment Randomized Protocol trial)
AU Detry, O.; Delwaide, J.; De Roover, A.; Meunier, P.; Van Daele, D.; Lamproye, A.; Honore, P.; Polus, M.
CS Service de Chirurgie Abdominale et Transplantation, CHU de Liege, Belg.
SO Revue Medicale de Liege (2009), 64(3), 168-170
CODEN: RMLIAC; ISSN: 0370-629X
PB Revue Medicale de Liege
DT Journal; General Review
LA French
AB A review. Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib (Nexavar, Bayer) is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 mo, without any radiol. response or improvement in the delay before symptomatic progression of the disease. The monthly cost of sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liege is taking part to a randomized, multicentric study evaluating the use of sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of sorafenib with other antitumoral agents.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(palliative management of hepatocarcinoma with sorafenib)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L19 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2009:1629506 CAPLUS
DN 153:162840
TI Platelet count less than SHARP: what does a case series reveal?
AU Saif, M. Wasif
CS Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, 06520, USA
SO Expert Opinion on Drug Safety (2010), 9(1), 1-8
CODEN: EODSA9; ISSN: 1474-0338
PB Informa Healthcare
DT Journal; General Review
LA English
AB A review. Hepatocellular carcinoma (HCC) is increasing in nos. worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar, Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival vs. placebo. Child-Pugh class A liver function and a platelet count of ≥ 60,000/mm3 were among the inclusion criteria for SHARP. No safety data in patients with < 60,000/mm3 of platelets are present. Thrombocytopenia is one of the most frequent challenges faced in patients with chronic liver diseases. We report a series of three patients with HCC and platelet count < 60,000/mm3 who were successfully treated with sorafenib with no complications. We describe the current data on sorafenib and challenges faced in patients with HCC. In addition, we emphasize the need for informed consent when facing factors that predispose to bleeding (esophageal varices, coagulopathy and thrombocytopenia), possible band ligation before the start of sorafenib, careful clin. monitoring and discontinuation of sorafenib when major bleeding occurs.
IT 475207-59-1, Nexavar
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nexavar was safe and effective but reduced platelet count in patient with hepatocellular carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2009:324660 CAPLUS
DN 151:235838
TI Sorafenib for the treatment of unresectable hepatocellular carcinoma
AU Kane, Robert C.; Farrell, Ann T.; Madabushi, Rajanikanth; Booth, Brian; Chattopadhyay, Somesh; Sridhara, Rajeshwari; Justice, Robert; Pazdur, Richard
CS Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
SO Oncologist (2009), 14(1), 95-100
CODEN: OCOLF6; ISSN: 1083-7159
PB AlphaMed Press
DT Journal
LA English
AB Purpose. To describe the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar; Bayer Pharmaceuticals Corp., Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Exptl. Design. The FDA independently analyzed an international, double-blind, placebo-controlled trial comparing the effect of best supportive care plus sorafenib or matching placebo on overall survival. Eligible patients had unresectable, biopsy-proven HCC and had not received prior systemic therapy. Results. Among the 602 randomized patients (placebo, 303; sorafenib, 299), baseline characteristics were well balanced, and 97% were Child-Pugh score A. HCC was "advanced" in 70% overall, as defined by extrahepatic metastases or by tumor radiog. visible in venous structures outside the liver. Underlying liver diseases included hepatitis B (18%), hepatitis C (28%), and alc.-related (26%). The trial was stopped following a prespecified second interim anal. showing a statistically significant survival advantage for sorafenib [median, 10.7 vs 7.9 mo; hazard ratio, 0.69 (95% confidence interval, (0.55, 0.87)), p = 0.00058]. Adverse events in sorafenib-treated patients included diarrhea in 55% (grade 3, 10%), hand-foot syndrome in 21% (grade 3,8%), rash in 19% (grade 3,1%), and cardiac ischemia or infarction in 2.7% (vs. 1.3% for placebo). On sorafenib, treatment-emergent hypertension occurred in 9% of patients (placebo, 4%) and was grade 3 in 4% (placebo, 1%); elevated serum lipase occurred in 40% (placebo, 37%); hypophosphatemia occurred in 35% (placebo, 11%). Conclusions. Sorafenib is the first systemic therapy to demonstrate a survival benefit in a randomized trial for unresectable HCC and has received FDA approval for this indication.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sorafenib for treating unresectable hepatocellular carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2008:1542770 CAPLUS
DN 151:48669
TI Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial
AU Cheng, Ann-Lii; Kang, Yoon-Koo; Chen, Zhendong; Tsao, Chao-Jung; Qin, Shukui; Kim, Jun Suk; Luo, Rongcheng; Feng, Jifeng; Ye, Shenglong; Yang, Tsai-Sheng; Xu, Jianming; Sun, Yan; Liang, Houjie; Liu, Jiwei; Wang, Jiejun; Tak, Won Young; Pan, Hongming; Burock, Karin; Zou, Jessie; Voliotis, Dimitris; Guan, Zhongzhen
CS National Taiwan University Hospital, Taipei, Taiwan
SO Lancet Oncology (2009), 10(1), 25-34
CODEN: LOANBN; ISSN: 1470-2045
PB Elsevier Ltd.
DT Journal
LA English
AB Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important etiol. factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific population is thus important. We did a multinational phase III, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular carcinoma. Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-wk cycles, with efficacy measured at the end of each 6-wk period. Eligible patients were stratified by the presence or absence of macroscopic vascular invasion or extrahepatic spread (or both), Eastern Cooperative Oncol. Group performance status, and geog. region. Randomization was done centrally and in a 2:1 ratio by means of an interactive voice-response system. There was no predefined primary endpoint; overall survival, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), and safety were assessed. Efficacy analyses were done by intention to treat. This trial is registered with, number Two hundred and seventy-one 271 patients from 23 centers in China, South Korea, and Taiwan were enrolled in the study. Of these, 226 patients were randomly assigned to the exptl. group (n=150) or to the placebo group (n=76). Median overall survival was 6.5 mo (95% CI 5.56-7.56) in patients treated with sorafenib, compared with 4.2 mo (3.75-5.46) in those who received placebo (hazard ratio [HR] 0.68 [95% CI 0.50-0.93]; p=0.014). Median TTP was 2.8 mo (2.63-3.58) in the sorafenib group compared with 1.4 mo (1.35-1.55) in the placebo group (HR 0.57 [0.42-0.79]; p=0.0005). The most frequently reported grade 3/4 drug-related adverse events in the 149 assessable patients treated with sorafenib were hand-foot skin reaction (HFSR; 16 patients [10.7%]), diarrhea (nine patients [6.0%]), and fatigue (five patients [3.4%]). The most common adverse events resulting in dose redns. were HFSR (17 patients [11.4%]) and diarrhea (11 patients [7.4%]); these adverse events rarely led to discontinuation. Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated. Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma. Funding: Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.

IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sorafenib was well tolerated and effective in treatment of patient with metastatic hepatocellular carcinoma in Asia-Pacific region)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



OSC.G 145 THERE ARE 145 CAPLUS RECORDS THAT CITE THIS RECORD (145 CITINGS)
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2008:798022 CAPLUS
DN 149:263859
TI Dissecting and Targeting the Growth Factor-Dependent and Growth Factor-Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma
AU Ammoun, Sylwia; Flaiz, Christine; Ristic, Natalia; Schuldt, Jennifer; Hanemann, C. Oliver
CS Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, PL6 8BU, UK
SO Cancer Research (2008), 68(13), 5236-5245
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Schwannomas are tumors of the nervous system that occur sporadically and in patients with the cancer predisposition syndrome neurofibromatosis type 2 (NF2). Schwannomas and all NF2-related tumors are caused by loss of the tumor suppressor merlin. Using our human in vitro model for schwannoma, we analyzed extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT signaling pathways, their upstream growth factor receptors, and their role in schwannoma cell proliferation and adhesion to find new systemic therapies for these tumors that, to date, are very difficult to treat. We show here that human primary schwannoma cells show an enhanced basal Raf/mitogen-activated protein/ERK kinase/ERK1/2 pathway activity compared with healthy Schwann cells. Due to a strong and prolonged activation of platelet-derived growth factor receptor β (PDGFRβ), which is highly overexpressed, ERK1/2 and AKT activation was further increased in schwannoma, leading to increased proliferation. Using specific inhibitors, we discovered that ERK1/2 activation involves the integrin/focal adhesion kinase/Src/Ras signaling cascades and PDGFRβ-mediated ERK1/2 activation is triggered through the phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway. Due to the complexity of signals leading to schwannoma cell proliferation, potential new therapeutic agents should target several signaling pathways. The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRβ-mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas. We conclude that our schwannoma in vitro model can be used to screen for new therapeutic targets in general and that sorafenib is possible candidate for future clin. trials.
IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006; growth factor-dependent and growth factor-independent ERK kinase pathway in human schwannoma)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471132 CAPLUS
DN 147:132413
TI Looking ahead in renal cell carcinoma: integrating new agents in the armamentarium of the urologist
AU Patard, Jean-Jacques
CS Rennes University Hospital, Rennes, Fr.
SO European Urology, Supplements (2007), 6(7), 505-509
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB A review. Urologists play a pivotal role in many aspects of the care of patients with renal cell carcinoma (RCC). However, until recently, in some European countries, they have rarely been involved in the systemic treatment of this disease or in the design of clin. trials. This is undoubtedly set to change with the emergence of new oral, molecularly targeted therapies for RCC. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) is one such therapy, which has already been shown to be efficacious and well tolerated for the treatment of RCC. Although targeted agents show great promise for the treatment of RCC, their precise role in the treatment of metastatic disease, and in adjuvant and neoadjuvant settings has yet to be defined. Drawing from their extensive experience of RCC, urologists will be instrumental in the design and application of clin. studies to define the role of targeted therapies in all settings of RCC and, ultimately, to integrate targeted therapies into clin. practice. Through increased understanding of the mol. pathways involved in RCC, research into diagnostic and prognostic markers, and commitment to clin. trials, urologists can be at the forefront of this progress.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. targeted therapy with Nexavar was effective and well tolerated in renal cell carcinoma patient)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471131 CAPLUS
DN 147:132412
TI New perspectives: an oral multikinase inhibitor in patients with advanced RCC
AU Escudier, Bernard
CS Institut Gustave-Roussy, Paris, Fr.
SO European Urology, Supplements (2007), 6(7), 499-504
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB A review. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) is an oral multikinase inhibitor that may provide dual action by inhibiting tumor cell proliferation and angiogenesis. Sorafenib was recently evaluated in the largest phase 3, randomized trial ever conducted in renal cell carcinoma (RCC): Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET). In TARGET, sorafenib significantly increased progression-free survival vs. placebo, which led to a change in the study protocol allowing patients in the placebo arm of the trial to cross over to receive sorafenib. At the time of crossover, sorafenib improved overall survival by 39% compared with placebo (hazard ratio = 0.72; 95% confidence interval 0.54-0.94; p = 0.02, not significant as per O'Brien-Fleming threshold for statistical significance: p = 0.0005). Sorafenib continued to show a trend towards improved overall survival at a subsequent anal. 6 mo post-crossover. Importantly, 84% of sorafenib-treated patients achieved investigator-assessed stable disease or better compared with 55% of placebo recipients. Sorafenib was well tolerated, had a manageable side-effect profile, and offered benefit with no compromise in quality of life. The data from the phase 3 TARGET study provided further evidence that sorafenib may be effective in a wide range of patients with advanced RCC. Clin. trials are planned to assess the potential of sorafenib as combination therapy and in the adjuvant setting.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral multikinase inhibitor Nexavar was well tolerated and increased progression-free as well as overall survival in patient with advanced renal cell carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471130 CAPLUS
DN 147:132411
TI Adjuvant therapy in renal cell carcinoma: where are we?
AU Eisen, Tim
CS University of Cambridge, Cambridge, UK
SO European Urology, Supplements (2007), 6(7), 492-498
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB This review summarizes available data and describes planned clin. trials designed to evaluate the potential of targeted agents as adjuvant therapy for renal cell carcinoma (RCC). Advanced RCC is refractory to standard cytotoxic chemotherapy, and clin. trials of adjuvant cytokine therapy in this therapeutic setting have not yet demonstrated clear evidence of clin. benefit. However, molecularly targeted therapies may offer a new approach for adjuvant therapy of this disease. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) and sunitinib (Sutent; Pfizer Inc, New York, NY, USA) are candidates for adjuvant therapy, because they are efficacious in the treatment of metastatic RCC and have side-effect profiles that can usually be well managed during long-term administration. The clin. benefit and tolerability of these agents as adjuvant therapies are being investigated in three ongoing phase 3 trials: ASSURE (adjuvant sorafenib or sunitinib in unfavorable renal cell carcinoma; Eastern Cooperative Oncol. Group 2805), STAR (sunitinib trial in adjuvant renal cancer) and SORCE (a phase 3, randomized, double-blind, controlled study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse). The results of these studies will address important clin. and translational questions, the answers to which may help define future treatment strategies and guide treatments towards the most appropriate patients.
IT 475207-59-1, Nexavar
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant therapy with Nexavar might be effective in renal cell carcinoma patient)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2006:1258840 CAPLUS
DN 146:219796
TI Sorafenib for the treatment of renal cell carcinoma
AU Hughes, Caren L.; Tan, Winston W.; Ferrone, Marcus
CS Oncology Specialty Resident, Division of Pharmacy, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA
SO Journal of Pharmacy Technology (2006), 22(5), 281-288
CODEN: JPTEEB; ISSN: 8755-1225
PB Harvey Whitney Books Co.
DT Journal; General Review
LA English
AB A review. Objective: To summarize the pharmacol., development, and clin. application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clin. literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Addnl. information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstrs., and clin. studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatol. reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in Dec. 2005 for treatment of advanced RCC. Conclusions: Soraferib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.
IT 284461-73-0, Sorafenib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phase I and II trial showed that tyrosine kinase inhibitor sorafenib blocked Raf kinase pathway and inhibited vascular growth factor responsible for angiogenesis and tumor growth in patient with renal cell carcinoma)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2006:1020380 CAPLUS
DN 145:431615
TI Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
AU Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan
CS Department of Cancer Research, Bayer Pharmaceuticals Corp., West Haven, CT, 06516, USA
SO Nature Reviews Drug Discovery (2006), 5(10), 835-844
CODEN: NRDDAG; ISSN: 1474-1776
PB Nature Publishing Group
DT Journal; General Review
LA English
AB A review. Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received .apprx.5 years after the initiation of the first Phase I trial.
IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and development of sorafenib, a multikinase inhibitor for treating cancer)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



OSC.G 220 THERE ARE 220 CAPLUS RECORDS THAT CITE THIS RECORD (223 CITINGS)
RE.CNT 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2003:736198 CAPLUS
DN 139:301125
TI BAY-43-9006(Bayer/Onyx)
AU Lee, John T.; McCubrey, James A.
CS Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858-4353, USA
SO Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(6), 757-763
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Current Drugs
DT Journal; General Review
LA English
AB A review. Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by Feb. 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
IT 284461-73-0, BAY 43-9006
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for treatment of cancer patients)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



OSC.G 60 THERE ARE 60 CAPLUS RECORDS THAT CITE THIS RECORD (60 CITINGS)
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 21:40:34 ON 16 JUN 2011)

     FILE 'REGISTRY' ENTERED AT 21:40:38 ON 16 JUN 2011
L1             STRUCTURE UPLOADED
L2            27 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4             2 S L3 SSS SAM
L5            82 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 21:45:37 ON 16 JUN 2011
L6          1704 S L5
L7             0 S RIEDL/IN
L8          1281 S DUMAS
L9            47 S RIEDL
L10            1 S KHIRE
L11            1 S LOWINGER
L12         3875 S SCOTT
L13        15656 S SMITH
L14       202638 S WOOD
L15            0 S NATERO
L16       223268 S L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14
L17            0 S L6 AND L16
L18         8417 S BAYER
L19           11 S L6 AND L18

     FILE 'USPATFULL' ENTERED AT 21:50:34 ON 16 JUN 2011

=> s l5
L20         390 L5

=> d l20 1-99 bib,ab,hitstr
```

L20 ANSWER 1 OF 390 USPATFULL on STN
AN 2011:153565 USPATFULL
TI Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer
IN LEE, Wendy, South San Francisco, CA, UNITED STATES
LADOUCEUR, Gaetan, Guilford, CT, UNITED STATES
DUMAS, Jacques, Waltham, MA, UNITED STATES
SMITH, Roger, Madison, CT, UNITED STATES
YING, Shihong, Orange, CT, UNITED STATES
WANG, Gan, Wallingord, CT, UNITED STATES
CHEN, Zhi, Lyndhurst, NJ, UNITED STATES
LIU, Qingjie, Orange, CT, UNITED STATES
MOKDAD, Holia Hatoum, Guilford, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 20110136809 A1 20110609
AI US 2010-941841 A1 20101108 (12)
RLI Division of Ser. No. US 2008-579093, filed on 15 Jan 2008, Pat. No. US 7838524 A 371 of International Ser. No. WO 2005-US15106, filed on 2 May 2005
PRAI US 2004-566445P 20040430 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-33
DRWN No Drawings
LN.CNT 4782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

##STR1##
IT 284461-73-0, BAY 43-9006
(substituted pyrazolylurea derivs. useful for cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 2 OF 390 USPATFULL on STN
AN 2011:145382 USPATFULL
TI Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
IN Wang, Yaolin, Edison, NJ, UNITED STATES
Wang, Yan, Warren, NJ, UNITED STATES
Lu, Brian Der-Hua, Westfield, NJ, UNITED STATES
Liu, Ming, Fanwood, NJ, UNITED STATES
Seidel-Dugan, Cynthia, Mountainside, NJ, UNITED STATES
Yao, Siu-Long, West Windsor, NJ, UNITED STATES
PI US 20110129456 A1 20110602
AI US 2009-991228 A1 20090504 (12)
WO 2009-US42657 20090504
20110221 PCT 371 date
PRAI US 2008-50405P 20080505 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the sequential administration of a cytotoxic agent followed by an IGF1R antagonist (e.g., an antibody) for the treatment of hyperproliferative disorders including cancer.
IT 284461-73-0, Sorafenib
(sequential administration of chemotherapeutic agents and anti-(insulin-like growth factor 1 receptor) for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 3 OF 390 USPATFULL on STN
AN 2011:139943 USPATFULL
TI SYSTEMS AND METHODS OF CANCER STAGING AND TREATMENT
IN Weiss, Glen, Phoenix, AZ, UNITED STATES
PI US 20110124700 A1 20110526
AI US 2009-735866 A1 20090219 (12)
WO 2009-US1046 20090219
20101202 PCT 371 date
PRAI US 2008-29656P 20080219 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1236
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of assessing the sensitivity of a cancer cell to a tyrosine kinase inhibitor are disclosed. Such methods include assessing the expression of miR-497 and correlating reduced expression with sensitivity to the tyrosine kinase inhibitor. Also disclosed are methods of assessing the sensitivity of a cell to a tyrosine kinase inhibitor that includes assessing the expression of FGF1, HOXC10, and/or LHFP. Additionally disclosed are methods of treating patients with tyrosine kinase inhibitors such as sunitinib based on results obtained from the disclosed methods and kits that facilitate the methods.
IT 284461-73-0, Sorafenib
(sensitivity to; methods for evaluating sensitivity of a cancer cell to tyrosine kinase inhibitors that involve detecting microRNA miR-497 expression and/or mRNAs or protein levels of FGF1, HOXC10, and/or LHFP genes)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 4 OF 390 USPATFULL on STN
AN 2011:132775 USPATFULL
TI QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS
IN Courtney, Stephen Martin, Oxfordshire, UNITED KINGDOM
Whittaker, Mark, Oxfordshire, UNITED KINGDOM
Mather, Owen Clifford, Oxfordshire, UNITED KINGDOM
Yarnold, Christopher John, Oxfordshire, UNITED KINGDOM
Barker, Oliver Robin, Oxfordshire, UNITED KINGDOM
Montalbetti, Christian Aldo Georges Napoleon, Oxfordshire, UNITED KINGDOM
Hesterkamp, Thomas, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Gardiner, Mihaly Daniel, Oxfordshire, UNITED KINGDOM
PI US 20110118258 A1 20110519
AI US 2008-599116 A1 20080515 (12)
WO 2008-IT326 20080515
20101215 PCT 371 date
PRAI GB 2007-9534 20070517
DT Utility
FS APPLICATION
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

##STR1##
IT 284461-73-0, Sorafenib
(codrug; preparation of 2-amino-7,8-dihydro-6H-quinazolin-5-one oximes as HSP90 inhibitors useful in treatment of HSP90-mediated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 5 OF 390 USPATFULL on STN
AN 2011:131599 USPATFULL
TI Protein Kinase Conjugates and Inhibitors
IN Singh, Juswinder, Ashland, MA, UNITED STATES
Petter, Russell Colyn, Stow, MA, UNITED STATES
Niu, Deqiang, Lexington, MA, UNITED STATES
Qiao, Lixin, Andover, MA, UNITED STATES
Kluge, Arthur, Lincoln, MA, UNITED STATES
Lobb, Roy, Westwood, MA, UNITED STATES
Ghosh, Shomir, Brookline, MA, UNITED STATES
Zhu, Zhendong, Westborough, MA, UNITED STATES
PA Avila Therapeutics, Inc., Waltham, MA, UNITED STATES (U.S. corporation)
PI US 20110117073 A1 20110519
AI US 2010-882484 A1 20100915 (12)
PRAI US 2009-242988P 20090916 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
IT 284461-73-0, Sorafenib
(preparation of pyridine and pyrimidine derivs. and their use as protein kinase conjugates and irreversible inhibitors of protein kinase useful in treatment of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 6 OF 390 USPATFULL on STN
AN 2011:125912 USPATFULL
TI COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
IN Zhang, Jiazhong, Foster City, CA, UNITED STATES
Ibrahim, Prabha N., Mountain View, CA, UNITED STATES
Bremer, Ryan, Oakland, CA, UNITED STATES
Spevak, Wayne, Berkeley, CA, UNITED STATES
Cho, Hanna, Oakland, CA, UNITED STATES
PA Plexxikon, Inc. (U.S. corporation)
PI US 20110112127 A1 20110512
AI US 2010-939998 A1 20101104 (12)
PRAI US 2009-259093P 20091106 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on Fms protein kinase, or on Fms and Kit protein kinase, or on Fms and Flt-3 protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Fms protein kinase, Kit protein kinase, or Flt-3 protein kinase including rheumatoid arthritis, osteoarthritis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, acute myeloid leukemia, melanoma, multiple myeloma, metastatic breast cancer, prostate cancer, pancreatic cancer, neurofibromatosis, brain metastases, and gastrointestinal stromal tumors.
IT 284461-73-0, Sorafenib
(codrug; preparation of azaindole derivs. as kinase modulators useful in the treatment of kinase-mediated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 7 OF 390 USPATFULL on STN
AN 2011:125197 USPATFULL
TI Novel genes and markers in type 2 diabetes and obesity
IN Salonen, Jukka T., Kuopio, FINLAND
Hypponen, Jelena, Kuopio, FINLAND
Kaikkonen, Jari, Kuopio, FINLAND
Pirskannen, Mia, Kuopio, FINLAND
Uimari, Pekka, Kuopio, FINLAND
Aalto, Juha-Matti, Sulinjarvi, FINLAND
PI US 20110111405 A1 20110512
AI US 2010-923066 A1 20100831 (12)
RLI Division of Ser. No. US 2007-798002, filed on 9 May 2007, Pat. No. US 7901885
PRAI US 2006-798706P 20060509 (60)
US 2006-798774P 20060509 (60)
US 2006-805522P 20060622 (60)
US 2006-819015P 20060707 (60)
US 2006-827306P 20060928 (60)
US 2006-863438P 20061030 (60)
US 2006-864681P 20061107 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.
IT 284461-73-0
(target for, in treatment of diabetes; alleles and polymorphisms associated with type 2 diabetes and obesity and their diagnostic use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 8 OF 390 USPATFULL on STN
AN 2011:125196 USPATFULL
TI Novel genes and markers in type 2 diabetes and obesity
IN Salonen, Jukka T., Kuopio, FINLAND
Hypponen, Jelena, Kuopio, FINLAND
Kaikkonen, Jari, Kuopio, FINLAND
Pirskanen, Mia, Kuopio, FINLAND
Uimari, Pekka, Kuopio, FINLAND
Aaalto, Juha-Matti, Siilinjarvi, FINLAND
PI US 20110111404 A1 20110512
AI US 2010-923065 A1 20100831 (12)
RLI Division of Ser. No. US 2007-798002, filed on 9 May 2007, Pat. No. US 7901885
PRAI US 2006-798706P 20060509 (60)
US 2006-798774P 20060509 (60)
US 2006-805522P 20060622 (60)
US 2006-819015P 20060707 (60)
US 2006-827306P 20060928 (60)
US 2006-863438P 20061030 (60)
US 2006-864681P 20061107 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.
IT 284461-73-0
(target for, in treatment of diabetes; alleles and polymorphisms associated with type 2 diabetes and obesity and their diagnostic use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 9 OF 390 USPATFULL on STN
AN 2011:124679 USPATFULL
TI SMALL MOLECULE INHIBITORS OF AUTOTAXIN AND METHODS OF USE
IN Braddock, Demetrios, Guilford, CT, UNITED STATES
PA Yale University (U.S. corporation)
PI US 20110110886 A1 20110512
AI US 2009-993397 A1 20090615 (12)
WO 2009-US3565 20090615
20110118 PCT 371 date
PRAI US 2008-131971P 20080613 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines demonstrate that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of ATX's enzymatic product, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors demonstrate structure activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against human malignancies driven by the ATX/LPA axis, especially including malignant melanoma, among numerous others including breast and ovarian cancers.
IT 284461-73-0, Sorafenib
(autotaxin inhibitors for treatment of cancer, and use with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 10 OF 390 USPATFULL on STN
AN 2011:118608 USPATFULL
TI COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY
IN Garcia-Echeverria, Carlos, Basel, SWITZERLAND
Maira, Sauveur-Michel, Habsheim, FRANCE
Stuart, Darrin, Pleasant Hill, CA, UNITED STATES
Wee, Susan, Skillman, NJ, UNITED STATES
Fritsch, Christine, Ranspach-le-bas, FRANCE
Nagel, Tobi, Oakland, CA, UNITED STATES
PA NOVARTIS AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 20110105521 A1 20110505
AI US 2009-3581 A1 20090710 (13)
WO 2009-US50192 20090710
20110111 PCT 371 date
PRAI EP 2008-160218 20080711
DT Utility
FS APPLICATION
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
IT 284461-73-0, Sorafenib
(combination of (a) phosphoinositide 3-kinase inhibitor and (b) modulator of Ras/Raf/Mek pathway)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 11 OF 390 USPATFULL on STN
AN 2011:118524 USPATFULL
TI HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT
IN Turcotte, Sandra, Montreal, CANADA
Chan, Denise A., Palo Alto, CA, UNITED STATES
Sutphin, Patrick D., Boston, MA, UNITED STATES
Giaccia, Amato J., Stanford, CA, UNITED STATES
Hay, Michael P., Aukland, NEW ZEALAND
Denny, William A., Auckland, NEW ZEALAND
Bonnet, Muriel Marie, Auckland, NEW ZEALAND
PA AUCKLAND UNISERVICES LIMITED, Auckland, NEW ZEALAND (non-U.S. corporation)
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, PALO ALTO, CA, UNITED STATES (U.S. corporation)
PI US 20110105436 A1 20110505
AI US 2009-921767 A1 20090310 (12)
WO 2009-US36696 20090310
20110105 PCT 371 date
PRAI US 2008-35358P 20080310 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 25
ECL Exemplary Claim: 1-17
DRWN 10 Drawing Page(s)
LN.CNT 7559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of pyridinyl-substituted thiazolamine derivs. useful in treatment, prevention and combination therapy of cancers resulting from von Hippel-Lindau disease)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 12 OF 390 USPATFULL on STN
AN 2011:117350 USPATFULL
TI METHODS FOR TREATING OR PREVENTING COLORECTAL CANCER
IN Wang, Yaolin, Edison, NJ, UNITED STATES
Wang, Yan, Warren, NJ, UNITED STATES
Liu, Ming, Fanwood, NJ, UNITED STATES
Bishop, Walter Robert, Pompto Plains, NJ, UNITED STATES
Seidel-Dugan, Cynthia, Mountainside, NJ, UNITED STATES
PI US 20110104256 A1 20110505
AI US 2009-934458 A1 20090323 (12)
WO 2009-US37953 20090323
20101217 PCT 371 date
PRAI US 2008-39197P 20080325 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2201
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides, for example, methods for treating or preventing colorectal cancer with an anti-IGF1R antibody in association with sunitinib or a combination of leucovorin and 5-fluorouracil.
IT 284461-73-0, Sorafenib
(anti-IGF-1 receptor antibody combined with chemotherapeutic agent, antitumor agent, radiotherapy or surgery for treating or preventing colorectal cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 13 OF 390 USPATFULL on STN
AN 2011:117255 USPATFULL
TI COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER
IN Burgess, Teresa L., Ventura, CA, UNITED STATES
Coxon, Angela, Moorpark, CA, UNITED STATES
Dussault, Isabelle, Westlake Village, CA, UNITED STATES
Kaplan-Lefko, Paula, Simi Valley, CA, UNITED STATES
Polverino, Anthony J., Bainbridge Island, WA, UNITED STATES
Beaupre, Darrin, Simi Valley, CA, UNITED STATES
PI US 20110104161 A1 20110505
AI US 2009-992359 A1 20090514 (12)
WO 2009-US44034 20090514
20110111 PCT 371 date
PRAI US 2008-127753P 20080514 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer, by--combining VEGF(R) inhibitors and inhibitors of HGF/SF:c-Met.

L20 ANSWER 14 OF 390 USPATFULL on STN
AN 2011:117252 USPATFULL
TI DEUTERIUM BEARING ANALOGS OF ANASTROZOLE AS AROMATASE INHIBITORS FOR THE TREATMENT OF BREAST CANCER
IN Harbeson, Scott L., Cambridge, MA, UNITED STATES
PI US 20110104158 A1 20110505
AI US 2009-937935 A1 20090415 (12)
WO 2009-US2354 20090415
20110103 PCT 371 date
PRAI US 2008-44998P 20080415 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel, substituted aralkyl heterocyclic compounds according to formula I, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering aromatase inhibitors. Formula (I), or a pharmaceutically acceptable salt thereof, wherein: each R.sup.1 is independently selected from CH.sub.3, CH.sub.2D, CHD.sub.2 or CD.sub.3; each R.sup.2 is independently selected from CH.sub.3, CH.sub.2D, CHD.sub.2 or CD.sub.3; each Y is independently selected from H or D; and when each R variable is CH.sub.3, at least one Y is D.

##STR1##
IT 284461-73-0, Sorafenib
(as second therapeutic agent; deuterium bearing analogs of anastrozole as aromatase inhibitors for treatment of breast cancer and other diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 15 OF 390 USPATFULL on STN
AN 2011:117251 USPATFULL
TI LIVER CANCER DRUG
IN Kinoshita, Yasuko, Kanagawa, JAPAN
Sugimoto, Masamichi, Kanagawa, JAPAN
Ishiguro, Takahiro, Kanagawa, JAPAN
PA Chugai Seiyaku Kabushiki Kaisha, Tokyo, JAPAN (non-U.S. corporation)
PI US 20110104157 A1 20110505
AI US 2009-936367 A1 20090319 (12)
WO 2009-JP1249 20090319
20101222 PCT 371 date
PRAI JP 2008-98309 20080404
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-62
DRWN 6 Drawing Page(s)
LN.CNT 2583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.
IT 284461-73-0, BAY43-9006
(humanized anti-human glypican 3 antibodies and fragments for treatment of hepatic cancer and hepatocellular carcinoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 16 OF 390 USPATFULL on STN
AN 2011:109786 USPATFULL
TI FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
IN Ramachandra, Sumant, Northbrook, IL, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
Masat, Linda, Walnut Creek, CA, UNITED STATES
Huang, Chao Bai, San Leandro, CA, UNITED STATES
Takeuchi, Toshihiko, Oakland, CA, UNITED STATES
Kantak, Seema, Pacifica, CA, UNITED STATES
Huang's, Chin-Yi, Freemon, CA, UNITED STATES
PI US 20110097340 A1 20110428
AI US 2008-739383 A1 20081020 (12)
WO 2008-US80531 20081020
20101210 PCT 371 date
PRAI US 2007-981808P 20071022 (60)
US 2008-46370P 20080418 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 36 Drawing Page(s)
LN.CNT 3874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
IT 284461-73-0, Sorafenib
(human anti-VEGF antibodies and conjugates for diagnosis and treatment of angiogenesis conditions)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 17 OF 390 USPATFULL on STN
AN 2011:109767 USPATFULL
TI COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER
IN BLAKEY, David Charles, Macclesfield, UNITED KINGDOM
BROWN, Jeffrey Lester, Waltham, MA, UNITED STATES
EMERY, Stephen Charles, Macclesfield, UNITED KINGDOM
PA ASTRAZENECA AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 20110097321 A1 20110428
AI US 2010-890101 A1 20100924 (12)
RLI Continuation of Ser. No. US 2008-97384, filed on 13 Jun 2008, ABANDONED A 371 of International Ser. No. WO 2006-GB4611, filed on 12 Dec 2006
PRAI US 2005-750551P 20051215 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 18
ECL Exemplary Claim: 1-18
DRWN 10 Drawing Page(s)
LN.CNT 2554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.
IT 284461-73-0, BAY43-9006
(combination of anti-angiopoietin 2 human monoclonal antibody and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 18 OF 390 USPATFULL on STN
AN 2011:109758 USPATFULL
TI ANTI-CANCER VACCINES
IN Molldrem, Jeffrey, Houston, TX, UNITED STATES
PA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (U.S. corporation)
PI US 20110097312 A1 20110428
AI US 2009-867083 A1 20090213 (12)
WO 2009-US33987 20090213
20101214 PCT 371 date
PRAI US 2008-29141P 20080215 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells.
IT 475207-59-1, Nexavar
(breast cancer vaccine comprising HLA-A2-restricted peptides that elicit cytotoxic T-cells)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 19 OF 390 USPATFULL on STN
AN 2011:109721 USPATFULL
TI KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
IN Arbogast, Christophe, Viuz-En-Sallaz, FRANCE
Bussat, Philippe, La Roche-sur-Foron, FRANCE
Fan, Hong, Shanghai, CHINA
Khurana, Sudha, San Jose, CA, UNITED STATES
Linder, Karen E., Kingston, NJ, UNITED STATES
Marinelli, Edmund R., Tucson, AZ, UNITED STATES
Nanjappan, Palaniappa, Princeton, NJ, UNITED STATES
Nunn, Adrian D., Lambertville, NJ, UNITED STATES
Pillai, Radhakrishna K., Cranbury, NJ, UNITED STATES
Pochon, Sibylle, Troinex, SWITZERLAND
Ramalingam, Kondareddiar, Dayton, NJ, UNITED STATES
Shrivastava, Ajay, Princeton, NJ, UNITED STATES
Song, Bo, Princeton, NJ, UNITED STATES
Swenson, Rolf E., Princeton, NJ, UNITED STATES
Von Wronski, Mathew A., Geneva, SWITZERLAND
Yan, Feng, Grand-Lancy, SWITZERLAND
PA BRACCO SUISSE SA, Manno, SWITZERLAND (non-U.S. corporation)
PI US 20110097275 A1 20110428
AI US 2010-898119 A1 20101005 (12)
RLI Continuation-in-part of Ser. No. US 2009-480578, filed on 8 Jun 2009, PENDING Continuation of Ser. No. US 2003-661156, filed on 11 Sep 2003, ABANDONED Continuation-in-part of Ser. No. US 2003-382082, filed on 3 Mar 2003, ABANDONED Continuation-in-part of Ser. No. WO 2003-US6731, filed on 3 Mar 2003, PENDING Continuation-in-part of Ser. No. US 2007-954130, filed on 11 Dec 2007, PENDING Continuation-in-part of Ser. No. US 2006-608395, filed on 8 Dec 2006, Pat. No. US 7794693 Continuation-in-part of Ser. No. US 2003-661156, filed on 11 Sep 2003, ABANDONED Continuation-in-part of Ser. No. US 2003-382082, filed on 3 Mar 2003, ABANDONED Continuation-in-part of Ser. No. WO 2003-US6731, filed on 3 Mar 2003, PENDING
PRAI US 2003-440411P 20030115 (60)
US 2002-360851P 20020301 (60)
US 2003-440411P 20030115 (60)
US 2002-360851P 20020301 (60)
US 2006-833342P 20060725 (60)
US 2005-749240P 20051209 (60)
US 2003-440411P 20030115 (60)
US 2002-360851P 20020301 (60)
US 2003-440411P 20030115 (60)
US 2002-360851P 20020301 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 138 Drawing Page(s)
LN.CNT 15066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K.sub.D<1 μM), and dimer and multimeric constructs comprising these

polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

IT 284461-73-0, Sorafenib
(as anticancer agent, monitoring effectiveness of; KDR and VEGF/KDR binding peptides and their use as ultrasound contrast agents for determining cancer therapy effectiveness and adjusting treatment)

RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 20 OF 390 USPATFULL on STN
AN 2011:103215 USPATFULL
TI 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
IN Martin, Christine, Essex, UNITED KINGDOM
Zhang, Ming, Essex, UNITED KINGDOM
Gaisser, Sabine, Essex, UNITED KINGDOM
Coates, Nigel, Essex, UNITED KINGDOM
Wilkinson, Barrie, Essex, UNITED KINGDOM
PI US 20110091452 A1 20110421
AI US 2007-294175 A1 20070330 (12)
WO 2007-EP53129 20070330
20101222 PCT 371 date
PRAI GB 2006-6527 20060331
GB 2006-14607 20060722
DT Utility
FS APPLICATION
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 4,5-dihydromacbecin analogues to the formula (IA) or (IB), or a pharmaceutically acceptable salt there of: wherein: R.sub.1 represents H or CONH.sub.2 that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.
IT 284461-73-0, Sorafenib
(production of 4,5-dihydromacbecin from engineered strains of Actinosynnema pretiosum for use in cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 21 OF 390 USPATFULL on STN
AN 2011:103184 USPATFULL
TI Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases
IN Mann, David M., San Diego, CA, UNITED STATES
PI US 20110091421 A1 20110421
AI US 2009-934950 A1 20090327 (12)
WO 2009-US38685 20090327
20101221 PCT 371 date
PRAI US 2008-40065P 20080327 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3694
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.
IT 284461-73-0, Sorafenib
(in treatment of vascular disease; gene expression profiling in pulmonary artery in selection of therapies for vascular-related diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 22 OF 390 USPATFULL on STN
AN 2011:97056 USPATFULL
TI ANTI-FGF19 ANTIBODIES AND METHODS USING SAME
IN DESNOYERS, LUC, SAN FRANCISCO, CA, UNITED STATES
FRENCH, DOROTHY, SAN CARLOS, CA, UNITED STATES
PA GENENTECH, INC., SOUTH SAN FRANCISCO, CA, UNITED STATES (U.S. corporation)
PI US 20110086032 A1 20110414
AI US 2010-913660 A1 20101027 (12)
RLI Continuation of Ser. No. US 2010-692468, filed on 22 Jan 2010, Pat. No. US 7846691 Division of Ser. No. US 2007-673411, filed on 9 Feb 2007, Pat. No. US 7678373
PRAI US 2006-772310P 20060210 (60)
US 2006-780608P 20060309 (60)
US 2007-885866P 20070119 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 26
ECL Exemplary Claim: 1-101
DRWN 28 Drawing Page(s)
LN.CNT 6327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
IT 284461-73-0, Sorafenib
(in combination therapy with antibody to human fibroblast growth factor 19)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 23 OF 390 USPATFULL on STN
AN 2011:96998 USPATFULL
TI Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
IN Kao, Kuo-Jang, Gainesville, FL, UNITED STATES
Huang, Andrew T., Durham, NC, UNITED STATES
PA CHINA SYNTHETIC RUBBER CORPORATION (U.S. corporation)
PI US 20110085973 A1 20110414
AI US 2009-933248 A1 20090318 (12)
WO 2009-US1689 20090318
20101108 PCT 371 date
PRAI US 2008-69910P 20080319 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 2830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
IT 284461-73-0, Sorafenib
(protein sequences of mammalian PLVAP antibodies and methods and agents for the diagnosis and treatment of hepatocellular carcinoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 24 OF 390 USPATFULL on STN
AN 2011:95012 USPATFULL
TI Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis
IN Hentemann, Martin, Hamden, CT, UNITED STATES
Wood, Jill, North Haven, CT, UNITED STATES
Scott, William, Peekswill, NY, UNITED STATES
Michels, Martin, Koln, GERMANY, FEDERAL REPUBLIC OF
Campbell, Ann-Marie, Monroe, CT, UNITED STATES
Bullion, Ann-Marie, Milford, CT, UNITED STATES
Rowley, Bruce R., New Hope, PA, UNITED STATES
Redman, Aniko, Durham, NC, UNITED STATES
PA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, Berlin, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20110083984 A1 20110414
AI US 2007-517875 A1 20071205 (12)
WO 2007-US24985 20071205
20101220 PCT 371 date
PRAI US 2006-873090P 20061205 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
IT 284461-73-0, BAY 43-9006
(codrug; preparation of substituted 2,3-dihydroimidazo[1,2-c]quinazolines as PI3K inhibitors for treating and preventing diseases-mediated by PI3K)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 25 OF 390 USPATFULL on STN
AN 2011:91679 USPATFULL
TI SELECTIVE INHIBITORS OF HISTONE DEACETYLASE
IN Verner, Erik, Belmont, CA, UNITED STATES
Balasubramanian, Sriram, San Carlos, CA, UNITED STATES
Buggy, Joseph J., Mountain View, CA, UNITED STATES
PI US 20110081409 A1 20110407
AI US 2009-988271 A1 20090415 (12)
WO 2009-US40709 20090415
20101201 PCT 371 date
PRAI US 2008-45198P 20080415 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 27
ECL Exemplary Claim: 1-30
DRWN 4 Drawing Page(s)
LN.CNT 7556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
IT 284461-73-0, Sorafenib
(codrug; preparation of benzimidazole, indole, azaindole, and pyrrole hydroxyamides as selective inhibitors of histone deacetylase 8 for treating cancer, arthritis, and other diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 26 OF 390 USPATFULL on STN
AN 2011:85860 USPATFULL
TI HUMANIZED ANTI-FGF19 ANTAGONISTS AND METHODS USING SAME
IN Dennis, Mark, San Carlos, CA, UNITED STATES
Desnoyers, Luc, San Francisco, CA, UNITED STATES
French, Dorothy, San Carlos, CA, UNITED STATES
PI US 20110076262 A1 20110331
AI US 2008-671974 A1 20080801 (12)
WO 2008-US71955 20080801
20100728 PCT 371 date
PRAI US 2007-953908P 20070803 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same.
IT 284461-73-0, Sorafenib
(humanized and chimeric anti-human FGF19 antibodies and fragments for prophylaxis and treatment of cell proliferative disease and cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 27 OF 390 USPATFULL on STN
AN 2011:79073 USPATFULL
TI Combination Therapy with an Antitumor Alkaloid
IN LePage, Doreen, Cambridge, MA, UNITED STATES
Aviles Marin, Pablo Manuel, Madrid, SPAIN
Guillen Navarro, Maria Jose, Madrid, SPAIN
PA Pharma Mar, S.A., Madrid, SPAIN (non-U.S. corporation)
PI US 20110070232 A1 20110324
AI US 2009-992812 A1 20090518 (12)
WO 2009-US44334 20090518
20101115 PCT 371 date
PRAI US 2008-53726P 20080516 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 45 Drawing Page(s)
LN.CNT 4274
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combinations of PM00104 with other anticancer drugs, and the use of these combinations in the treatment of cancer.
IT 284461-73-0, Sorafenib
(combination therapy with antitumor alkaloid)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 28 OF 390 USPATFULL on STN
AN 2011:67332 USPATFULL
TI VITAMIN D3 AND ANALOGS THEREOF FOR TREATING ALOPECIA
IN Jimenez, Joaquin, Miami, FL, UNITED STATES
Narain, Niven Rajin, Cambridge, MA, UNITED STATES
McCook, John Patrick, Frisco, TX, UNITED STATES
PI US 20110059917 A1 20110310
AI US 2010-853431 A1 20100810 (12)
PRAI US 2009-234178P 20090814 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 41 Drawing Page(s)
LN.CNT 3937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.
IT 284461-73-0, Sorafenib
(vitamin D3 and analogs thereof for treating chemotherapy-induced alopecia)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 29 OF 390 USPATFULL on STN
AN 2011:60643 USPATFULL
TI Treatment of Histone Deacetylase Mediated Disorders
IN Gore, Lia, Denver, CO, UNITED STATES
De Ryckere, Deborah, Boulder, CO, UNITED STATES
PI US 20110053991 A1 20110303
AI US 2008-743809 A1 20081119 (12)
WO 2008-US84072 20081119
20101111 PCT 371 date
PRAI US 2007-989053P 20071119 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2630
AB Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of histone deacetylase mediated disorders.
IT 284461-73-0, Sorafenib
(treatment of histone deacetylase mediated disorders such as cancer with Class inhibitor and second inhibitor and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 30 OF 390 USPATFULL on STN
AN 2011:60620 USPATFULL
TI AMINOPYRIMIDINE INHIBITORS OF TYROSINE KINASE
IN Zhang, Chengzhi, San Diego, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20110053968 A1 20110303
AI US 2010-793205 A1 20100603 (12)
PRAI US 2009-185533P 20090609 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof

##STR1##
IT 284461-73-0, Sorafenib
(deuterated aminopyrimidine inhibitors of tyrosine kinase for treatment of diseases such as cancer in relation to decreased enzyme metabolism and toxicity and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 31 OF 390 USPATFULL on STN
AN 2011:50798 USPATFULL
TI TETRAHYDROBENZOTHIOPHENE DERIVATIVES
IN Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Pekari, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA NYCOMED GMBH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20110044938 A1 20110224
AI US 2007-377539 A1 20070815 (12)
WO 2007-EP58462 20070815
20101108 PCT 371 date
PRAI EP 2006-119037 20060816
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9673
AB Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0
(preparation of tetrahydrobenzothiophene derivs. as antitumor, antiproliferative and apoptosis-inducing agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 32 OF 390 USPATFULL on STN
AN 2011:43976 USPATFULL
TI ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS
IN Shin, Seung-Uon, Miami, FL, UNITED STATES
Rosenblatt, Joseph David, Miami, FL, UNITED STATES
Morrison, Sherie L., Los Angeles, CA, UNITED STATES
PA University of Miami, Miami, FL, UNITED STATES (U.S. corporation)
PI US 20110038865 A1 20110217
AI US 2008-665007 A1 20080626 (12)
WO 2008-US68434 20080626
20100830 PCT 371 date
PRAI US 2007-946245P 20070626 (60)
DT Utility
FS APPLICATION
LREP NOVAK DRUCE + QUIGG LLP (WPB), 525 Okeechobee Blvd, 15th Floor, City Place Tower, West Palm Beach, FL, 33401, US
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4737
AB Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules.
IT 284461-73-0, Sorafenib
(in combination with antibody-endostatin fusion proteins for tumor therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 33 OF 390 USPATFULL on STN
AN 2011:37807 USPATFULL
TI Combination Therapy for the Treatment of Cancer
IN Ratushny, Vladimir, Woodbury, NY, UNITED STATES
Golemis, Erica, Oreland, PA, UNITED STATES
Astsaturov, Igor, Philadelphia, PA, UNITED STATES
Serebriiskii, Iiya G., Rockedge, PA, UNITED STATES
Weiner, Louis M., Washington, DC, UNITED STATES
PI US 20110033461 A1 20110210
AI US 2009-922310 A1 20090312 (12)
WO 2009-US36976 20090312
20101014 PCT 371 date
PRAI US 2008-36027P 20080312 (61)
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 649
AB Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
IT 284461-73-0, Sorafenib
(synergistic combination therapy for treatment of cancer comprising Aurora kinase inhibitor EGFR inhibitor and optionally antiproliferative agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 34 OF 390 USPATFULL on STN
AN 2011:37765 USPATFULL
TI Methods and Compositions for Treating Cancer
IN AURELLAN, LAURE, BALTIMORE, MD, UNITED STATES
COLUNGA, ARIC, BALTIOMRE, MD, UNITED STATES
LAING, JENNIFER, BALTIMORE, MD, UNITED STATES
PA UNIVERSITY OF MARYLAND, BALTIMORE, MD, UNITED STATES (U.S. corporation)
PI US 20110033419 A1 20110210
AI US 2010-853073 A1 20100809 (12)
PRAI US 2009-232157P 20090807 (61)
DT Utility
FS APPLICATION
LREP Nevrivy Patent Law Group P.L.L.C, 1055 Thomas Jefferson Ave., N.W., Suite M-100, Washington, DC, 20007, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 2098
AB The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10.
IT 475207-59-1, Nexavar
(methods and compns. comprising HSV-2 virus lacking protein kinase activity of ICP10 gene for treating cancer)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 35 OF 390 USPATFULL on STN
AN 2011:32216 USPATFULL
TI COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES
IN Johansen, Lisa M., Belmont, MA, UNITED STATES
Lehar, Joseph, Lexington, MA, UNITED STATES
Hoffstrom, Benjamin G., Cambridge, MA, UNITED STATES
Olinger, Gene G., Frederick, MD, UNITED STATES
Stossel, Andrea R., Thurmont, MD, UNITED STATES
PI US 20110028564 A1 20110203
AI US 2010-710203 A1 20100222 (12)
PRAI US 2009-154279P 20090220 (61)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.
IT 284461-73-0, Sorafenib 475207-59-1, Sorafenib Tosylate
(compns. and methods for treatment of filovirus-mediated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 36 OF 390 USPATFULL on STN
AN 2011:30884 USPATFULL
TI MN/CA IX and EGFR Pathway Inhibition
IN Dorai, Thambi, Nanuet, NY, UNITED STATES
PI US 20110027225 A1 20110203
AI US 2010-900282 A1 20101007 (12)
RLI Division of Ser. No. US 2007-927150, filed on 29 Oct 2007, Pat. No. US 7820159
PRAI US 2006-855507P 20061031 (60)
DT Utility
FS APPLICATION
LREP Leona L. Lauder, Attorney at Law, Suite 1026, 235 Montgomery Street, San Francisco, CA, 94104-3008, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.
IT 284461-73-0, Sorafenib
(MN gene-encoded carbonic anhydrase IX and EGFR pathway inhibition in treating preneoplastic/neoplastic diseases in relation to therapy selection and combination chemotherapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 37 OF 390 USPATFULL on STN
AN 2011:24400 USPATFULL
TI NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Baer, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Vennemann, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Muehltal, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Padiya, Kamlesh, Virar (West), INDIA
Joshi, Hemant, Navi Mumbai, INDIA
Joshi, Uday, Thane, INDIA
Makhija, Mahindra, Ghatkopar, INDIA
Harel, Dipak, Maharashtra, INDIA
PA 4SC AG, Planegg-Martinsried, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20110021494 A1 20110127
AI US 2008-678806 A1 20080919 (12)
WO 2008-EP8208 20080919
20100823 PCT 371 date
PRAI EP 2007-116791 20070919
IN 2007-MU1819 20070919
IN 2008-MU616 20080324
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1-33
DRWN No Drawings
LN.CNT 11227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases.

##STR1##
IT 284461-73-0, Bay 43-9006 475207-59-1, Nexavar
(codrug; preparation of novel fused tetrahydropyridine compds. as HDAC inhibitors useful in treatment and prophylaxis of HDAC-related diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 38 OF 390 USPATFULL on STN
AN 2011:24387 USPATFULL
TI Novel Compounds and Methods for Their Production
IN Martin, Christine, Essex, UNITED KINGDOM
PI US 20110021481 A1 20110127
AI US 2007-513967 A1 20071109 (12)
WO 2007-GB50679 20071109
20101012 PCT 371 date
PRAI GB 2006-22342 20061109
GB 2007-20875 20071024
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4731
AB The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine.
IT 284461-73-0
(novel ansamycins produced by genetically engineered Streptomyces hygroscopicus geldanus strains)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 39 OF 390 USPATFULL on STN
AN 2011:23245 USPATFULL
TI 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes
IN Garcia-Echeverria, Carlos, Basel, SWITZERLAND
PI US 20110020338 A1 20110127
AI US 2009-933463 A1 20090324 (12)
WO 2009-EP53472 20090324
20100920 PCT 371 date
PRAI EP 2008-153311 20080326
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 101/2, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1-12
DRWN 4 Drawing Page(s)
LN.CNT 945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds of formula (I) or (II)

##STR1##

in the treatment of mammalian target of VEGF-driven angiogenic diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
IT 284461-73-0, Sorafenib
(5-imidazoquinolines and pyridine derivs. as potent modulators of VEGF-driven angiogenic processes)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 40 OF 390 USPATFULL on STN
AN 2011:23124 USPATFULL
TI TREATMENT OF MELANOMA
IN Young, Malcolm Philip, Newcastle Upon Tyne, UNITED KINGDOM
Thomas, Catherine Mary, Newcastle Upon Tyne, UNITED KINGDOM
Idowu, Olusola Clement, Newcastle Upon Tyne, UNITED KINGDOM
PA E-THERAPEUTICS PLC, Tyne& Wear, UNITED KINGDOM (non-U.S. corporation)
PI US 20110020217 A1 20110127
AI US 2008-738664 A1 20081010 (12)
WO 2008-GB3415 20081010
20101004 PCT 371 date
PRAI GB 2007-19771 20071010
DT Utility
FS APPLICATION
LREP K&L Gates LLP, STATE STREET FINANCIAL CENTER, One Lincoln Street, BOSTON, MA, 02111-2950, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 282
AB There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.
IT 284461-73-0, Sorafenib 475207-59-1, Sorafenib tosylate
(treatment of melanoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 41 OF 390 USPATFULL on STN
AN 2011:17393 USPATFULL
TI ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
Hatoum-Makdad, Holia, Hamden, CT, UNITED STATES
PI US 20110015195 A1 20110120
AI US 2010-888887 A1 20100923 (12)
RLI Continuation of Ser. No. US 2003-361858, filed on 11 Feb 2003, Pat. No. US 7838541
PRAI US 2002-354950P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2151
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
IT 284461-73-0P 284461-74-1P
(preparation of aryl ureas with angiogenesis inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 42 OF 390 USPATFULL on STN
AN 2011:16323 USPATFULL
TI ANTI-IGF1R
IN Wang, Yan, Warren, NJ, UNITED STATES
Pachter, Jonathan A., East Setauket, NY, UNITED STATES
Hailey, Judith Anne, East Windsor, NJ, UNITED STATES
Brams, Peter, Sacramento, CA, UNITED STATES
Williams, Denise, Livermore, CA, UNITED STATES
Srinivasan, Mohan, San Jose, CA, UNITED STATES
Feingersh, Mary Diane, Hayward, CA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20110014117 A1 20110120
AI US 2008-663651 A1 20080625 (12)
WO 2008-US7920 20080625
20100924 PCT 371 date
PRAI US 2007-946803P 20070628 (60)
DT Utility
FS APPLICATION
LREP MERCK, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.
IT 284461-73-0, Sorafenib
(in combination therapy with anti-IGF1R antibodies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 43 OF 390 USPATFULL on STN
AN 2011:10841 USPATFULL
TI Anticancer Treatments
IN LePage, Doreen, Cambridge, MA, UNITED STATES
Aviles Marin, Pablo Manuel, Madrid, SPAIN
Guillen, Maria Jose, Madrid, SPAIN
PA , Pharma Mar, S.A., Madrid, SPAIN (U.S. individual)
PI US 20110009335 A1 20110113
AI US 2009-920427 A1 20090306 (12)
WO 2009-US36327 20090306
20100831 PCT 371 date
PRAI US 2008-34870P 20080307 (61)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036-4003,
US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 2932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combinations of aplidine with another anticancer drug selected from sorafenib, temsirolimus, and sunitinib, and the use of these combinations in the treatment of cancer.
IT 284461-73-0, Sorafenib
(improved anticancer treatments)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 44 OF 390 USPATFULL on STN
AN 2011:4676 USPATFULL
TI USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF ABNORMAL VENOUS PROLIFERATION
IN Schwartz, Jason Joel, Salt lake City, UT, UNITED STATES
Kennedy, Thomas P., Charlotte, NC, UNITED STATES
PI US 20110003890 A1 20110106
AI US 2008-741979 A1 20081110 (12)
WO 2008-US83028 20081110
20100914 PCT 371 date
PRAI US 2007-986362P 20071108 (60)
DT Utility
FS APPLICATION
LREP Ballard Spahr LLP, SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915, US
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such angiogenesis antagonists to treat end-stage liver disease and end-stage liver disease complications. The present application also describes the use of such angiogenesis antagonists to treat disorders of altered venous proliferation such hemorrhoids and varicose veins.
IT 284461-73-0, Sorafenib
(angiogenesis antagonists for conditions of abnormal venous proliferation)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 45 OF 390 USPATFULL on STN
AN 2011:4619 USPATFULL
TI NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION
IN Kato, Tetsuya, Ibaraki, JAPAN
Kawanishi, Nobuhiko, Ibaraki, JAPAN
Mita, Takashi, Ibaraki, JAPAN
Nonoshita, Katsumasa, Ibaraki, JAPAN
Ohkubo, Mitsuru, Ibaraki, JAPAN
PI US 20110003833 A1 20110106
AI US 2009-866955 A1 20090218 (12)
WO 2009-JP53312 20090218
20100810 PCT 371 date
PRAI US 2008-66724P 20080222 (61)
DT Utility
FS APPLICATION
LREP MERCK, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of formula I: wherein: R.sub.1 is a hydrogen atom, F, CN, etc.; R.sub.2 is CO, SO.sub.2, etc.; R.sub.3 is a phenyl which may be substituted; X.sub.1, X.sub.2, and X.sub.3 each independently CH, N, etc. provided, however, that among X.sub.1, X.sub.2 and X.sub.3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W.sub.1, W.sub.2, and W.sub.3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.

##STR1##
IT 284461-73-0, Sorafenib
(codrug; preparation of novel aminopyridines and aminopyrimidines as selective Aurora A inhibitors useful as therapeutic agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 46 OF 390 USPATFULL on STN
AN 2011:3658 USPATFULL
TI METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT
IN Lubit, Beverly W., Kinnelon, NJ, UNITED STATES
Lipkin, Pamela R., New York, NY, UNITED STATES
PI US 20110002866 A1 20110106
AI US 2010-881945 A1 20100914 (12)
RLI Continuation-in-part of Ser. No. US 2008-235664, filed on 23 Sep 2008, Pat. No. US 7550508 Continuation-in-part of Ser. No. US 2008-235683, filed on 23 Sep 2008, Pat. No. US 7645800 Continuation-in-part of Ser. No. US 2008-235704, filed on 23 Sep 2008, Pat. No. US 7514474 Continuation-in-part of Ser. No. US 2008-235736, filed on 23 Sep 2008, Pat. No. US 7632867 Continuation-in-part of Ser. No. US 2008-235747, filed on 23 Sep 2008, Pat. No. US 7553874 Continuation-in-part of Ser. No. US 2008-235762, filed on 23 Sep 2008, Pat. No. US 7649021 Continuation-in-part of Ser. No. US 2008-235776, filed on 23 Sep 2008, Pat. No. US 7517912 Continuation-in-part of Ser. No. US 2008-235791, filed on 23 Sep 2008, Pat. No. US 7638557 Continuation-in-part of Ser. No. US 2008-235807, filed on 23 Sep 2008, Pat. No. US 7553875 Continuation-in-part of Ser. No. US 2008-235887, filed on 23 Sep 2008, Pat. No. US 7635720 Continuation-in-part of Ser. No. US 2008-235926, filed on 23 Sep 2008, Pat. No. US 7541382 Continuation-in-part of Ser. No. US 2008-235966, filed on 23 Sep 2008, Pat. No. US 7632868 Continuation-in-part of Ser. No. US 2008-236024, filed on 23 Sep 2008, PENDING Continuation-in-part of Ser. No. WO 2008-US77357, filed on 23 Sep 2008, PENDING Continuation-in-part of Ser. No. US 2009-565335, filed on 23 Sep 2009, PENDING Continuation-in-part of Ser. No. WO 2009-US58040, filed on 23 Sep 2009, PENDING
PRAI US 2009-242320P 20090914 (61)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2007-984198P 20071031 (60)
US 2008-99226P 20080923 (61)
US 2008-99226P 20080923 (61)
DT Utility
FS APPLICATION
LREP GREENBERG TRAURIG, LLP, 200 PARK AVE., P.O. BOX 677, FLORHAM PARK, NJ, 07932, US
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15257
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The described invention relates to delivery of compositions comprising at least one prostaglandin analog to prevent or reduce hair loss (e.g.

brittle hair growth, thin hair growth, short hair growth, sparse hair growth) or alopecia associated with chemotherapy.

IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)

RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 47 OF 390 USPATFULL on STN
AN 2010:370384 USPATFULL
TI Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
IN NOGUERA-TROISE, IRENE, STATEN ISLAND, NY, UNITED STATES
THURSTON, GAVIN, WHITE PLAINS, NY, UNITED STATES
THIBAULT, ALAIN, BETHESDA, MD, UNITED STATES
PA REGENERON PHARMACEUTICALS, INC., TARRYTOWN, NY, UNITED STATES (U.S. corporation)
PI US 20100330106 A1 20101230
AI US 2010-823680 A1 20100625 (12)
PRAI US 2009-220465P 20090625 (61)
US 2010-301881P 20100205 (61)
DT Utility
FS APPLICATION
LREP REGENERON PHARMACEUTICALS, INC, 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2531
AB The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided.
IT 284461-73-0
(co-therapy with; method of treating cancer with Dll4 antagonist, particularly anti-Dll4 antibodies, and chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 48 OF 390 USPATFULL on STN
AN 2010:363608 USPATFULL
TI TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER
IN Pekari, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PI US 20100324038 A1 20101223
AI US 2009-510362 A1 20090728 (12)
RLI Division of Ser. No. US 2007-883596, filed on 17 Sep 2007, Pat. No. US 7714135
PRAI EP 2005-100895 20050209
EP 2005-104488 20050525
EP 2005-112158 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-20
DRWN No Drawings
LN.CNT 4733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of formula I, wherein Ra is --C(O)OR1, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or Q is optionally substituted by Rca and/or Rcb, and is Har, or Q is optionally substituted by Rda and/or Rdb, and is Het, or Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer.

##STR1##

IT 284461-73-0, Sorafenib
(preparation of tetrahydropyridothiophenes with cell-cycle dependent, antiproliferative and apoptosis-inducing activity useful in treatment of hyperproliferative diseases such as cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 49 OF 390 USPATFULL on STN
AN 2010:363535 USPATFULL
TI CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF
IN GUENTHER, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schaefer, Olaf, Biberach an der Riss, GERMANY, FEDERAL REPUBLIC OF
Teifel, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Paulini, Klaus, Maintal, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100323963 A1 20101223
AI US 2010-728075 A1 20100319 (12)
RLI Continuation of Ser. No. US 2007-850747, filed on 6 Sep 2007, Pat. No. US 7741277
PRAI EP 2006-18750 20060907
US 2006-842357P 20060906 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, L.L.P., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
IT 284461-73-0, Sorafenib
(combination chemotherapy; manufacturing process for conjugates of disorazoles and their derivs. with cell-binding mols.)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 50 OF 390 USPATFULL on STN
AN 2010:356561 USPATFULL
TI CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF
IN GUENTHER, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schaefer, Olaf, Biberach an der Riss, GERMANY, FEDERAL REPUBLIC OF
Teifel, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Paulini, Klaus, Maintal, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100317580 A1 20101216
AI US 2010-728050 A1 20100319 (12)
RLI Continuation of Ser. No. US 2007-850747, filed on 6 Sep 2007, Pat. No. US 7741277
PRAI EP 2006-18750 20060907
US 2006-842357P 20060906 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, L.L.P., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-20
DRWN 17 Drawing Page(s)
LN.CNT 2601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
IT 284461-73-0, Sorafenib
(combination chemotherapy; manufacturing process for conjugates of disorazoles and their derivs. with cell-binding mols.)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 51 OF 390 USPATFULL on STN
AN 2010:355622 USPATFULL
TI POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION
IN SUNDARAM, Mallikarjun, Randolph, NJ, UNITED STATES
KISHIMOTO, Takashi Kei, Lexington, MA, UNITED STATES
ROY, Sucharita, Tyngsboro, MA, UNITED STATES
PA Momenta Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20100316640 A1 20101216
AI US 2010-816369 A1 20100615 (12)
RLI Continuation-in-part of Ser. No. US 2010-762268, filed on 16 Apr 2010, PENDING Continuation-in-part of Ser. No. WO 2008-US82223, filed on 3 Nov 2008, PENDING
PRAI US 2007-985123P 20071102 (60)
DT Utility
FS APPLICATION
LREP LANDO & ANASTASI, LLP, ONE MAIN STREET, SUITE 1100, CAMBRIDGE, MA,
02142, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
IT 284461-73-0, Sorafenib
(polysaccharide compns. for treatment and prevention of disorders associated with progenitor cell mobilization)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 52 OF 390 USPATFULL on STN
AN 2010:350256 USPATFULL
TI Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process
IN Rao, Dharmaraj Ramachandra, Thane (West), INDIA
Kankan, Rajendra Narayanrao, Mumbai, INDIA
Ghagare, Maruti, Thane (West), INDIA
Chikhalikar, Sandip, Mumbai, INDIA
PA CIPLA LIMITED, Mumbai, INDIA (non-U.S. corporation)
PI US 20100311980 A1 20101209
AI US 2008-677195 A1 20080910 (12)
WO 2008-GB3048 20080910
20100723 PCT 371 date
PRAI IN 2007-MU1734 20070910
IN 2009-1733 20090910
DT Utility
FS APPLICATION
LREP CONLEY ROSE, P.C., 5601 GRANITE PARKWAY, SUITE 750, PLANO, TX, 75024, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A)

##STR1##

wherein R' is selected from the group consisting of hydrogen, --C(O)OA, --C(O)CX.sub.3, --C(O)NH.sub.2, --C(O)--NHOH or

##STR2##

There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.
IT 284461-73-0P, Sorafenib
(process for the preparation of sorafenib, a RAF kinase inhibitor, and intermediates for use in the process)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1P, Sorafenib tosylate
(process for the preparation of sorafenib, a RAF kinase inhibitor, and intermediates for use in the process)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 53 OF 390 USPATFULL on STN
AN 2010:349965 USPATFULL
TI COMBINATION THERAPY WITH ORGANIC ARSENICALS
IN Wallner, Barbara P., Cohasset, MA, UNITED STATES
Komarnitsky, Philip B., Chestnut Hill, MA, UNITED STATES
PA ZIOPHARM Oncology, Inc, Boston, MA, UNITED STATES (U.S. corporation)
PI US 20100311689 A1 20101209
AI US 2008-740661 A1 20081031 (12)
WO 2008-US12385 20081031
20100601 PCT 371 date
PRAI US 2007-1575P 20071102 (61)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE,
BOSTON, MA, 02110-2624, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.
IT 284461-73-0, Sorafenib
(organic arsenical compound-antitumor agent combination for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 54 OF 390 USPATFULL on STN
AN 2010:349954 USPATFULL
TI METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS
IN Bean, Bruce P., Waban, MA, UNITED STATES
Binshtok, Alexander, Brookline, MA, UNITED STATES
Woolf, Clifford J., Newton, MA, UNITED STATES
PI US 20100311678 A1 20101209
AI US 2008-681509 A1 20081003 (12)
WO 2008-US11454 20081003
20100823 PCT 371 date
PRAI US 2007-997715P 20071004 (60)
US 2008-51180P 20080507 (61)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 913
AB This invention features methods and compositions for treating cancer and modulating signal transduction and metabolism pathways. For example, the methods and compositions of the invention can be used to kill or inhibit the growth or spread of cancer cells. The invention also features a method of identifying a compound that modulates a signal transduction or metabolic pathway.
IT 284461-73-0, Sorafenib
(tyrosine kinase inhibitor; treating cancer and modulating signal transduction and metabolism pathways)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 55 OF 390 USPATFULL on STN
AN 2010:348781 USPATFULL
TI NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT
IN Li, Chiang Jia, Cambridge, MA, UNITED STATES
Mikule, Keith, Norwood, MA, UNITED STATES
Li, Youzhi, Westwood, MA, UNITED STATES
PI US 20100310503 A1 20101209
AI US 2008-677516 A1 20080910 (12)
WO 2008-US75906 20080910
20100812 PCT 371 date
RLI Division of Ser. No. US 2007-13372, filed on 13 Dec 2007, PENDING
PRAI US 2007-971144P 20070910 (60)
DT Utility
FS APPLICATION
LREP Milstein Zhang & Wu LLC, 49 Lexington Street, Suite 6,
Newton, MA,
02465-1062, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 1892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(Stat3 pathway inhibitors or cancer stem cell inhibitors for combination cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 56 OF 390 USPATFULL on STN
AN 2010:342529 USPATFULL
TI Molecular profiling of tumors
IN Von Hoff, Daniel D., Phoenix, AZ, UNITED STATES
Wright, Alan, Phoenix, AZ, UNITED STATES
McGinniss, Matthew J., San Diego, CA, UNITED STATES
Bender, Ryan P., Phoenix, AZ, UNITED STATES
Loesch, David M., Phoenix, AZ, UNITED STATES
Alarcon, Arlet, Phoenix, AZ, UNITED STATES
Penny, Robert J., Phoenix, AZ, UNITED STATES
Pawlowski, Traci, Phoenix, AZ, UNITED STATES
PI US 20100304989 A1 20101202
AI US 2010-658770 A1 20100212 (12)
PRAI US 2009-151758P 20090211 (61)
US 2009-170565P 20090417 (61)
US 2009-229686P 20090729 (61)
US 2009-217289P 20090528 (61)
US 2009-279970P 20091027 (61)
US 2009-261709P 20091116 (61)
US 2010-294440P 20100112 (61)
DT Utility
FS APPLICATION
LREP WILSON, SONSINI, GOODRICH & ROSATI, 650
PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 94 Drawing Page(s)
LN.CNT 9444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
IT 284461-73-0, Sorafenib
(mol. profiling of tumors for identifying treatments)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 57 OF 390 USPATFULL on STN
AN 2010:335078 USPATFULL
TI Methods for providing personalized medicine test ex vivo for hematological neoplasms
IN Ballesteros, Juan, Madrid, SPAIN
Bennett, Teresa, Salamanca, SPAIN
Primo, Daniel, Salamanca, SPAIN
Orfao, Alberto, Salama, SPAIN
Jackson, Coyt, Salamanca, SPAIN
Lago, Santiago, Malaga, SPAIN
Matoses, Maria, Malaga, SPAIN
Suarez, Lilia, Cala del Moral - Malaga, SPAIN
Sapia, Sandra, Malaga, SPAIN
Bosanquet, Andrew, Bath, UNITED KINGDOM
Gorrochategui, Julian, Madrid, SPAIN
Tudela, Consuelo, Madrid, SPAIN
Hernandez, Pilar, Salamanca, SPAIN
Caveda, Luis Ignacio, Madrid, SPAIN
PA Vivia Biotech S.L., Valladolid, SPAIN (non-U.S. corporation)
PI US 20100298255 A1 20101125
AI US 2010-783465 A1 20100519 (12)
PRAI US 2009-179685P 20090519 (61)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 3975
AB Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.
IT 284461-73-0, Sorafenib
(in drug composition for testing; personalized medicine tests ex vivo for analyzing cellular responsiveness of hematol. neoplasms to drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 58 OF 390 USPATFULL on STN
AN 2010:333945 USPATFULL
TI APROTININ-LIKE POLYPEPTIDES FOR DELIVERING AGENTS CONJUGATED THERETO TO TISSUES
IN Beliveau, Richard, Montreal, CANADA
Demeule, Michel, Beaconsfield, CANADA
Che, Christian, Montreal, CANADA
Regina, Anthony, Montreal, CANADA
PA ANGIOCHEM INC., Montreal, QC, CANADA (non-U.S. corporation)
PI US 20100297120 A1 20101125
AI US 2008-601803 A1 20080529 (12)
WO 2008-CA1030 20080529
20100802 PCT 371 date
RLI Continuation-in-part of Ser. No. US 2007-807597, filed on 29 May 2007, PENDING Continuation-in-part of Ser. No. US 2007-807917, filed on 30 May 2007, PENDING
PRAI US 2007-8880P 20071220 (61)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 3136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB.
IT 284461-73-0, Sorafenib
(aprotinin-like polypeptides for delivering agents conjugated thereto to tissues)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 59 OF 390 USPATFULL on STN
AN 2010:333900 USPATFULL
TI COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
IN Chan, Thomas C.K., Winchester, MA, UNITED STATES
France, Dennis S., Winchester, MA, UNITED STATES
Ishii, Kenichi, Shizuoka, JAPAN
Pucci, Paolo, Westport, CT, UNITED STATES
PA ArQule, Inc., Woburn, MA, UNITED STATES (U.S. corporation)
Kyowa Hakko Kirin Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20100297075 A1 20101125
AI US 2010-704361 A1 20100211 (12)
PRAI US 2009-152138P 20090212 (61)
US 2009-170471P 20090417 (61)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C, ONE FINANCIAL CENTER, BOSTON, MA, 02111, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 4966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.
IT 284461-73-0, Sorafenib
(co-agent; preparation of (pyrroloquinolinyl)(indolyl)pyrrolediones and -pyrrolidinediones for combination chemotherapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 60 OF 390 USPATFULL on STN
AN 2010:327110 USPATFULL
TI INDAZOLE INHIBITORS OF TYROSINE KINASE
IN Rao, Tadimeti, San Diego, CA, UNITED STATES
Zhang, Chengzhi, San Diego, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100291025 A1 20101118
AI US 2010-759389 A1 20100413 (12)
PRAI US 2009-168807P 20090413 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 1005 North Warson Road, Suite 201, ST. LOUIS, MO, 63132, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(indazole inhibitors of tyrosine kinase)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 61 OF 390 USPATFULL on STN
AN 2010:320438 USPATFULL
TI NOVEL TETRAHYDROPYRIDOTHIOPHENES
IN Pekari, Klaus, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
PI US 20100285149 A1 20101111
AI US 2007-377475 A1 20070815 (12)
WO 2007-EP58432 20070815
20100802 PCT 371 date
PRAI EP 2006-119034 20060816
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0
(preparation of tetrahydropyridothiophene derivs. as anticancer, antiproliferative and apoptosis-inducing agents for use alone or in combination with other drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 62 OF 390 USPATFULL on STN
AN 2010:320301 USPATFULL
TI METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS
IN Dunn, JR., William A., Gainesville, FL, UNITED STATES
Akin, Debra E., Micanopy, FL, UNITED STATES
Progulske-Fox, Ann, Gainesville, FL, UNITED STATES
Ostrov, David A., Gainesville, FL, UNITED STATES
PA University of FLorida Research Foundation Inc., Gainesville, FL, UNITED STATES (U.S. corporation)
PI US 20100285012 A1 20101111
AI US 2009-811646 A1 20090105 (12)
WO 2009-US30102 20090105
20100702 PCT 371 date
PRAI US 2008-19239P 20080105 (61)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO Box
142950, GAINESVILLE, FL, 32614, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1-29
DRWN 7 Drawing Page(s)
LN.CNT 562
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8).
IT 284461-73-0, Sorafenib 1173159-45-9
1173159-97-1
(pyridinylpyridinecarbothioamide and/or cambendazole, alone or in combination with other agents, for treatment of cancer and pathogenic infection)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 1173159-45-9 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mixt. with N-2-pyridinyl-2-pyridinecarbothioamide (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 39122-38-8
CMF C11 H9 N3 S



RN 1173159-97-1 USPATFULL
CN Carbamic acid, N-[2-(4-thiazolyl)-1H-benzimidazol-6-yl]-, 1-methylethyl ester, mixt. with 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 26097-80-3
CMF C14 H14 N4 O2 S



L20 ANSWER 63 OF 390 USPATFULL on STN
AN 2010:320295 USPATFULL
TI Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases
IN LI, Chiang Jia, Cambridge, MA, UNITED STATES
Liu, Ji-Feng, Winchester, MA, UNITED STATES
Li, Youzhi, Westwood, MA, UNITED STATES
Li, Wei, Wayland, MA, UNITED STATES
Rogoff, Harry, Worcester, MA, UNITED STATES
PI US 20100285006 A1 20101111
AI US 2008-676869 A1 20080905 (12)
WO 2008-US75418 20080905
20100802 PCT 371 date
PRAI US 2007-970410P 20070906 (60)
US 2007-13389P 20071213 (61)
US 2008-74295P 20080620 (61)
DT Utility
FS APPLICATION
LREP Milstein Zhang & Wu LLC, 49 Lexington Street, Suite 6, Newton, MA, 02465-1062, US
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof.
IT 284461-73-0
(co-drug; preparation of thiazole-indolinone derivs. as CSCPK inhibitors useful for treatment of cancers and other diseases related to the kinases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 64 OF 390 USPATFULL on STN
AN 2010:320289 USPATFULL
TI USE OF VEGFR-2 INHIBITORS FOR TREATING METASTATIC CANCER
IN Mamluk, Roni, Mazkeret Batia, ISRAEL
PA BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 20100285000 A1 20101111
AI US 2008-674144 A1 20080820 (12)
WO 2008-US9890 20080820
20100714 PCT 371 date
PRAI US 2007-965574P 20070820 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, PATENT DOCKETING Floor 39, One International Place,
Boston, MA, 02110-2624, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application provides compositions and methods for treating metastatic cancer. Patients having or at risk of developing metastases may be treated. Compositions useful for the invention include VEGFR-2 specific inhibitors.
IT 284461-73-0, Sorafenib
(co-therapy with; fibronectin type III domain analogs that inhibit VEGFR-2 for treating metastatic cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 65 OF 390 USPATFULL on STN
AN 2010:314554 USPATFULL
TI USE OF ALLOPURINOL FOR THE TREATMENT OF HAND FOOT SKIN REACTION
IN Rodemer, Yolanda, WilhemsHaven-Rustersiel, GERMANY, FEDERAL REPUBLIC OF
PI US 20100280051 A1 20101104
AI US 2010-770179 A1 20100429 (12)
PRAI EP 2009-382058 20090429
US 2009-214894P 20090429 (61)
DT Utility
FS APPLICATION
LREP COOPER & DUNHAM, LLP, 30 Rockefeller Plaza, 20th Floor, NEW YORK, NY,
10112, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase Inhibitor (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.
IT 284461-73-0, Sorafenib
(use of allopurinol for treatment of hand foot skin reaction induced by multitargeted kinase therapy of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 66 OF 390 USPATFULL on STN
AN 2010:306459 USPATFULL
TI COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
IN Evans, Dean Brent, Oberwil, SWITZERLAND
Jacques, Christian J., Hamburg, NJ, UNITED STATES
PA NOVARTIS AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 20100272717 A1 20101028
AI US 2008-745976 A1 20081204 (12)
WO 2008-US85535 20081204
20100603 PCT 371 date
PRAI US 2007-13335P 20071213 (61)
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 101/2, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
IT 284461-73-0, BAY 43-9006
(synergistic combinations of therapeutic agents comprising vascular disrupting agent such as 5,6-dimethylxanthenone-4-acetic acid, for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 67 OF 390 USPATFULL on STN
AN 2010:300804 USPATFULL
TI Targeting MicroRNAs for the Treatment of Liver Cancer
IN Bennett, C. Frank, Carlsbad, CA, UNITED STATES
Chajut, Ayelet, Ramat Hasharon, ISRAEL
Esau, Christine, La Jolla, CA, UNITED STATES
Marcusson, Eric G., San Francisco, CA, UNITED STATES
Yerushalmi, Noga, Nes Ziona, ISRAEL
PA REGULUS THERAPEUTICS INC., Carlsbad, CA, UNITED STATES (U.S. corporation)
ROSETTA GENOMICS LTD., Rehovot, ISRAEL (non-U.S. corporation)
PI US 20100267814 A1 20101021
AI US 2008-740211 A1 20081029 (12)
WO 2008-US81645 20081029
20100428 PCT 371 date
PRAI US 2007-983231P 20071029 (60)
DT Utility
FS APPLICATION
LREP Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, PA, 19312-1183, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1-169
DRWN 9 Drawing Page(s)
LN.CNT 3415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
IT 284461-73-0
(in liver cancer therapy; oligonucleotide analogs binding specific microRNAs for treatment of liver cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 68 OF 390 USPATFULL on STN
AN 2010:300796 USPATFULL
TI LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
IN Bumcrot, David, Belmont, MA, UNITED STATES
Akinc, Akin, Needham, MA, UNITED STATES
Sah, Dinah Wen-Yee, Boston, MA, UNITED STATES
Novobrantseva, Tatiana, Cambridge, MA, UNITED STATES
PI US 20100267806 A1 20101021
AI US 2010-723471 A1 20100312 (12)
PRAI US 2009-159788P 20090312 (61)
US 2009-231579P 20090805 (61)
US 2009-285947P 20091211 (61)
DT Utility
FS APPLICATION
LREP ALNYLAM/FENWICK, SILICON VALLEY CENTER, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94041, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 8354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
IT 284461-73-0, Sorafenib
(lipid-formulated double-stranded siRNA compns. and methods for inhibiting expression of human EG5 and VEGF genes)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 69 OF 390 USPATFULL on STN
AN 2010:300652 USPATFULL
TI BETA GLUCANS AND METHODS OF USE THEREOF
IN Weitberg, Alan B., Newport, RI, UNITED STATES
PA ImmuDyne, Inc., Mt. Kisco, NY, UNITED STATES (U.S. corporation)
PI US 20100267661 A1 20101021
AI US 2010-726175 A1 20100317 (12)
PRAI US 2009-161024P 20090317 (61)
DT Utility
FS APPLICATION
LREP DLA PIPER LLP (US), 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to therapeutic uses of beta glucan for treating cancer, cytopenia, and symptoms associated with negative side effects of chemotherapy. As such, the current invention provides methods of using beta glucan for treating cancer, for increasing hematopoiesis, and for improving the quality of life of subjects undergoing chemotherapeutic treatment.
IT 475207-59-1, Nexavar
(therapeutic use of Beta glucans for treatment of cancer, cytopenia and side effects of chemotherapy)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 70 OF 390 USPATFULL on STN
AN 2010:300628 USPATFULL
TI TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR
IN Rios, Israel, Menlo Park, CA, UNITED STATES
Tuthill, Cynthia W., Menlo Park, CA, UNITED STATES
PA SciClone Pharmaceuticals, Inc., Foster City, CA, UNITED STATES (U.S. corporation)
PI US 20100267637 A1 20101021
AI US 2008-747438 A1 20081212 (12)
WO 2008-US86545 20081212
20100610 PCT 371 date
PRAI US 2007-13476P 20071213 (61)
DT Utility
FS APPLICATION
LREP COOLEY LLP, ATTN: Patent Group, Suite 1100, 777 - 6th Street, NW, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor.
IT 284461-73-0, Sorafenib
(treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 71 OF 390 USPATFULL on STN
AN 2010:299531 USPATFULL
TI QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS
IN Gerlach, Matthias, Brachttal, GERMANY, FEDERAL REPUBLIC OF
Seipelt, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Grossostheim, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
Czech, Michael, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
Claus, Eckhard, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100266538 A1 20101021
AI US 2010-731243 A1 20100325 (12)
PRAI EP 2009-157141 20090402
US 2009-165953P 20090402 (61)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders.

##STR1##
IT 284461-73-0
(co-drug; preparation of quinoxaline derivs. and their use for treating benign and malignant tumor disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 72 OF 390 USPATFULL on STN
AN 2010:293957 USPATFULL
TI HDAC Inhibitors
IN Ashwell, Mark A., Carlisle, MA, UNITED STATES
Tandon, Manish, Framingham, MA, UNITED STATES
Namdev, Nivedita D., Westford, MA, UNITED STATES
Lapierre, Jean-Marc, Pelham, NH, UNITED STATES
Liu, Yanbin, Acton, MA, UNITED STATES
Wu, Hui, Malden, MA, UNITED STATES
PA ARQULE, INC., Woburn, MA, UNITED STATES (U.S. corporation)
PI US 20100261710 A1 20101014
AI US 2008-671351 A1 20080821 (12)
WO 2008-US73873 20080821
20100520 PCT 371 date
PRAI US 2007-965584P 20070821 (60)
DT Utility
FS APPLICATION
LREP Sunstein Kann Murphy & Timbers LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.
IT 284461-73-0, Sorafenib
(codrug; preparation of hydroxamic acid compds. as HDAC inhibitors useful in treatment of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 73 OF 390 USPATFULL on STN
AN 2010:292927 USPATFULL
TI QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
IN Tung, Roger, Lexington, MA, UNITED STATES
PA Concert Pharmaceuticals, Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 20100260674 A1 20101014
AI US 2010-694249 A1 20100126 (12)
RLI Continuation-in-part of Ser. No. US 2007-957442, filed on 15 Dec 2007, PENDING
PRAI US 2006-875320P 20061215 (60)
US 2009-147458P 20090126 (61)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.
IT 284461-73-0, Sorafenib
(quinazoline derivs. and methods of treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 74 OF 390 USPATFULL on STN
AN 2010:278327 USPATFULL
TI MUTATED NETRIN 4, FRAGMENTS THEREOF AND USES THEREOF AS DRUGS
IN Plouet, Jean, Paris, FRANCE
Plouet, Isabelle Clarisse Solange, Paris, FRANCE legal representative
Plouet, Claire Charlotte, Paris, FRANCE legal representative
Plouet, Anne Florence, Paris, FRANCE legal representative
Leconte, Laurence, Antony, FRANCE
Lejmi, Esma, Issy Les Moulineaux, FRANCE
PA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris Cedex 16, FRANCE (non-U.S. corporation)
IVS INSTITUT DES VAISSEAUX ET DU SANG, Paris Cedex 10, FRANCE (non-U.S. corporation)
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC, PARIS CEDIX 13, FRANCE (non-U.S. corporation)
PI US 20100247520 A1 20100930
AI US 2008-523074 A1 20080121 (12)
WO 2008-EP50662 20080121
20090714 PCT 371 date
PRAI EP 2007-290075 20070119
DT Utility
FS APPLICATION
LREP YOUNG & THOMPSON, 209 Madison Street, Suite 500, Alexandria, VA, 22314,
US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1-18
DRWN 9 Drawing Page(s)
LN.CNT 2218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a protein comprising or consisting of one of the following sequences: the sequence SEQ ID NO: 2 or SEQ ID NO: 4, or a fragment of said sequence represented by one of the sequences SEQ ID NO: 2q, q varying from 3 to 36, or the sequence SEQ ID NO: 185 to SEQ ID NO: 209. It also relates to a nucleotide sequence coding for said protein.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(combination chemotherapy with; netrin-4 mutants and fragments and their uses as anti-angiogenic drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 75 OF 390 USPATFULL on STN
AN 2010:272181 USPATFULL
TI METHODS TO IDENTIFY MODULATORS OF B-RAF PROTEIN KINASE AND THEIR USE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
IN Hitz, Christiane, Munchen, GERMANY, FEDERAL REPUBLIC OF
Holter, Sabine, Munchen, GERMANY, FEDERAL REPUBLIC OF
Kuhn, Ralf, Freising, GERMANY, FEDERAL REPUBLIC OF
Wurst, Wolfgang, Munchen, GERMANY, FEDERAL REPUBLIC OF
Wefers, Benedikt, Markt Schwaben, GERMANY, FEDERAL REPUBLIC OF
PA HELMHOLTZ ZENTRUM MUNCHEN, 85764 Neuherberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100242127 A1 20100923
AI US 2008-602753 A1 20080603 (12)
WO 2008-EP4416 20080603
20100604 PCT 371 date
PRAI US 2007-941846P 20070604 (60)
DT Utility
FS APPLICATION
LREP PILLSBURY WINTHROP SHAW PITTMAN LLP, ATTENTION: DOCKETING DEPARTMENT, P.O BOX 10500, McLean, VA, 22102, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for identifying a compound capable of modulating an anxiety or depression disorder comprising the steps of: (a) contacting a composition comprising a B-Raf protein or a B-Raf gene in expressible form or a transcript thereof with a compound under conditions that allow for an interaction of the B-Raf protein or the B-Raf gene or a transcript thereof and the compound; and (b) measuring whether said interaction, if any, results in (i) a change of B-Raf kinase activity compared to B-Raf kinase activity in the absence of said compound; (ii) a modulation of the expression of the B-Raf gene compared to B-Raf gene expression in the absence of said compound; or (iii) the formation of a complex between the compound and the B-Raf protein, wherein such a change in activity, modulation of expression or the formation of a complex is indicative of the compound being a modulator of an anxiety or depression disorder. Further, the invention relates to a method for treating an anxiety or depression disorder in an individual comprising administering to the individual an effective amount of a compound inhibiting B-Raf kinase activity or gene expression and to a use of a compound that inhibits B-Raf kinase activity or gene expression in the manufacture of a pharmaceutical composition for treating an anxiety or depression disorder. Moreover, the invention relates to a method of diagnosing a B-Raf associated anxiety or depression disorder and to a genetically engineered mouse. Finally, the invention also relates to a method of identifying another gene contributing to the pathophysiology of an anxiety or depression disorder apart from B-Raf.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(B-Raf protein kinase modulator identification, use for treatment of anxiety and depression, and diagnostic and gene identification methods)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 76 OF 390 USPATFULL on STN
AN 2010:269717 USPATFULL
TI SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS
IN Diwan, Anil R., West Haven, CT, UNITED STATES
Onton, Ann Louise, Woodbridge, CT, UNITED STATES
Tatake, Jayant G., Sandy Hook, CT, UNITED STATES
PA ALLEXCEL., INC., West Haven, CT, UNITED STATES (U.S. corporation)
PI US 20100239659 A1 20100923
AI US 2007-669245 A1 20070719 (12)
WO 2007-US73880 20070719
20100517 PCT 371 date
DT Utility
FS APPLICATION
LREP KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells.
IT 284461-73-0, Sorafenib
(anticancer agent; self-assembling amphiphilic polyethylene glycol derivs. for encapsulating anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 77 OF 390 USPATFULL on STN
AN 2010:269715 USPATFULL
TI COMPOSITE FOR LIVER-SPECIFIC DELIVERY AND RELEASE OF THERAPEUTIC NUCLEIC ACIDS OR DRUGS
IN KIM, Meehyein, Yongin-si, KOREA, REPUBLIC OF
Kim, Soo In, Yongin-si, KOREA, REPUBLIC OF
Shin, Duckhyang, Yongin-si, KOREA, REPUBLIC OF
Park, Mahnhoon, Yongin-si, KOREA, REPUBLIC OF
PA MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, Yongin-si, KOREA, REPUBLIC OF (non-U.S. corporation)
PI US 20100239657 A1 20100923
AI US 2010-791600 A1 20100601 (12)
RLI Division of Ser. No. US 2007-741287, filed on 27 Apr 2007, PENDING
PRAI KR 2006-110402 20061109
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
IT 284461-73-0, Sorafenib
(apolipoprotein A-I conjugates with liposomes for delivering nucleic acids and drugs to liver)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 78 OF 390 USPATFULL on STN
AN 2010:269710 USPATFULL
TI IMMUNOLIPOSOMES FOR TREATMENT OF CANCER
IN Rochlitz, Christoph, Riehen, SWITZERLAND
Mamot, Christoph, Basel, SWITZERLAND
PA UNIVERSITATSSPITAL BASEL, BASEL, SWITZERLAND (non-U.S. corporation)
PI US 20100239652 A1 20100923
AI US 2008-680698 A1 20080926 (12)
WO 2008-EP62958 20080926
20100329 PCT 371 date
DT Utility
FS APPLICATION
LREP DICKSTEIN SHAPIRO LLP, 1633 Broadway, NEW YORK, NY, 10019, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to immunoliposomes for multiple treatment of human patients suffering from cancer, particularly a cancer represented by a locally advanced or metastatic tumor and to compositions used in said method. The invention further relates to the use of immunoliposomes for the treatment of multi-drug resistance in cancer therapy.
IT 284461-73-0, Sorafenib
(immunoliposomes for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 79 OF 390 USPATFULL on STN
AN 2010:269634 USPATFULL
TI AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE
IN Xi, Ning, Thousand Oaks, CA, UNITED STATES
PI US 20100239576 A1 20100923
AI US 2010-728153 A1 20100319 (12)
PRAI US 2009-162260P 20090321 (61)
DT Utility
FS APPLICATION
LREP Ning Xi, 565 Timberwood Ave., Thousand Oaks, CA, 91360, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
IT 284461-73-0, Sorafenib
(codrug; preparation of heterocyclic amino ester derivs. as protein tyrosine kinase and signal transduction modulators useful in treatment of hyperproliferative disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 80 OF 390 USPATFULL on STN
AN 2010:262915 USPATFULL
TI Gene Expression Profiles and Methods of Use
IN Taylor, Ian, Madison, CT, UNITED STATES
Bigwood, Douglas, Madison, CT, UNITED STATES
PA SIEMENS HEALTHCARE DIAGNOSTICS INC., Tarrytown, NY, UNITED STATES (U.S. corporation)
PI US 20100233680 A1 20100916
AI US 2006-92987 A1 20061110 (12)
WO 2006-US43855 20061110
20100604 PCT 371 date
PRAI US 2005-735581P 20051112 (60)
DT Utility
FS APPLICATION
LREP SIEMENS CORPORATION, INTELLECTUAL PROPERTY DEPARTMENT, 170 WOOD AVENUE SOUTH, ISELIN, NJ, 08830, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer.
IT 284461-73-0, Sorafenib
(determining response to; genetic markers for assessing response of patient to treatment with antitumor agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 81 OF 390 USPATFULL on STN
AN 2010:255321 USPATFULL
TI SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL
IN Brennan, Anthony B., Gainesville, FL, UNITED STATES
Long, Christopher James, Titusville, FL, UNITED STATES
Bagan, Joseph W., Greenwood Village, CO, UNITED STATES
Schumacher, James Frederick, Cumming, GA, UNITED STATES
Spiecker, Mark M., Denver, CO, UNITED STATES
PA UNIVERSITY OF FLORIDA, Gainesville, FL, UNITED STATES (U.S. corporation)
PI US 20100226943 A1 20100909
AI US 2009-550870 A1 20090831 (12)
RLI Continuation-in-part of Ser. No. US 2006-567103, filed on 5 Dec 2006, Pat. No. US 7650848 Continuation-in-part of Ser. No. US 2005-202532, filed on 12 Aug 2005, Pat. No. US 7143709 Continuation-in-part of Ser. No. US 2004-780424, filed on 17 Feb 2004, Pat. No. US 7117807
DT Utility
FS APPLICATION
LREP CANTOR COLBURN, LLP, 20 Church Street, 22nd Floor, Hartford, CT, 06103, US
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 5532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein is an article that includes a first plurality of spaced features. The spaced features are arranged in a plurality of groupings; the groupings of features include repeat units; the spaced features within a grouping are spaced apart at an average distance of about 1 nanometer to about 500 micrometers; each feature having a surface that is substantially parallel to a surface on a neighboring feature; each feature being separated from its neighboring feature; the groupings of features being arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20.
IT 3795-88-8, Levofuraltadone
(Surface topogs. for non-toxic bioadhesion control)
RN 3795-88-8 USPATFULL
CN 2-Oxazolidinone, 5-(4-morpholinylmethyl)-3-[[(5-nitro-2-furanyl)methylene]amino]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L20 ANSWER 82 OF 390 USPATFULL on STN
AN 2010:249926 USPATFULL
TI PREVENTION OF SURGICAL ADHESIONS
IN Puder, Mark, Medfield, MA, UNITED STATES
Greene, Arin K., Wellesley, MA, UNITED STATES
PA CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA, UNITED STATES (U.S. corporation)
PI US 20100222371 A1 20100902
AI US 2009-620665 A1 20091118 (12)
PRAI US 2008-116546P 20081120 (61)
US 2008-116860P 20081121 (61)
DT Utility
FS APPLICATION
LREP DAVID S. RESNICK, NIXON PEABODY LLP, 100 SUMMER STREET, BOSTON, MA, 02110-2131, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans wherein an individual is administered a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib. The invention applies to human and veterinary applications. The inventive method has been shown to be especially effective in preventing adhesion formation in the peritoneum following surgery.
IT 284461-73-0, Sorafenib
(method for minimization or prevention of adhesion formation during or following a surgical procedure)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 83 OF 390 USPATFULL on STN
AN 2010:248804 USPATFULL
TI AGENTS AND METHODS FOR TREATMENT OF CANCER
IN BENDER, Robert, Ottawa, CANADA
GRAHAM, Charles H., Battersea, CANADA
COPPLE, Christine D., Potomac, MD, UNITED STATES
PI US 20100221247 A1 20100902
AI US 2009-569289 A1 20090929 (12)
PRAI US 2008-100825P 20080929 (61)
US 2009-177845P 20090513 (61)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, LLP, FLOOR 30, SUITE 3000, ONE POST OFFICE SQUARE,
BOSTON, MA, 02109, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-3
DRWN No Drawings
LN.CNT 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes compositions that are useful for the treatment, prevention and/or amelioration of cancer.
IT 284461-73-0, Sorafenib
(agents and methods for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 84 OF 390 USPATFULL on STN
AN 2010:248803 USPATFULL
TI METHODS AND COMPOSITIONS FOR TREATING CANCER
IN Goydos, James S., East Brunswick, NJ, UNITED STATES
Chen, Suzie, Highland Park, NJ, UNITED STATES
PA UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, New Brunswick, NJ, UNITED STATES (U.S. corporation)
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ, UNITED STATES (U.S. corporation)
PI US 20100221246 A1 20100902
AI US 2009-560119 A1 20090915 (12)
RLI Continuation-in-part of Ser. No. US 2007-855890, filed on 14 Sep 2007, Pat. No. US 7691377 Continuation-in-part of Ser. No. US 2005-91076, filed on 28 Mar 2005, Pat. No. US 7385103
PRAI US 2008-97029P 20080915 (61)
US 2005-649022P 20050201 (60)
US 2004-563131P 20040416 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor.
IT 284461-73-0, Sorafenib
(methods and compns. for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 85 OF 390 USPATFULL on STN
AN 2010:220820 USPATFULL
TI AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER
IN Hitoshi, Yasumichi, Brisbane, CA, UNITED STATES
Holland, Sacha, San Francisco, CA, UNITED STATES
Payan, Donald G., Hillsborough, CA, UNITED STATES
PA RIGEL PHARMACEUTICALS, INC., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20100196511 A1 20100805
AI US 2010-688746 A1 20100115 (12)
PRAI US 2009-145448P 20090116 (61)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 6101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.
IT 284461-73-0, Sorafenib
(axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 86 OF 390 USPATFULL on STN
AN 2010:214239 USPATFULL
TI MORPHOLINYL ANTHRACYCLINE DERIVATIVE COMBINED WITH PROTEIN KINASE INHIBITORS
IN Geroni, Maria Cristina, Milan, ITALY
Valota, Olga, Legnano, ITALY
Ballinari, Dario, San Donato Milanese, ITALY
Marsiglio, Aurelio, Saronno, ITALY
PA NERVIANO MEDICAL SCIENCES S.R.L., Nerviano (MI), ITALY (non-U.S. corporation)
PI US 20100190736 A1 20100729
AI US 2008-671246 A1 20080723 (12)
WO 2008-EP59621 20080723
20100309 PCT 371 date
PRAI EP 2007-113731 20070802
DT Utility
FS APPLICATION
LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 447
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

##STR1##
IT 284461-73-0, Sorafenib
(morpholinyl anthracycline derivative combined with protein kinase inhibitors for treatment of tumors and other proliferative disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 87 OF 390 USPATFULL on STN
AN 2010:213279 USPATFULL
TI PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL KIT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
IN Bolondi, Luigi, Bologna, ITALY
Giovannini, Catia, Bologna, ITALY
Chieco, Pasquale, San Lazzaro Di Savena, ITALY
Marcu, Kenneth, Stony Brook, NY, UNITED STATES
PI US 20100189775 A1 20100729
AI US 2007-452825 A1 20070725 (12)
WO 2007-IB52957 20070725
20100317 PCT 371 date
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA,
22203, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 855
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides pharmaceutical compositions for the treatment of hepatocellular carcinoma (HCC) comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof.
IT 284461-73-0, Sorafenib
(Notch3 inhibitor composition and pharmaceutical kit for the treatment of hepatocellular carcinoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 88 OF 390 USPATFULL on STN
AN 2010:213277 USPATFULL
TI 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
IN Mortimore, Michael, Oxfordshire, UNITED KINGDOM
Young, Stephen Clinton, Oxfordshire, UNITED KINGDOM
Lorrie Everitt, Simon Robert, Oxfordshire, UNITED KINGDOM
Knegtel, Ronald, Oxfordshire, UNITED KINGDOM
Pinder, Joanne Louise, Oxfordshire, UNITED KINGDOM
Rutherford, Alistair Peter, Oxfordshire, UNITED KINGDOM
Durrant, Steven, Oxfordshire, UNITED KINGDOM
Brenchley, Guy, Oxfordshire, UNITED KINGDOM
Charrier, Jean-Damien, Oxfordshire, UNITED KINGDOM
O'Donnell, Michael, Oxfordshire, UNITED KINGDOM
PI US 20100189773 A1 20100729
AI US 2007-448489 A1 20071221 (12)
WO 2007-US26190 20071221
20091110 PCT 371 date
PRAI US 2006-876307P 20061221 (60)
US 2007-922291P 20070406 (60)
US 2007-947707P 20070703 (60)
US 2007-989014P 20071119 (60)
DT Utility
FS APPLICATION
LREP Jonathan P. O''Brien, Ph.D., Honigman Miller Schwartz and Cohn, 350 East Michigan Avenue, Suite 300, KALAMAZOO, MI, 49007, US
CLMN Number of Claims: 91
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
IT 284461-73-0, BAY 43-9006
(coadministration; preparation of cyanopyrrolopyridinylpyrimidines as polo-like kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 89 OF 390 USPATFULL on STN
AN 2010:213185 USPATFULL
TI Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer
IN Sicard, Helene, Marseille, FRANCE
PA INNATE PHARMA S.A., Marseille, FRANCE (non-U.S. corporation)
PI US 20100189681 A1 20100729
AI US 2008-601628 A1 20080521 (12)
WO 2008-IB2197 20080521
20091222 PCT 371 date
PRAI US 2007-941441P 20070601 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO Box 142950, GAINESVILLE, FL, 32614, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-68
DRWN 7 Drawing Page(s)
LN.CNT 2483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention therefore provides novel approaches and strategies for efficient regulation of γδ T cells in vivo, in a subject, particularly a human subject or a non-human primate. The present invention now discloses particular compositions and methods that can be used to induce the proliferation of γδ T cells in vivo, in a subject. These compositions and methods employ the conjoint treatment of an individual with a γδ T cell activating compound and IL-2 and are particularly suited for immunotherapy in a subject, particularly in a subject having a cancer or an infectious disease.
IT 284461-73-0, Sorafenib
(improved methods of using phosphoantigens for the treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 90 OF 390 USPATFULL on STN
AN 2010:208208 USPATFULL
TI ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
IN Singh, Juswinder, Ashland, MA, UNITED STATES
Petter, Russell Colyn, Stow, MA, UNITED STATES
Niu, Dequiang, Lexington, MA, UNITED STATES
PA Avila Therapeutics, Inc., Waltham, MA, UNITED STATES (U.S. corporation)
PI US 20100185419 A1 20100722
AI US 2009-554433 A1 20090904 (12)
PRAI US 2008-94782P 20080905 (61)
DT Utility
FS APPLICATION
LREP McDermott Will & Emery, 600 13th Street, NW,
Washington, DC, 20005-3096,
US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is an algorithm and method for designing an inhibitor that covalently binds a target polypeptide. The algorithm and method can be used to rapidly and efficiently convert reversible inhibitors into irreversible inhibitors.
IT 284461-73-0DP, derivs.
(as irreversible inhibitors of c-kit kinase; rational design of irreversible inhibitors of target proteins binding cysteine residues adjacent to ligand-binding domain for drug use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 91 OF 390 USPATFULL on STN
AN 2010:206520 USPATFULL
TI NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT
IN Desai, Neil P., Los Angelea, CA, UNITED STATES
Soon-Shiong, Patrick, Los Angeles, CA, UNITED STATES
Trieu, Vuong, Calabasas, CA, UNITED STATES
PI US 20100183728 A1 20100722
AI US 2008-530188 A1 20080307 (12)
WO 2008-US3096 20080307
20100304 PCT 371 date
PRAI US 2007-905735P 20070307 (60)
US 2007-905767P 20070307 (60)
US 2007-905669P 20070307 (60)
US 2007-905787P 20070307 (60)
US 2007-905662P 20070307 (60)
US 2007-905750P 20070307 (60)
US 2007-905672P 20070307 (60)
US 2007-905663P 20070307 (60)
US 2007-905734P 20070307 (60)
US 2007-923248P 20070413 (60)
US 2007-923456P 20070413 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
IT 284461-73-0, Sorafenib
(nanoparticle comprising rapamycin and albumin as anticancer agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 92 OF 390 USPATFULL on STN
AN 2010:194230 USPATFULL
TI TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPIES
IN Drygin, Denis, San Diego, CA, UNITED STATES
Anderes, Kenna, San Diego, CA, UNITED STATES
Ho, Caroline B., Valley Center, CA, UNITED STATES
Bliesath, Joshua R., Escondido, CA, UNITED STATES
Proffitt, Christopher B., Poway, CA, UNITED STATES
O'Brien, Sean, Carlsbad, CA, UNITED STATES
Rice, William G., Del Mar, CA, UNITED STATES
PI US 20100173013 A1 20100708
AI US 2010-684053 A1 20100107 (12)
RLI Continuation-in-part of Ser. No. WO 2009-US46948, filed on 10 Jun 2009, PENDING
PRAI US 2009-143282P 20090108 (61)
US 2009-228121P 20090723 (61)
US 2009-262079P 20091117 (61)
DT Utility
FS APPLICATION
LREP COOLEY LLP, ATTN: Patent Group, Suite 1100, 777 - 6th Street, NW, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 3336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.
IT 284461-73-0, Sorafenib
(treatment of neoplastic disorders using combination therapies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 93 OF 390 USPATFULL on STN
AN 2010:188373 USPATFULL
TI DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS
IN Singh, Sharat, Rancho Santa Fe, CA, UNITED STATES
Harvey, Jeanne, Livermore, CA, UNITED STATES
Kim, Phillip, Irvine, CA, UNITED STATES
Liu, Xinjun, San Diego, CA, UNITED STATES
Liu, Limin, San Diego, CA, UNITED STATES
Barham, Robert, San Marcos, CA, UNITED STATES
Neri, Bruce, Carlsbad, CA, UNITED STATES
PA Prometheus Laboratories, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20100167945 A1 20100701
AI US 2009-511017 A1 20090728 (12)
RLI Continuation of Ser. No. WO 2009-US35013, filed on 24 Feb 2009, PENDING
PRAI US 2008-140558P 20081223 (61)
US 2008-117908P 20081125 (61)
US 2008-108384P 20081024 (61)
US 2008-106404P 20081017 (61)
US 2008-31319P 20080225 (61)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 7427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
IT 284461-73-0, Sorafenib
(drug selection for breast cancer therapy using antibody-based arrays)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 94 OF 390 USPATFULL on STN
AN 2010:188367 USPATFULL
TI MULTIGENE ASSAY TO PREDICT OUTCOME IN AN INDIVIDUAL WITH GLIOBLASTOMA
IN Aldape, Kenneth, Houston, TX, UNITED STATES
Colman, Howard, Houston, TX, UNITED STATES
Zhang, Li, Bellaire, TX, UNITED STATES
PI US 20100167939 A1 20100701
AI US 2008-529628 A1 20080229 (12)
WO 2008-US55472 20080229
20100114 PCT 371 date
PRAI US 2007-892825P 20070302 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100,
HOUSTON, TX,
77010-3095, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 5162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns prognosis for glioblastoma and/or assessment of the response of an individual to therapy for glioblastoma treatment. In particular, expression analysis of two or more specific genes provided in the invention is determined to predict outcome for the individual and/or to predict if the individual will respond to therapy, such as chemoradiation, for example. In specific embodiments, a multigene set from a sample from the individual is compared to a reference set of housekeeping genes.
IT 284461-73-0, Sorafenib
(in therapy of glioblastoma, selection of; gene expression profiling of glioblastoma in diagnosis, prognosis, and selection of therapies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 95 OF 390 USPATFULL on STN
AN 2010:187754 USPATFULL
TI Quantitative Assays for Ras p21 in Body Fluids
IN Carney, Walter P., North Andover, MA, UNITED STATES
Hamer, Peter J., Reading, MA, UNITED STATES
Pierce, Karen, Action, MA, UNITED STATES
Brown-Shimer, Sheryl, Boston, MA, UNITED STATES
PI US 20100167324 A1 20100701
AI US 2006-917471 A1 20060623 (11)
WO 2006-US24647 20060623
20100315 PCT 371 date
PRAI US 2005-694082P 20050623 (60)
DT Utility
FS APPLICATION
LREP SIEMENS CORPORATION, INTELLECTUAL PROPERTY DEPARTMENT, 170 WOOD AVENUE SOUTH, ISELIN, NJ, 08830, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1728
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.
IT 284461-73-0, BAY 43-9006
(ELISA development and characterization to measure serial changes in total ras p21 levels in body fluids for diagnostic/prognostic use in preneoplastic/neoplastic diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 96 OF 390 USPATFULL on STN
AN 2010:187130 USPATFULL
TI PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS
IN Thompson, Neil Thomas, Cambridge, UNITED KINGDOM
Boyle, Robert George, Cambridge, UNITED KINGDOM
Collins, Ian, Sutton, UNITED KINGDOM
Garrett, Michelle Dawn, Sutton, UNITED KINGDOM
Lyons, John Francis, Cambridge, UNITED KINGDOM
Thompson, Kyla Merriom, Cambridge, UNITED KINGDOM
PA ASTEX THERAPEUTICS LIMITED, Cambridge, UNITED KINGDOM (non-U.S. corporation)
CANCER RESEARCH TECHNOLOGY LIMITED, London, UK (non-U.S. corporation)
PI US 20100166699 A1 20100701
AI US 2006-993823 A1 20060621 (11)
WO 2006-GB2297 20060621
20100309 PCT 371 date
PRAI US 2005-693315P 20050623 (60)
US 2005-693367P 20050623 (60)
US 2005-693314P 20050623 (60)
US 2005-693492P 20050623 (60)
US 2005-693309P 20050623 (60)
DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203, US
CLMN Number of Claims: 130
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R.sup.1 and NR.sup.2R.sup.3 and a maximum chain length of 4 atoms extending between E and NR.sup.2R.sup.3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR.sup.2R.sup.3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR.sup.2R.sup.3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R is an aryl or heteroaryl group; and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.

##STR1##
IT 475207-59-1, Nexavar
(codrug; preparation of pyrazole derivs. as protein kinase modulators useful as anticancer agents in combination chemotherapy)
RN 475207-59-1 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 97 OF 390 USPATFULL on STN
AN 2010:178499 USPATFULL
TI KLOTHO BETA
IN Desnoyers, Luc, San Francisco, CA, UNITED STATES
PI US 20100158914 A1 20100624
AI US 2008-594443 A1 20080401 (12)
WO 2008-US59032 20080401
20100223 PCT 371 date
PRAI US 2007-916187P 20070504 (60)
US 2007-909699P 20070402 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 7306
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4.
IT 284461-73-0, Sorafenib
(co-treatment with; Klotho β interaction with fibroblast growth factor 19 and fibroblast growth factor receptor type 4 and the use of this interaction as a therapeutic and/or diagnostic target)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 98 OF 390 USPATFULL on STN
AN 2010:171078 USPATFULL
TI PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS
IN DUMAS, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PI US 20100152251 A1 20100617
AI US 2010-692845 A1 20100125 (12)
RLI Division of Ser. No. US 2007-775457, filed on 10 Jul 2007, Pat. No. US 7678811 Continuation of Ser. No. US 2003-361850, filed on 11 Feb 2003, ABANDONED
PRAI US 2002-354935P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1-35
DRWN No Drawings
LN.CNT 2027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
IT 284461-73-0
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-74-1P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-03-3P 583840-04-4P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



L20 ANSWER 99 OF 390 USPATFULL on STN
AN 2010:169774 USPATFULL
TI ANTI-IGF ANTIBODIES
IN ADAM, Paul, Vienna, AUSTRIA
BORGES, Eric, Maria Enzersdorf, AUSTRIA
PA BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Ingelheim am Rhein, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100150940 A1 20100617
AI US 2009-636195 A1 20091211 (12)
PRAI EP 2008-171554 20081212
DT Utility
FS APPLICATION
LREP MICHAEL P. MORRIS, BOEHRINGER INGELHEIM USA CORPORATION, 900 RIDGEBURY RD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 2824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
IT 284461-73-0, Sorafenib
(combination therapy with; human anti-insulin-like growth factor antibodies and their use to treat cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



=> d l20 100-199 bib,ab,hitstr

L20 ANSWER 100 OF 390 USPATFULL on STN
AN 2010:169753 USPATFULL
TI CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES
IN Appleton, Brent A., San Francisco, CA, UNITED STATES
Wiesmann, Christian, Bottmingen, SWITZERLAND
Wu, Yan, Foster City, CA, UNITED STATES
PI US 20100150919 A1 20100617
AI US 2007-598625 A1 20070517 (12)
WO 2007-US69185 20070517
20100225 PCT 371 date
DT Utility
FS APPLICATION
LREP Arnold & Porter LLP (24126), Attn: IP Docketing Dept., 555 Twelfth
Street, N.W., Washington, DC, 20004-1206, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications.
IT 284461-73-0, Sorafenib
(anti-neuropilin antibodies and chemotherapy for cancer therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 101 OF 390 USPATFULL on STN
AN 2010:169730 USPATFULL
TI DIAMINOQUINAZOLINE INHIBITORS OF DIHYDROFOLATE REDUCTASE
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
Sarshar, Sepehr, Cardiff by the Sea, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100150896 A1 20100617
AI US 2009-636517 A1 20091211 (12)
PRAI US 2008-121965P 20081212 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new diaminoquinazoline inhibitors of dihydrofolate reductase activity, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(diaminoquinazoline compds. for treatment of dihydrofolate reductase-mediated disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 102 OF 390 USPATFULL on STN
AN 2010:162726 USPATFULL
TI TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS
IN Wilhelm, Scott, Morristown, NJ, UNITED STATES
Richard, Gedrich, Louisville, CO, UNITED STATES
PI US 20100144749 A1 20100610
AI US 2006-93515 A1 20061114 (12)
WO 2006-US44237 20061114
20081113 PCT 371 date
PRAI US 2005-735852P 20051114 (60)
US 2006-787692P 20060331 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.
IT 284461-73-0P, Sorafenib
(sorafenib for treatment of cancer with acquired resistance to KIT tyrosine kinase inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1, Sorafenib tosylate
(sorafenib for treatment of cancer with acquired resistance to KIT tyrosine kinase inhibitor)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-74-1P
(sorafenib for treatment of cancer with acquired resistance to KIT tyrosine kinase inhibitor)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 103 OF 390 USPATFULL on STN
AN 2010:161439 USPATFULL
TI PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR
IN Liepold, Bernd, Dossenheim, GERMANY, FEDERAL REPUBLIC OF
Rosenberg, Jorg, Ellerstadt, GERMANY, FEDERAL REPUBLIC OF
Knobloch, Martin, Neuhofen, GERMANY, FEDERAL REPUBLIC OF
Nehen, Christian, Hassloch, GERMANY, FEDERAL REPUBLIC OF
PA ABBOTT GMBH & CO. KG, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100143459 A1 20100610
AI US 2007-447488 A1 20071108 (12)
WO 2007-EP62101 20071108
20100122 PCT 371 date
PRAI EP 2006-23367 20061109
US 2007-999579P 20071019 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.
IT 284461-73-0, Sorafenib
(pharmaceutical oral dosage form of tyrosine kinase inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 104 OF 390 USPATFULL on STN
AN 2010:161437 USPATFULL
TI Extended soluble PH20 polypeptides and uses thereof
IN Wei, Ge, San Diego, CA, UNITED STATES
Selvam, Krishnasamy Panneer, Poway, CA, UNITED STATES
Bookbinder, Louis, San Diego, CA, UNITED STATES
Frost, Gregory I., Del Mar, CA, UNITED STATES
PI US 20100143457 A1 20100610
AI US 2009-653245 A1 20091209 (12)
PRAI US 2009-281240P 20091113 (61)
US 2008-201384P 20081209 (61)
DT Utility
FS APPLICATION
LREP K&L Gates LLP, 3580 Carmel Mountain Road, Suite 200, San Diego, CA, 92130, US
CLMN Number of Claims: 89
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 6880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
IT 284461-73-0D, Sorafenib, derivs.
(combination with PH20 hyaluronidase derivs.; soluble C-terminal truncation derivs. of PH20 hyaluronidase for use in hyaluronan degradation in improving drug access to targets)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 105 OF 390 USPATFULL on STN
AN 2010:161334 USPATFULL
TI TRIAZINE DNA MODIFIERS
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
Sarshar, Sepehr, Cardiff by the Sea, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100143354 A1 20100610
AI US 2009-630897 A1 20091204 (12)
PRAI US 2008-119934P 20081204 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new triazine DNA modifiers, pharmaceutical compositions thereof, and methods of use thereof

##STR1##

IT 284461-73-0, Sorafenib
(triazine DNA modifiers, composition comprising same and therapeutical uses thereof)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 106 OF 390 USPATFULL on STN
AN 2010:161320 USPATFULL
TI METHODS AND COMPOSITIONS FOR TREATING CANCER
IN Kolhe, Parag, Chesterfield, MO, UNITED STATES
Radhakrishnan, Vinay, Thousand Oaks, CA, UNITED STATES
Witchey-Lakshmanan, Leonore, Piscataway, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20100143340 A1 20100610
AI US 2007-518405 A1 20071211 (12)
WO 2007-US25321 20071211
20100224 PCT 371 date
PRAI US 2006-874641P 20061213 (60)
US 2007-972504P 20070914 (60)
US 2007-974241P 20070921 (60)
US 2007-979269P 20071011 (60)
DT Utility
FS APPLICATION
LREP MERCK, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 3168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for preventing or treating a medical disorder in a subject comprising administering to the subject an effective amount of a stable pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof.
IT 284461-73-0, Sorafenib
(codrug; methods and compns. for treating cancer and other disorders with an anti-IGF1 receptor antibody or antigen-binding fragment thereof)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 107 OF 390 USPATFULL on STN
AN 2010:161276 USPATFULL
TI PODOPHYLLOTOXIN INHIBITORS OF TOPOISOMERASE II
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100143296 A1 20100610
AI US 2009-634947 A1 20091210 (12)
PRAI US 2008-121256P 20081210 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(deuterated podophyllotoxin compds. as topoisomerase II inhibitors useful in mono- and combination therapy of topoisomerase II-mediated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 108 OF 390 USPATFULL on STN
AN 2010:161275 USPATFULL
TI QUINAZOLINE INHIBITORS OF EGFR TYROSINE KINASE
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
Sarshar, Sepehr, Cardiff by the Sea, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100143295 A1 20100610
AI US 2009-631334 A1 20091204 (12)
PRAI US 2008-120118P 20081205 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new quinazoline inhibitors of EGFR tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(novel quinazoline compds. as EGFR tyrosine kinase inhibitors useful in prophylaxis, mono- and combination therapy of cancers, non-malignant neoplasms and other EGFR tyrosine kinase-mediated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 109 OF 390 USPATFULL on STN
AN 2010:153106 USPATFULL
TI STEROID MODULATORS OF PROGESTERONE RECEPTOR AND/OR GLUCOCORTICOID RECEPTOR
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
Shahbaz, Manouchehr, San Diego, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100135956 A1 20100603
AI US 2009-623593 A1 20091123 (12)
PRAI US 2008-116850P 20081121 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(steroid modulators of progesterone receptor and/or glucocorticoid receptor for therapeutic use alone or in combination)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 110 OF 390 USPATFULL on STN
AN 2010:146163 USPATFULL
TI USE OF PLASMA HSP90 RELATED TO MALIGNANCY
IN Sausville, Edward A., Silver Spring, MD, UNITED STATES
Burger, Angelika M., Baltimore, MD, UNITED STATES
PA University of Maryland Balitmore, Baltimore, MD, UNITED STATES (U.S. corporation)
PI US 20100129829 A1 20100527
AI US 2007-515770 A1 20071126 (12)
WO 2007-US85529 20071126
20091231 PCT 371 date
PRAI US 2006-861166P 20061127 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX,
77010-3095, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.
IT 284461-73-0, Sorafenib
(Hsp90 for cancer therapy monitoring and for diagnosis and/or prognostication of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 111 OF 390 USPATFULL on STN
AN 2010:145717 USPATFULL
TI ANTI-FGF19 ANTIBODIES AND METHODS USING SAME
IN DESNOYERS, Luc, San Francisco, CA, UNITED STATES
French, Dorothy, San Carlos, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20100129381 A1 20100527
US 7846691 B2 20101207
AI US 2010-692468 A1 20100122 (12)
RLI Division of Ser. No. US 2007-673411, filed on 9 Feb 2007, Pat. No. US 7678373
PRAI US 2007-885866P 20070119 (60)
US 2006-780608P 20060309 (60)
US 2006-772310P 20060210 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1-101
DRWN 28 Drawing Page(s)
LN.CNT 6275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
IT 284461-73-0, Sorafenib
(in combination therapy with antibody to human fibroblast growth factor 19)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 112 OF 390 USPATFULL on STN
AN 2010:145652 USPATFULL
TI Anti-MN Antibodies and Methods of Using Same
IN Tamburini, Paul, Kensington, CT, UNITED STATES
Hamden, Gerald Ranges, Hamden, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
McCabe, Timothy, Branford, CT, UNITED STATES
Trail, Pamela, Edmonds, WA, UNITED STATES
Ha, Sha, Lansdale, PA, UNITED STATES
PA Bayer Healthcare LLC, Tarrytown, NY, UNITED STATES (U.S. corporation)
PI US 20100129315 A1 20100527
AI US 2006-86320 A1 20061212 (12)
WO 2006-US47445 20061212
20091123 PCT 371 date
PRAI US 2005-749716P 20051212 (60)
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents
& Licensing, Bayer HealthCare LLC -
Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY,
10591, US
CLMN Number of Claims: 91
ECL Exemplary Claim: 1
DRWN 49 Drawing Page(s)
LN.CNT 4596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.
IT 284461-73-0, Sorafenib
(human anti-human MN protein antibody Fab fragments and immunoconjugates for diagnosis and treatment of cancer or other MN protein-related disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 113 OF 390 USPATFULL on STN
AN 2010:126490 USPATFULL
TI Evaluating RTK Target Drugs
IN Davis, Darren W., Houston, TX, UNITED STATES
PA Apocell, Inc, Houston, TX, UNITED STATES (U.S. corporation)
PI US 20100112617 A1 20100506
AI US 2008-532396 A1 20080307 (12)
WO 2008-US56208 20080307
20100111 PCT 371 date
PRAI US 2007-895981P 20070320 (60)
DT Utility
FS APPLICATION
LREP BAKER & MCKENZIE LLP, Pennzoil Place, South Tower, 711 Louisiana, Suite
3400, HOUSTON, TX, 77002-2716, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of evaluating receptor tyrosine kinase drug efficacy are demonstrated. The methods generally relate to evaluation methods using phospho-RTK over total RTK ratio (pRTK/tRTK). An algorithm is provided that allows the user to combine the pRTK/tRTK ratios from several kinase together with other kinds of measurements to obtain a PDX value that is indicative of drug efficacy.
IT 284461-73-0, Sorafenib
(receptor tyrosine kinase target drug evaluation method)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 114 OF 390 USPATFULL on STN
AN 2010:125805 USPATFULL
TI Methods and Compositions for Detecting Receptor Ligand Mimetics
IN Khazak, Vladimir, Brooklyn, NY, UNITED STATES
Weber, Lutz, Germering, GERMANY, FEDERAL REPUBLIC OF
PA ALPHAPTOSE GMBH, Hamburg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20100111930 A1 20100506
AI US 2007-514328 A1 20071109 (12)
WO 2007-EP62177 20071109
20091229 PCT 371 date
PRAI US 2006-858033P 20061110 (60)
DT Utility
FS APPLICATION
LREP K&L Gates LLP, P.O. Box 1135, CHICAGO, IL, 60690, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1-36
DRWN 3 Drawing Page(s)
LN.CNT 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method to determine the utility of small molecules as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biological assays on a systematic array of compounds, comprising known protein receptor ligands and other biologically active molecules to determine if a proposed small molecule is a functional equivalent of a receptor ligand, having therapeutic utility as a pharmaceutically relevant and useful agent either alone or in combination with other molecules.
IT 284461-73-0, Sorafenib
(methods and compns. for detecting receptor ligand mimetics)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 115 OF 390 USPATFULL on STN
AN 2010:125776 USPATFULL
TI TRIAZOLE INHIBITORS OF AROMATASE
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
Sarshar, Sepehr, Cardiff by the Sea, CA, UNITED STATES
Shahbaz, Manouchehr M., San Diego, CA, UNITED STATES
PA AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20100111901 A1 20100506
AI US 2009-611278 A1 20091103 (12)
PRAI US 2008-110820P 20081103 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new triazole modulators of aromatase activity, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(methods and compostions containing triazole compds. for treatment of aromatase-mediated disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 116 OF 390 USPATFULL on STN
AN 2010:118101 USPATFULL
TI METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR
IN Matsui, Junji, Ibaraki, JAPAN
Semba, Taro, Ibaraki, JAPAN
PA Esai R & D Management Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20100105031 A1 20100429
AI US 2006-997543 A1 20060801 (11)
WO 2006-JP315563 20060801
20080131 PCT 371 date
PRAI JP 2005-223440 20050801
DT Utility
FS APPLICATION
LREP DICKSTEIN SHAPIRO LLP, 1633 Broadway, NEW YORK, NY, 10019, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a method for the prediction of the efficacy of a vascularization inhibitor. In the method, the anti-tumor effect of a vascularization inhibitor can be predicted by measuring the number of blood vessels surrounded by pericytes in a tumor and using the measurement value as a measure for the anti-tumor effect.
IT 284461-73-0
(method for predicting antitumor efficacy of angiogenesis inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 117 OF 390 USPATFULL on STN
AN 2010:117731 USPATFULL
TI BENZOPYRANOPYRAZOLES
IN Vennemann, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Lindenmaier, Andreas, Steinen-Holistein, GERMANY, FEDERAL REPUBLIC OF
Braunger, Jurgen, Modling, AUSTRIA
Boehm, Markus, Rheinfelden, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Muhltal, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20100104659 A1 20100429
AI US 2007-373433 A1 20070712 (12)
WO 2007-EP57195 20070712
20090928 PCT 371 date
PRAI EP 2006-117124 20060713
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I, in which Ra, Rb and Rc have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.
IT 284461-73-0
(preparation of benzopyranopyrazole derivs. as Eg5 inhibitors, antiproliferative and apoptosis-inducing agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 118 OF 390 USPATFULL on STN
AN 2010:111977 USPATFULL
TI Use of Endothelial Interrupters in the Treatment of Neurodegenerative Diseases
IN Grammas, Paula, Lubbock, TX, UNITED STATES
Schiffer, Randolph B., Las Vegas, NV, UNITED STATES
PA Texas Tech University System, Lubbock, TX, UNITED STATES (U.S. corporation)
PI US 20100099731 A1 20100422
AI US 2009-571146 A1 20090930 (12)
PRAI US 2008-101886P 20081001 (61)
DT Utility
FS APPLICATION
LREP Roman Aguilera III, TTUS Office of Technology Commercialization, Box 42007, Lubbock, TX, 79409-2007, US
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In various embodiments, the present invention relates generally to methods of treating at least one neurodegenerative disease by administering a medicament comprising an endothelial interrupter.
IT 475207-59-1, Nexavar
(use of thrombin inhibitor as an endothelial interrupter in the treatment of neurodegenerative diseases)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 119 OF 390 USPATFULL on STN
AN 2010:110944 USPATFULL
TI COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT
IN Goh, Kay Lin, Singapore, SINGAPORE
Khng, Hwee Hoon, Singapore, SINGAPORE
Sabanayagam, Vasantha Malar, Johor Bahru, MALAYSIA
Sangthongpitag, Kanda, Singapore, SINGAPORE
Stunkel, Walter, Singapore, SINGAPORE
Tan, Yong Cheng, Singapore, SINGAPORE
Wood, Jeanette Marjorie, Singapore, SINGAPORE
PA S'BIO PTE LTD, SINGAPORE SCIENCE PARK 11, SINGAPORE (non-U.S. corporation)
PI US 20100098691 A1 20100422
AI US 2008-530050 A1 20080307 (12)
WO 2008-SG74 20080307
20091119 PCT 371 date
PRAI US 2001-9768870 20010124
US 2007-905293P 20070307 (60)
US 2007-905299P 20070307 (60)
DT Utility
FS APPLICATION
LREP CONNOLLY BOVE LODGE & HUTZ LLP, 1875 EYE STREET, N.W., SUITE 1100,
WASHINGTON, DC, 20006, US
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition for the treatment of cancer as well as methods of treatment of cancer that are based on the finding that certain benzimidazole based anti-cancer agents can be used in combination with a second anti-cancer agent to achieve desirable therapeutic outcomes. More specifically the present invention relates to a pharmaceutical composition including a benzimidazole based anti-cancer agent and a second anti-cancer agent. The invention also relates to methods of treatment of cancer including administration of a benzimidazole based anti-cancer agent and a second anti-cancer agent to a patient in need thereof.
IT 284461-73-0, Sorafenib
(benzimidazole based anti-cancer agent useful in combination therapy of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 120 OF 390 USPATFULL on STN
AN 2010:110943 USPATFULL
TI PHARMACEUTICAL COMPOSITION
IN Soga, Shiro, Machida-shi, JAPAN
Ishii, Toshihiko, Sunto-gun, JAPAN
Nakashima, Takayuki, Sunto-gun, JAPAN
Shiotsu, Yukimasa, Sunto-gun, JAPAN
Akinaga, Shiro, Sunto-gun, JAPAN
PA KYOWA HAKKO KIRIN CO., LTD., Chiyoda-ku, Tokyo, JAPAN (non-U.S. corporation)
PI US 20100098690 A1 20100422
AI US 2008-529380 A1 20080305 (12)
WO 2008-JP53908 20080305
20090901 PCT 371 date
PRAI JP 2007-53675 20070305
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 1290 Avenue of the Americas, NEW YORK, NY, 10104-3800, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a pharmaceutical composition comprising a combination of an Hsp 90 family protein inhibitor and at least one compound, the said pharmaceutical composition wherein the Hsp 90 family protein inhibitor is a benozoyl compound represented by formula (I):

##STR1##

[wherein n represents an integer of 1 to 5; R.sup.1 represents substituted or unsubstituted lower alkyl, CONR.sup.7R.sup.8 (wherein R.sup.7 and R.sup.8, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like; R.sup.2 represents substituted or unsubstituted aryl, or the like; R.sup.3 and R.sup.5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R.sup.4 represents a hydrogen atom, hydroxy or halogen; and R.sup.6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like], or a prodrug thereof; or a pharmaceutically acceptable salt thereof, and the like.
IT 284461-73-0, Sorafenib
(pharmaceutical compns. containing combination of Hsp90 inhibitors and other active components)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 121 OF 390 USPATFULL on STN
AN 2010:110893 USPATFULL
TI Compositions and Methods for Convection Enhanced Delivery of High Molecular Weight Neurotherapeutics
IN Bankiewicz, Krystof S., Oakland, CA, UNITED STATES
Kunwar, Sandeep, Woodside, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20100098639 A1 20100422
AI US 2009-603384 A1 20091021 (12)
RLI Division of Ser. No. US 2007-740508, filed on 26 Apr 2007, ABANDONED
PRAI US 2006-795371P 20060426 (60)
US 2007-900492P 20070209 (60)
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVENUE, SUITE 200, EAST
PALO ALTO, CA, 94303, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 1697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.
IT 284461-73-0, Sorafenib
(convection-enhanced local delivery of high mol. weight neurotherapeutics for treatment of CNS disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 122 OF 390 USPATFULL on STN
AN 2010:105206 USPATFULL
TI METHODS OF TREATING CANCER
IN LAUGHLIN, MARK, Sunnyvale, CA, UNITED STATES
Anderson, Mark B., Oakland, CA, UNITED STATES
Willardsen, Adam, Salt Lake City, UT, UNITED STATES
Pleiman, Chris, Holladay, UT, UNITED STATES
PA Myriad Pharmaceuticals, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 20100093773 A1 20100415
AI US 2009-574632 A1 20091006 (12)
RLI Continuation of Ser. No. WO 2008-US59910, filed on 10 Apr 2008, PENDING
PRAI US 2007-910944P 20070410 (60)
DT Utility
FS APPLICATION
LREP Myriad PHARMACEUTICALS, Inc., c/o CPA Global, P.O. Box 52050, Minneapolis, MN, 55402, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.
IT 284461-73-0, Sorafenib
(in combination therapy; preparation and use of quinazoline derivative for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 123 OF 390 USPATFULL on STN
AN 2010:105160 USPATFULL
TI COMPOUNDS AND METHODS OF USE
IN Xi, Ning, Thousand Oaks, CA, UNITED STATES
PI US 20100093727 A1 20100415
AI US 2009-576375 A1 20091009 (12)
PRAI US 2008-105414P 20081014 (61)
DT Utility
FS APPLICATION
LREP Ning Xi, 565 Timberwood Ave., Thousand Oaks, CA, 91360, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
IT 284461-73-0, Sorafenib
(codrug; novel compds. as protein tyrosine kinase modulators and modulators of inter- and intra-cellular signaling useful in treatment and prevention of hyperproliferative disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 124 OF 390 USPATFULL on STN
AN 2010:103924 USPATFULL
TI METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR
IN Uenaka, Toshimitsu, Ibaraki, JAPAN
Yamamoto, Yuji, Ibaraki, JAPAN
Matsui, Junji, Ibaraki, JAPAN
PA Eisai R&D Management Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20100092490 A1 20100415
AI US 2006-997719 A1 20060802 (11)
WO 2006-JP315698 20060802
20080228 PCT 371 date
PRAI JP 2005-224173 20050802
JP 2006-164700 20060614
DT Utility
FS APPLICATION
LREP DICKSTEIN SHAPIRO LLP, 1633 Broadway, NEW YORK, NY, 10019, US
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4030
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.
IT 284461-73-0, Sorafenib
(method for assaying anti-tumor effect of angiogenesis inhibitor by evaluating EGF-dependency)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 125 OF 390 USPATFULL on STN
AN 2010:98136 USPATFULL
TI Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
IN Bumcrot, David, Belmont, MA, UNITED STATES
Sah, Dinah Wen-Yee, Boston, MA, UNITED STATES
Toudjarska, Ivanka, Medford, MA, UNITED STATES
PI US 20100087508 A1 20100408
AI US 2009-552207 A1 20090901 (12)
RLI Continuation of Ser. No. WO 2009-US36223, filed on 5 Mar 2009, PENDING
PRAI US 2008-34019P 20080305 (61)
US 2008-83367P 20080724 (61)
US 2008-86381P 20080805 (61)
US 2008-112079P 20081106 (61)
US 2009-150664P 20090206 (61)
DT Utility
FS APPLICATION
LREP ALNYLAM/FENWICK, SILICON VALLEY CENTER, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94041, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 6586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
IT 284461-73-0, Sorafenib
(compns. comprising dsRNA and methods for inhibiting expression of Eg5 and VEGF genes)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 126 OF 390 USPATFULL on STN
AN 2010:98127 USPATFULL
TI PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING TEMOZOLOMIDE AND MULTI-TARGETED KINASE INHIBITORS
IN Wang, Yaolin, Short Hills, NJ, UNITED STATES
Liu, Ming, Fanwood, NJ, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
PA SCHERING CORPORATION, Kenilworth, NJ, UNITED STATES (U.S. corporation)
PI US 20100087499 A1 20100408
AI US 2008-523809 A1 20080128 (12)
WO 2008-US1061 20080128
20091124 PCT 371 date
PRAI US 2007-887245P 20070130 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1-4
DRWN 4 Drawing Page(s)
LN.CNT 863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides formulations, kits and methods useful for treating cell proliferative disorder. In particular, the formulations, kits and methods include temozolomide (TMZ) in combination with a multi-targeted kinase inhibitor.
IT 284461-73-0, Sorafenib
(compns. and methods of using temozolomide and multi-targeted kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 127 OF 390 USPATFULL on STN
AN 2010:97147 USPATFULL
TI TREATMENT OF MELANOMA
IN Heise, Carla C., Benicia, CA, UNITED STATES
Hollenbach, Paul, Castro Valley, CA, UNITED STATES
Menezes, Daniel, Emeryville, CA, UNITED STATES
Pryer, Nancy, Kensington, CA, UNITED STATES
Rendahl, Katherine, Berkeley, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
PA NOVARTIS AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 20100086518 A1 20100408
AI US 2008-530231 A1 20080307 (12)
WO 2008-US56122 20080307
20090908 PCT 371 date
PRAI US 2007-894046P 20070309 (60)
US 2007-911406P 20070412 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

##STR1##
IT 284461-73-0, Sorafenib
(treatment of melanoma with benzimidazolyl quinolinone derivs. and combination with other agents in relation to inhibition of FGF-mediated angiogenesis)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 128 OF 390 USPATFULL on STN
AN 2010:91478 USPATFULL
TI High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
IN Oksenberg, Donna, Palo Alto, CA, UNITED STATES
Sukovich, Drew, Martinez, CA, UNITED STATES
Minami, Tomoe, Dublin, CA, UNITED STATES
Lamerdin, Jane, Livermore, CA, UNITED STATES
Westwick, John K., San Ramon, CA, UNITED STATES
PA Odyssey Thera, Inc., San Ramon, CA, UNITED STATES (U.S. corporation)
PI US 20100081632 A1 20100401
AI US 2009-382066 A1 20090306 (12)
PRAI US 2008-64462P 20080306 (61)
DT Utility
FS APPLICATION
LREP Isaac A. Angres, Suite 304B, 2001 Jefferson Davis Highway, Arlington, VA, 22202, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of assaying protein-protein interactions associated with proteins involved in lipid pathways using a protein fragment complementation assays, said method comprising the steps of: (a) identifying protein molecules that interact with said protein associated with lipid pathways; (b) selecting a protein reporter molecule; (c) effecting fragmentation of said protein reporter molecule such that said fragmentation results in reversible loss of reporter function; (d) fusing or attaching fragments of said protein reporter molecule separately to said interacting protein molecules as defined in step (a); (e) transfecting cells with nucleic acid constructs coding for the products of step (d); (f) reassociating said reporter fragments through interactions of the protein molecules that are fused or attached to said fragments; and (g) measuring directly or Indirectly the activity of said reporter molecule resulting from the reassociation of said reporter fragments.
IT 284461-73-0
(as inhibitor of PCSK9-LDLR interactions; identification of protein interactions in lipid metabolism and screening for therapeutic agents for lipid disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 129 OF 390 USPATFULL on STN
AN 2010:83916 USPATFULL
TI Combinations for the treatment of cancer
IN Chang, David, Calabasas, CA, UNITED STATES
PA Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)
PI US 20100074909 A1 20100325
AI US 2009-592103 A1 20091119 (12)
RLI Continuation of Ser. No. US 2006-386271, filed on 21 Mar 2006, PENDING
PRAI US 2005-664381P 20050322 (60)
DT Utility
FS APPLICATION
LREP AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
IT 284461-73-0 475207-59-1, Nexavar
(combinations for the treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 130 OF 390 USPATFULL on STN
AN 2010:83904 USPATFULL
TI Methods and Compositions related to HIF-1 alpha
IN Huang, Eric L., North Salt Lake, UT, UNITED STATES
PA University of Utah Research Foundation, Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 20100074897 A1 20100325
AI US 2007-517132 A1 20071203 (12)
WO 2007-US86264 20071203
20090710 PCT 371 date
PRAI US 2006-868188P 20061201 (60)
DT Utility
FS APPLICATION
LREP Ballard Spahr LLP, SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 5201
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compositions and methods related to HIF-1α.
IT 284461-73-0, Bay 43-9006 475207-59-1, Sorafenib tosylate
(antibodies and inhibitory nucleic acids for targeing HIF-1α and for diagnosing/treating tumor or metastasis)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 131 OF 390 USPATFULL on STN
AN 2010:83870 USPATFULL
TI N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
IN MAIER, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
BAR, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
BECKERS, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
ZIMMERMANN, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
SCHNEIDER, Siegfried, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
GEKELER, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20100074862 A1 20100325
AI US 2009-628690 A1 20091201 (12)
RLI Division of Ser. No. US 2007-885832, filed on 7 Sep 2007, PENDING A 371 of International Ser. No. WO 2006-EP60712, filed on 14 Mar 2006
PRAI EP 2005-102019 20050315
EP 2005-108735 20050921
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-25
DRWN No Drawings
LN.CNT 7120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of sulfonylpyrrole derivs. as histone deacetylase inhibitors useful in treatment and prevention of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 132 OF 390 USPATFULL on STN
AN 2010:77653 USPATFULL
TI COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
IN Atadja, Peter Wisdom, Acton, CA, UNITED STATES
Shao, Wenlin, Dedham, MA, UNITED STATES
Bhalla, Kapil N., Martinez, GA, UNITED STATES
PI US 20100069458 A1 20100318
AI US 2008-526962 A1 20080213 (12)
WO 2008-US53798 20080213
20090813 PCT 371 date
PRAI US 2007-890005P 20070215 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
IT 284461-73-0, Sorafenib
(combinations of therapeutic agents comprising N-hydroxy-3-[4-[[[2-(2-Me-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 133 OF 390 USPATFULL on STN
AN 2010:76372 USPATFULL
TI COMBINATION WITH BIS (THIOHYDRAZIDE AMIDES) FOR TREATING CANCER
IN Jacobson, Eric, Northborough, MA, UNITED STATES
PA Synta Pharmaceuticals Corp. (U.S. corporation)
PI US 20100068174 A1 20100318
AI US 2007-310273 A1 20070820 (12)
WO 2007-US18354 20070820
20091117 PCT 371 date
PRAI US 2006-839113P 20060821 (60)
DT Utility
FS APPLICATION
LREP Foley & Lardner LLP, 111 HUNTINGTON AVENUE, 26TH FLOOR, BOSTON, MA,
02199-7610, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3133
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are methods of treating an immunosensitive cancer with bis(thio-hydrazide amides) or pharmaceutically-acceptable salts thereof and an immunotherapy.
IT 284461-73-0, Sorafenib
(bis(thiohydrazide amide) combination with immunotherapy for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 134 OF 390 USPATFULL on STN
AN 2010:70488 USPATFULL
TI HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER
IN Smith, Roger, Chester Springs, PA, UNITED STATES
Nagarathnam, Dhanapalan, Bethany, CT, UNITED STATES
PA Bayer Healthcare LLC, Tarrytown, NY, UNITED STATES (U.S. corporation)
PI US 20100063107 A1 20100311
AI US 2007-520609 A1 20071220 (12)
WO 2007-US88365 20071220
20091102 PCT 371 date
PRAI US 2006-875830P 20061220 (60)
US 2007-986773P 20071109 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide and alternative forms thereof (e.g., salts, solvates, hydrates, prodrugs, polymorphs and metabolites); pharmaceutical compositions which contain them; and methods for treating cancer using them.
IT 284461-73-0, BAY 43-9006
(codrug; preparation of novel Ph pyrazolyl ureas for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 135 OF 390 USPATFULL on STN
AN 2010:61774 USPATFULL
TI PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3-[3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]-UREA
IN Curry, Jayne Elizabeth, Cambridge, UNITED KINGDOM
Gallagher, Neil James, Basel, SWITZERLAND
Lyons, John Francis, Cambridge, UNITED KINGDOM
Thompson, Neil Thomas, Cambridge, UNITED KINGDOM
PA ASTEX THERAPEUTICS LIMITED, Cambridge, UNITED KINGDOM (non-U.S. corporation)
PI US 20100055094 A1 20100304
AI US 2007-306479 A1 20070629 (12)
WO 2007-GB2447 20070629
20090629 PCT 371 date
PRAI US 2006-806214P 20060629 (60)
DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1-213
DRWN 12 Drawing Page(s)
LN.CNT 11004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I')

##STR1##

or a salt, solvate, tautomer or N-oxide thereof, wherein R.sup.1, E, A and M are as defined in the claims.
IT 284461-73-0
(claimed auxiliary compound; preparation of benzimidazole derivs. for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 136 OF 390 USPATFULL on STN
AN 2010:54498 USPATFULL
TI COMPOSITION FOR TREATMENT OF UNDIFFERENTIATED GASTRIC CANCER
IN Yamamoto, Yuji, Tsukuba-shi, JAPAN
PI US 20100048620 A1 20100225
AI US 2008-524754 A1 20080128 (12)
WO 2008-JP51697 20080128
20090728 PCT 371 date
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P.O. BOX 770, Church Street Station, New York, NY,
10008-0770, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 5044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2.

##STR1##
IT 284461-73-0, Sorafenib
(composition for treatment of undifferentiated-type of gastric cancer containing
quinoline derivs. in combination with antitumor agent or FGFR2 inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 137 OF 390 USPATFULL on STN
AN 2010:45659 USPATFULL
TI Prostaglandin E2 Binding Proteins and Uses Thereof
IN Gu, Jjijie, Shrewsbury, MA, UNITED STATES
Hutchins, Charles W., Green Oaks, IL, UNITED STATES
Zhu, Rong-rong, Southborough, MA, UNITED STATES
Shen, Jianwei, Lake Bluff, IL, UNITED STATES
Harris, Maria C., Shrewsbury, MA, UNITED STATES
Belanger, Eileen, Northbridge, MA, UNITED STATES
Murtaza, Anwar, Westborough, MA, UNITED STATES
Tarcsa, Edit, Westborough, MA, UNITED STATES
Stine, William B., Shrewsbury, MA, UNITED STATES
Hsieh, Chung-ming, Newton, MA, UNITED STATES
PA ABBOTT LABORATORIES, Abbott Park, IL, UNITED STATES (U.S. corporation)
PI US 20100040537 A1 20100218
AI US 2009-499646 A1 20090708 (12)
PRAI US 2008-134264P 20080708 (61)
US 2008-197258P 20081023 (61)
DT Utility
FS APPLICATION
LREP ABBOTT BIORESEARCH, 100 RESEARCH DRIVE, WORCESTER, MA, 01605-4314, US
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 7753
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses prostaglandin E.sub.2 (PGE.sub.2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E.sub.2 and neutralize prostaglandin E.sub.2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E.sub.2 and for inhibiting prostaglandin E.sub.2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E.sub.2 activity is detrimental.
IT 475207-59-1, Nexavar
(prostaglandin E2 binding antibodies and derivs. and uses thereof)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 138 OF 390 USPATFULL on STN
AN 2010:33260 USPATFULL
TI Methods of Using Phosphoantigen for the Treatment of Cancer
IN Tiollier, Jerome, Marseille, FRANCE
Scard, Helene, Marseille, FRANCE
Bonnafous, Cecile, Marseille, FRANCE
PA INNATE PHARMA, S.A., Marseille, FRANCE (non-U.S. corporation)
PI US 20100029674 A1 20100204
AI US 2007-438998 A1 20071116 (12)
WO 2007-EP62456 20071116
20090226 PCT 371 date
PRAI US 2007-938020P 20070515 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO Box
142950, GAINESVILLE, FL, 32614, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1-105
DRWN 2 Drawing Page(s)
LN.CNT 3899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods useful for treating a cancer in mammals, including humans. The methods and compositions typically comprise use of a chemotherapeutic agent and a γδ T cell activator such that the composition is effective for treating a cancer. Preferably the composition enhances the effect of the γδ T cell activator and/or prevents or delays the escape of a tumor from control chemotherapy, particularly an anti-angiogenic chemotherapeutic agent.
IT 284461-73-0, Sorafenib 475207-59-1, Sorafenib tosylate
(improved methods of using phosphoantigen for treatment of cancer with γδ T cell activator in combination with chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 139 OF 390 USPATFULL on STN
AN 2010:24227 USPATFULL
TI COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S
IN Lyons, John Francis, London, UNITED KINGDOM
Squires, Matthew Simon, Cambridge, UNITED KINGDOM
Thompson, Neil Thomas, Cambridge, UNITED KINGDOM
Gallagher, Neil James, Basel, SWITZERLAND
PA ASTEX THERAPEUTICS LIMITED, Cambridge, UNITED KINGDOM (non-U.S. corporation)
PI US 20100021420 A1 20100128
AI US 2007-373827 A1 20070713 (12)
WO 2007-GB2654 20070713
20090622 PCT 371 date
PRAI GB 2006-14457 20060720
US 2006-830968P 20060714 (60)
DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-154
DRWN 7 Drawing Page(s)
LN.CNT 8634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination comprising (a) a compound of formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is R.sup.1-A-NR.sup.4-- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO.sub.2, C.dbd.O, NR.sup.9(C.dbd.O) or 0(C.dbd.O) wherein R.sup.9 is hydrogen or C.sub.1-4 hydrocarbyl optionally substituted by hydroxy or C.sub.1-4 alkoxy; Y is a bond or an alkylene chain of 1 to 3 carbon atoms; R.sup.1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or an optionally substituted C.sub.1-8 hydrocarbyl group wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO.sub.2; R.sup.2 is hydrogen; halogen; C.sub.1-4 alkoxy; or a C.sub.1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C.sub.1-4 alkoxy; R.sup.3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R.sup.4 is hydrogen or a C.sub.1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C.sub.1-4 alkoxy; and (b) a compound of formula (I'") or salts, tautomers, solvates and N-oxides thereof: wherein R.sup.1 is 2,6-dichlorophenyl; R.sup.2a and R.sup.2b are both hydrogen; and R.sup.3 is a group: formula (A) where R.sup.4 is C.sub.1-4 alkyl.

##STR1##
IT 284461-73-0
(preparation of benzoylaminopyrazolecarboxamides as CDK kinase inhibitors useful in the treatment of proliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 140 OF 390 USPATFULL on STN
AN 2010:18689 USPATFULL
TI Protein Kinase Targeted Therapeutics
IN Watterson, D. Martin, Chicago, IL, UNITED STATES
Van Eldik, Linda J., Chicago, IL, UNITED STATES
PA NORTHWESTERN UNIVERSITY, Evanston, IL, UNITED STATES (U.S. corporation)
PI US 20100016587 A1 20100121
US 7919485 B2 20110405
AI US 2009-566153 A1 20090924 (12)
RLI Continuation of Ser. No. US 2007-833152, filed on 2 Aug 2007, PENDING
PRAI US 2006-834962P 20060802 (60)
DT Utility
FS APPLICATION
LREP Casimir Jones, S.C., 2275 DEMING WAY, SUITE 310, MIDDLETON, WI, 53562, US
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
IT 284461-73-0, Sorafenib
(preparation of phenyl(pyridinyl)pyridazinamines for protein kinase targeted therapeutics)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 141 OF 390 USPATFULL on STN
AN 2010:18438 USPATFULL
TI NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION
IN Iwasawa, Yoshikazu, Tsukuba-shi, JAPAN
Kato, Tetsuya, Tsukuba-shi, JAPAN
Kawanishi, Nobuhiko, Moriya-shi, JAPAN
Masutani, Kouta, Tsukuba-shi, JAPAN
Mita, Takashi, Tsukuba-shi, JAPAN
Nonoshita, Katsumasa, Tsukuba-shi, JAPAN
Ohkubo, Mitsuru, Ushiku-shi, JAPAN
PI US 20100016335 A1 20100121
AI US 2007-310307 A1 20070829 (12)
WO 2007-JP67251 20070829
20090220 PCT 371 date
PRAI JP 2006-236472 20060831
US 2007-926086P 20070425 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4778
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of formula I:

##STR1##

wherein: R.sub.1 is a hydrogen atom, F, CN, etc.; R.sub.1' is a hydrogen atom or lower alkyl which may be substituted; R.sub.2 is O, S, SO, SO.sub.2, etc.; R.sub.3 is a phenyl which may be substituted; X.sub.1, X.sub.2, and X.sub.3 each independently CH, N, etc. provided, however, that among X.sub.1, X.sub.2 and X.sub.3, the number of nitrogen is 0 or 1; W is the following residue:

##STR2##

wherein: W.sub.1, W.sub.2, and W.sub.3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.
IT 284461-73-0, Sorafenib
(coadministration; preparation of 2-(azolylamino)pyridine derivs. having aurora A-selective inhibitory activity and synergistic anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
O
MeNH
C
O

L20 ANSWER 142 OF 390 USPATFULL on STN
AN 2010:17266 USPATFULL
TI Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer
IN Winqvist, Ola, Uppsala, SWEDEN
Thorn, Magnus, Uppsala, SWEDEN
PA Sentoclone AB, Sundbyberg, SWEDEN (non-U.S. corporation)
PI US 20100015161 A1 20100121
AI US 2009-505156 A1 20090717 (12)
PRAI DK 2008-1025 20080718
US 2008-81804P 20080718 (61)
DT Utility
FS APPLICATION
LREP THORPE NORTH & WESTERN, LLP., P.O. Box 1219, SANDY, UT, 84091-1219, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved cancer therapy using a combination treatment with tumour-reactive T-lymphocytes obtained by an in vitro method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes and inhibitors of vessel formation inhibitors, notably inhibitors of VEGF.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in treatment of cancer and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 143 OF 390 USPATFULL on STN
AN 2010:17241 USPATFULL
TI CAMPTOTHECIN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IN Michel, Matthieu, Le Vesinet, FRANCE
Ravel, Denis, Paris, FRANCE
Ribes, Fabien, Marseille, FRANCE
Tranchant, Isabelle, Le Kremlin-Bicetre, FRANCE
PA DIATOS, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20100015136 A1 20100121
AI US 2007-295508 A1 20070330 (12)
WO 2007-IB1697 20070330
20090818 PCT 371 date
PRAI EP 2006-290500 20060330
US 2006-792312P 20060417 (60)
DT Utility
FS APPLICATION
LREP GOODWIN PROCTER LLP, PATENT ADMINISTRATOR, 53 STATE STREET, EXCHANGE PLACE, BOSTON, MA, 02109-2881, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-42
DRWN 1 Drawing Page(s)
LN.CNT 2949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.
IT 284461-73-0, Sorafenib
(preparation of camptothecin-peptide conjugates and pharmaceutical compns. containing them)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 144 OF 390 USPATFULL on STN
AN 2010:11372 USPATFULL
TI BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
IN RICKLES, Richard, Arlington, MA, UNITED STATES
Lee, Margaret S., Middleton, MA, UNITED STATES
PA CombinatoRx, Incorporated, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20100009934 A1 20100114
AI US 2009-480034 A1 20090608 (12)
PRAI US 2008-60064P 20080609 (61)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 3060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
IT 475207-59-1, Nexavar
(β-Adrenergic receptor agonists for treatment of B-cell proliferative disorders, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 145 OF 390 USPATFULL on STN
AN 2010:11368 USPATFULL
TI TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN CONBINATION WITH ANTI-TUMOR AGENTS
IN Sherman, Barry M., Hillsborough, CA, UNITED STATES
Bradley, Charles, Half Moon Bay, CA, UNITED STATES
Ossovskaya, Valeria S., San Francisco, CA, UNITED STATES
PA BiPar Sciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20100009930 A1 20100114
AI US 2009-502943 A1 20090714 (12)
RLI Continuation of Ser. No. US 2008-269833, filed on 12 Nov 2008, PENDING
PRAI US 2007-987335P 20071112 (60)
US 2007-12364P 20071207 (61)
US 2008-58528P 20080603 (61)
DT Utility
FS APPLICATION
LREP BiPar Sciences Inc. c/o Morrison Foerster, 755 Page Mill Road, Palo Alto, CA, 94304, US
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
IT 475207-59-1, Nexavar
(PARP inhibitor for treatment of uterine cancer, endometrial cancer, and ovarian cancer, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 146 OF 390 USPATFULL on STN
AN 2010:10830 USPATFULL
TI USE OF MELANOMA INHIBITORY ACTIVITY (MIA) PROTEIN AS AN EARLY INDICATOR FOR THERAPEUTIC RESPONSE IN MELANOMA
IN Tan, Nguyen, San Leandro, CA, UNITED STATES
Venetsanakos, Eleni, Oakland, CA, UNITED STATES
Faure, Michel, Oakland, NJ, UNITED STATES
Heise, Carla, Benicia, CA, UNITED STATES
PA , Novartis AG, Basel, SWITZERLAND (U.S. individual)
PI US 20100009392 A1 20100114
AI US 2007-375074 A1 20070726 (12)
WO 2007-US16848 20070726
20090518 PCT 371 date
PRAI US 2006-820756P 20060728 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.
IT 284461-73-0, Sorafenib
(use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 147 OF 390 USPATFULL on STN
AN 2010:5003 USPATFULL
TI BIOMARKERS OF TARGET MODULATION, EFFICACY, DIAGNOSIS AND/OR PROGNOSIS FOR RAF INHIBITORS
IN Aziz, Natasha, Emeryville, CA, UNITED STATES
Moler, Edward, Emeryville, CA, UNITED STATES
Stuart, Darrin, Emeryville, CA, UNITED STATES
Heise, Carla, Emeryville, CA, UNITED STATES
Aardelen, Kim, Emeryville, CA, UNITED STATES
PA Novartis AG (U.S. corporation)
PI US 20100004253 A1 20100107
AI US 2007-441888 A1 20070919 (12)
WO 2007-US78946 20070919
20090527 PCT 371 date
PRAI US 2006-845601P 20060919 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS VACCINES AND DIAGNOSTICS INC., INTELLECTUAL PROPERTY- X100B, P.O. BOX 8097, Emeryville, CA, 94662-8097, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to Raf kinase inhibition, are measured and identifications or adjustments may be made accordingly.
IT 284461-73-0, BAY 43-9006
(gene expression biomarkers for prediction of target modulation and efficacy of Raf inhibitors and diagnosis and/or prognosis of melanoma and other cancers)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 148 OF 390 USPATFULL on STN
AN 2010:4984 USPATFULL
TI SPECIFIC KINASE INHIBITORS
IN Santi, Daniel V., San Francisco, CA, UNITED STATES
Reid, Ralph C., San Rafael, CA, UNITED STATES
Hutchinson, C. Richard, Cross Plains, WI, UNITED STATES
Sundermann, Kurt F., Burlingame, CA, UNITED STATES
Lau, Janice, San Mateo, CA, UNITED STATES
PA Kosan Biosciences Incorporated (U.S. corporation)
PI US 20100004234 A1 20100107
AI US 2009-536884 A1 20090806 (12)
RLI Continuation of Ser. No. US 2005-236244, filed on 26 Sep 2005, PENDING
PRAI US 2004-613680P 20040927 (60)
US 2004-629575P 20041118 (60)
US 2005-698520P 20050711 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site.
IT 284461-73-0, BAY 43-9006
(resorcylic acid lactone kinase inhibitors, and therapeutic use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 149 OF 390 USPATFULL on STN
AN 2010:3988 USPATFULL
TI Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
IN Frost, Gregory I., Del Mar, CA, UNITED STATES
Jiang, Ping, San Diego, CA, UNITED STATES
Thompson, Curtis B., Encinitas, CA, UNITED STATES
PI US 20100003238 A1 20100107
AI US 2009-386222 A1 20090414 (12)
PRAI US 2008-124278P 20080414 (61)
US 2008-130357P 20080529 (61)
US 2008-195624P 20081008 (61)
DT Utility
FS APPLICATION
LREP K&L Gates LLP, 3580 Carmel Mountain Road, Suite 200, San Diego, CA, 92130, US
CLMN Number of Claims: 94
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 10141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.
IT 284461-73-0, Sorafenib
(combination therapy with; modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 150 OF 390 USPATFULL on STN
AN 2010:3942 USPATFULL
TI TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS
IN Sherman, Barry M., Hillsborough, CA, UNITED STATES
Bradley, Charles, Half Moon Bay, CA, UNITED STATES
Ossovskaya, Valeria S., San Francisco, CA, UNITED STATES
PA BiPar Sciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20100003192 A1 20100107
AI US 2009-496593 A1 20090701 (12)
RLI Continuation of Ser. No. US 2008-269024, filed on 11 Nov 2008, PENDING
PRAI US 2007-987333P 20071112 (60)
US 2007-12364P 20071207 (61)
US 2008-58528P 20080603 (61)
DT Utility
FS APPLICATION
LREP BiPar Sciences Inc. c/o Morrison Foerster, 755 Page Mill Road, Palo Alto, CA, 94304, US
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
IT 475207-59-1, Nexavar
(PARP inhibitor for treatment of uterine cancer, endometrial cancer, and ovarian cancer, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 151 OF 390 USPATFULL on STN
AN 2009:363258 USPATFULL
TI Methods for Developing and Assessing Therapeutic Agents
IN Altiok, Soner, Tampa, FL, UNITED STATES
PI US 20090325202 A1 20091231
AI US 2007-308005 A1 20070604 (12)
WO 2007-US13104 20070604
20090716 PCT 371 date
PRAI US 2006-811038P 20060605 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 2138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Assays are provided that can effectively assess tumor response to one or more therapeutic agents. Preferred assays of the invention include assessment of posttranslation modification and expression of target proteins.
IT 284461-73-0, Sorafenib
(methods for developing and assessing therapeutic agents for treating neoplasia and metabolic disease by determining expression of signaling and metabolic proteins)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 152 OF 390 USPATFULL on STN
AN 2009:355756 USPATFULL
TI METHOD FOR TREATING CANCER HARBORING EGFR MUTATIONS
IN Solca, Flavio, Vienna, AUSTRIA
PA BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090318480 A1 20091224
AI US 2007-441180 A1 20070914 (12)
WO 2007-EP59735 20070914
20090409 PCT 371 date
PRAI EP 2006-120856 20060918
EP 2007-101505 20070131
DT Utility
FS APPLICATION
LREP MICHAEL P. MORRIS, BOEHRINGER INGELHEIM USA CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour.
IT 284461-73-0, BAY-43-9006
(method for treating cancer harboring EGFR mutations using BIBW2992 in combination with other chemotherapeutic agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 153 OF 390 USPATFULL on STN
AN 2009:354737 USPATFULL
TI USE OF ONCOLYTIC VIRUSES AND ANTIANGIOGENIC AGENTS IN THE TREATMENT OF CANCER
IN Karrasch, Matthias, Erlangen, GERMANY, FEDERAL REPUBLIC OF
Mescheder, Axel, Woerthsee, GERMANY, FEDERAL REPUBLIC OF
PA MediGene AG, Planegg/Martinsried, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090317456 A1 20091224
AI US 2007-445019 A1 20071015 (12)
WO 2007-EP8930 20071015
20090722 PCT 371 date
PRAI US 2006-851598P 20061013 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-71
DRWN 3 Drawing Page(s)
LN.CNT 2175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy.
IT 284461-73-0, BAY 43-9006
(oncolytic viruses and antiangiogenic agents in treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 154 OF 390 USPATFULL on STN
AN 2009:347789 USPATFULL
TI METHODS FOR TREATING THYROID CANCER
IN Brose, Marcia S., Bryn Mawr, PA, UNITED STATES
PI US 20090311175 A1 20091217
AI US 2009-436957 A1 20090507 (12)
PRAI US 2008-71598P 20080507 (61)
US 2008-114423P 20081113 (61)
DT Utility
FS APPLICATION
LREP Pearl Cohen Zedek Latzer, LLP, 1500 Broadway, 12th Floor, New York, NY, 10036, US
CLMN Number of Claims: 81
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering to the subject a composition comprising a multi-kinase inhibitor.
IT 284461-73-0, Sorafenib
(enhancing iodine absorption by administering multi-kinase inhibitor for treating thyroid cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 155 OF 390 USPATFULL on STN
AN 2009:341955 USPATFULL
TI NOVEL TETRAHYDRO-ISOQUINOLINES
IN Weber, Lutz, Germering, GERMANY, FEDERAL REPUBLIC OF
Khazak, Vladimir, Brooklyn, NY, UNITED STATES
Ross, Gunther, Munchen, GERMANY, FEDERAL REPUBLIC OF
Kalinski, Cedric, Munchen, GERMANY, FEDERAL REPUBLIC OF
Burdack, Christoph, Munchen, GERMANY, FEDERAL REPUBLIC OF
PI US 20090306130 A1 20091210
AI US 2007-441266 A1 20070914 (12)
WO 2007-US78464 20070914
20090818 PCT 371 date
PRAI US 2006-845095P 20060915 (60)
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1023
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of novel tetrahydroisoquinoline compds. useful in prevention, mono- and combination therapy of various diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 156 OF 390 USPATFULL on STN
AN 2009:341928 USPATFULL
TI PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS
IN Boyer, Stephen, Bethany, CT, UNITED STATES
Cantin, David, Hamden, CT, UNITED STATES
Liang, Sidney X., Bethany, CT, UNITED STATES
PI US 20090306103 A1 20091210
AI US 2007-300751 A1 20070518 (12)
WO 2007-US11981 20070518
20090520 PCT 371 date
PRAI US 2006-801700P 20060519 (60)
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pyridonecarboxamide derivatives, pharmaceutical compositions which contain the same and methods for treating hyper-proliferative disorders and angiogenesis disorders using the same.
IT 284461-73-0, Sorafenib
(preparation of novel pyridonecarboxamides for use in mono- and combination therapy of hyperproliferative and angiogenesis disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 157 OF 390 USPATFULL on STN
AN 2009:341926 USPATFULL
TI COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS
IN Solca, Flavio, Wien, AUSTRIA
Amelsberg, Andree, Danbury, CT, UNITED STATES
Stehle, Gerd, Ehingen, GERMANY, FEDERAL REPUBLIC OF
Van Meel, Jacobus C.A., Moedling, AUSTRIA
Baum, Anke, Wien, AUSTRIA
PI US 20090306101 A1 20091210
AI US 2006-93322 A1 20061109 (12)
WO 2006-EP68314 20061109
20080909 PCT 371 date
PRAI EP 2005-110669 20051111
DT Utility
FS APPLICATION
LREP MICHAEL P. MORRIS, BOEHRINGER INGELHEIM USA CORPORATION, 900 RIDGEBURY RD, P. O. BOX 3686, RIDGEFIELD, CT, 06877-0368, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
IT 284461-73-0, BAY-43-9006
(EGFR/HER2 inhibitor combination treatment for cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 158 OF 390 USPATFULL on STN
AN 2009:341845 USPATFULL
TI Combination therapy comprising diaryl ureas for treating diseases
IN Scheuring, Urban, Siegburg, GERMANY, FEDERAL REPUBLIC OF
Bernard, Ingo, Lindlar, GERMANY, FEDERAL REPUBLIC OF
Garbe, Claus, Tubingen, GERMANY, FEDERAL REPUBLIC OF
Schittek, Birgit, Bodelshusen, GERMANY, FEDERAL REPUBLIC OF
Meier, Friedegund, Tubingen, GERMANY, FEDERAL REPUBLIC OF
PA Bayer Healthcare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090306020 A1 20091210
AI US 2006-920952 A1 20060513 (11)
WO 2006-EP4523 20060513
20090422 PCT 371 date
PRAI EP 2005-11475 20050527
EP 2005-11476 20050527
EP 2005-11478 20050527
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound and an PI3K/AKT signaling pathway inhibitor. Useful combinations include e.g. BAY-43-9006 as a diaryl urea compound.
IT 284461-73-0
(BAY 43-9006; combination comprising diaryl ureas and inhibitors of PI3 kinase/AKT kinase signaling for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-74-1 475207-59-1
(combination comprising diaryl ureas and inhibitors of PI3 kinase/AKT kinase signaling for treating cancer)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-,
4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 159 OF 390 USPATFULL on STN
AN 2009:340520 USPATFULL
TI Ang2 and Vegf Inhibitor Combinations
IN Oliner, Jonathan, Newbury Park, CA, UNITED STATES
Kendall, Richard, Thousand Oaks, CA, UNITED STATES
Kumar, Rakesh, Phoexnixville, PA, UNITED STATES
PA AMGEN INC., Thousand Oaks, CA, UNITED STATES (U.S. corporation)
PI US 20090304694 A1 20091210
AI US 2007-223003 A1 20070119 (12)
WO 2007-US1365 20070119
20090123 PCT 371 date
PRAI US 2006-762493P 20060127 (60)
DT Utility
FS APPLICATION
LREP LARRY S. MILLSTEIN, Holland & Knight LLP,
1600 Tysons Boulevard, Suite
700, McLean, VA, 22102-4867, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for using Ang2 inhibitors in combination with VEGF inhibitors to treat disease. The invention also provides compositions, kits, formulations, and specific disease treatments relating thereto.

L20 ANSWER 160 OF 390 USPATFULL on STN
AN 2009:333886 USPATFULL
TI Novel Compounds and Methods for Their Production
IN Gaisser, Sabine, Essex, UNITED KINGDOM
Martin, Christine, Essex, UNITED KINGDOM
Zhang, Ming, Essex, UNITED KINGDOM
Wilkinson, Barrie, Essex, UNITED KINGDOM
Coates, Nigel, Essex, UNITED KINGDOM
Nur-E-Alam, Mohammed, Essex, UNITED KINGDOM
Galtatzis, Nikolaos, Essex, UNITED KINGDOM
PI US 20090298804 A1 20091203
AI US 2007-294267 A1 20070330 (12)
WO 2007-EP53130 20070330
20090804 PCT 371 date
PRAI GB 2006-6548 20060331
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 15-desmethoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.
IT 284461-73-0
(production of 15-desmethoxymacbecin analogs from engineered strains of Actinosynnema pretiosum for use in cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 161 OF 390 USPATFULL on STN
AN 2009:332559 USPATFULL
TI Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Hummel, Rolf-Peter, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Feth, Martin, Kelkheim-Hornau, GERMANY, FEDERAL REPUBLIC OF
Muller, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
PA Nycomed GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090297473 A1 20091203
AI US 2006-992018 A1 20060908 (11)
WO 2006-EP66189 20060908
20080314 PCT 371 date
PRAI EP 2005-108716 20050921
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula 1,

##STR1##

in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.
IT 284461-73-0, BAY43-9006
(codrug; preparation of sulfonylpyrrole derivs. as HDAC inhibitors useful in treatment and prophylaxis of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 162 OF 390 USPATFULL on STN
AN 2009:325450 USPATFULL
TI SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
IN MacLachlan, Ian, Mission, CANADA
Judge, Adam, Vancouver, CANADA
PA Protiva Biotherapeutics, Inc., Burnaby, CANADA (non-U.S. corporation)
PI US 20090291131 A1 20091126
AI US 2008-343342 A1 20081223 (12)
PRAI US 2008-100653P 20080926 (61)
US 2008-45228P 20080415 (61)
US 2007-17075P 20071227 (61)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 7282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.
IT 284461-73-0, SOrafenib
(combination therapy for cancer; silencing of polo-like kinase 1 expression using interfering RNA)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 163 OF 390 USPATFULL on STN
AN 2009:325408 USPATFULL
TI THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS
IN Hariharan, Kandasamy, San Diego, CA, UNITED STATES
Dong, Jianying, San Diego, CA, UNITED STATES
PA Biogen Idec MA Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20090291088 A1 20091126
AI US 2009-422045 A1 20090410 (12)
PRAI US 2008-71087P 20080411 (61)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX,
P.L.L.C., 1100 NEW YORK AVE., N.W.,
WASHINGTON, DC, 20005, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 71 Drawing Page(s)
LN.CNT 15713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.
IT 475207-59-1, Sorafenib tosylate
(human, chimeric and humanized anti-human IGF-1 receptor antibodies or fragments in combination with other compds. for cancer therapy)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 164 OF 390 USPATFULL on STN
AN 2009:313795 USPATFULL
TI Compositions And Methods For Immunotherapy
IN BROWN, Joe Ernest, Grass Valley, CA, UNITED STATES
PI US 20090281047 A1 20091112
AI US 2009-418342 A1 20090403 (12)
PRAI US 2008-42210P 20080403 (61)
DT Utility
FS APPLICATION
LREP BLACK LOWE & GRAHAM, PLLC, 701 FIFTH AVENUE, SUITE 4800, SEATTLE, WA, 98104, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy
IT 475207-59-1, Sorafenib tosylate
(compns. and methods for immunotherapy using benzaldehyde derivs. and combination with addnl. therapeutic agents for treatment of microbial infections and proliferative disorders)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 165 OF 390 USPATFULL on STN
AN 2009:313245 USPATFULL
TI Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
IN Wirtz, Ralph Markus, Koln, GERMANY, FEDERAL REPUBLIC OF
Munnes, Marc, Erkrath, GERMANY, FEDERAL REPUBLIC OF
PA Siemens Healthcare Diagnostics Inc., Tarrytown, NY, UNITED STATES (U.S. corporation)
PI US 20090280493 A1 20091112
AI US 2007-440490 A1 20070904 (12)
WO 2007-EP59283 20070904
20090309 PCT 371 date
PRAI EP 2006-18836 20060908
DT Utility
FS APPLICATION
LREP SIEMENS CORPORATION, INTELLECTUAL PROPERTY DEPARTMENT, 170 WOOD AVENUE SOUTH, ISELIN, NJ, 08830, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia using gene expression profile as diagnostic markers in relation to chromosomal rearrangements)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 166 OF 390 USPATFULL on STN
AN 2009:312893 USPATFULL
TI PEPTIDE
IN Harrop, Richard, Oxford, UNITED KINGDOM
Shingler, William, Oxford, UNITED KINGDOM
Kingsman, Susan, Oxford, UNITED KINGDOM
PA OXFORD BIOMEDICA (UK) LIMITED, OXFORD, UNITED KINGDOM (non-U.S. corporation)
PI US 20090280138 A1 20091112
AI US 2006-914084 A1 20060512 (11)
WO 2006-GB1769 20060512
20081014 PCT 371 date
PRAI GB 2005-9835 20050513
GB 2005-16303 20050808
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their use in diagnosis and therapy of cancer.
IT 284461-73-0, Sorafenib
(in combination therapy with peptide epitopes of 5T4 oncofetal antigen)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 167 OF 390 USPATFULL on STN
AN 2009:312885 USPATFULL
TI METHOD FOR THE TREATMENT OF ANTHRAX TOXICITY
IN Chan, Joanne, Medford, MA, UNITED STATES
Bolcome, III, Robert E., Allston, MA, UNITED STATES
PA CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA, UNITED STATES (U.S. corporation)
PI US 20090280130 A1 20091112
AI US 2007-304495 A1 20070613 (12)
WO 2007-US13813 20070613
20081212 PCT 371 date
PRAI US 2006-813755P 20060614 (60)
DT Utility
FS APPLICATION
LREP DAVID S. RESNICK, NIXON PEABODY LLP, 100 SUMMER STREET, BOSTON, MA, 02110-2131, US
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Bacillus anthracis is a spore-forming Gram positive bacterium that is the causative agent of anthrax infection. Vascular leakage and pleural effusions are hallmarks of the fulminant phase of human anthrax disease following infection. The present invention provides a method of halting, treating, and preventing the rapid toxic effects of human anthrax disease by blocking the VEGF pathway with chemical inhibitors of the VEGFR signaling pathway. The invention is also applicable as an anti-anthrax therapeutic in bio-warfare defense.
IT 284461-73-0, Sorafenib
(method for treatment of anthrax toxicity using inhibitors of VEGF signaling pathway and combination with antibiotics and anthrax antitoxin agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 168 OF 390 USPATFULL on STN
AN 2009:307561 USPATFULL
TI NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF
IN Gerlach, Matthias, Brachttal, GERMANY, FEDERAL REPUBLIC OF
Seipelt, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Grossostheim, GERMANY, FEDERAL REPUBLIC OF
Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PA ZENTARIS GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090275534 A1 20091105
AI US 2008-117942 A1 20080509 (12)
PRAI EP 2007-107976 20070510
US 2007-917129P 20070510 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, L.L.P., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
IT 284461-73-0, Sorafenib
(codrug; preparation of pyridopyrazine derivs. useful in treatment and prophylaxis of malignant disorders and other disorders based on pathol. cell proliferations)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 169 OF 390 USPATFULL on STN
AN 2009:300632 USPATFULL
TI QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
IN Masse, Craig E., Cambridge, MA, UNITED STATES
Tung, Roger, Lexington, MA, UNITED STATES
PA Concert Pharmaceuticals, Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 20090269354 A1 20091029
AI US 2009-413510 A1 20090327 (12)
PRAI US 2009-157549P 20090304 (61)
US 2008-40647P 20080328 (61)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.
IT 284461-73-0, Sorafenib
(codrug; preparation of quinazoline derivs. as inhibitors of cell surface receptor tyrosine kinases for disease treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 170 OF 390 USPATFULL on STN
AN 2009:295008 USPATFULL
TI ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER
IN Yamamoto, Yuji, Ibaraki, JAPAN
Matsushima, Tomohiro, Ibaraki, JAPAN
Tsuruoka, Akihiko, Ibaraki, JAPAN
Obaishi, Hiroshi, Ibaraki, JAPAN
Nakagawa, Takayuki, Ibaraki, JAPAN
PA Eisai R & D Management Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20090264464 A1 20091022
AI US 2007-439339 A1 20070827 (12)
WO 2007-JP67088 20070827
20090227 PCT 371 date
PRAI JP 2006-230816 20060828
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P.O. BOX 770, Church Street Station, New York, NY,
10008-0770, US
CLMN Number of Claims: 82
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof:

##STR1##

The therapeutic agent comprises a substance having the activity of inhibiting kinase activity of fibroblast growth factor receptor 2 ("FGFR2"). The therapeutic agent can be used for treating undifferentiated gastric cancer, and can also be used to treat organisms comprising a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both. The present invention further relates to a pharmaceutical composition comprising an FGFR2 inhibitory and methods of treatment therewith. The present invention also relates to a method for predicting the effect of an FGFR2 inhibitory substance on a patient.
IT 284461-73-0
(quinolinylurea analogs as antitumor agents for undifferentiated gastric cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 171 OF 390 USPATFULL on STN
AN 2009:293907 USPATFULL
TI Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Hummel, Rolf-Peter, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Feth, Martin, Kelkheim-Hornau, GERMANY, FEDERAL REPUBLIC OF
Muller, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Volz, Jurgen, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PA Nycomed GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090263353 A1 20091022
AI US 2006-992015 A1 20060908 (11)
WO 2006-EP66197 20060908
20080314 PCT 371 date
PRAI EP 2005-108728 20050921
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I,

##STR1##

in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.
IT 284461-73-0, BAY43-9006
(codrug; preparation of sulfonylpyrrole derivs. as HDACs inhibitors useful in treatment and prevention of benign and malignant neoplasia)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 172 OF 390 USPATFULL on STN
AN 2009:293903 USPATFULL
TI METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS
IN Story, Michael John, Carrickalinga, AUSTRALIA
Wayte, Kenneth Michael, Ocean Reef, AUSTRALIA
PI US 20090263349 A1 20091022
AI US 2007-375903 A1 20070803 (12)
WO 2007-AU1092 20070803
20090221 PCT 371 date
PRAI AU 2006-904195 20060803
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 SW SALMON STREET, SUITE 1600, PORTLAND, OR, 97204, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin.
IT 284461-73-0, Sorafenib
(steroid saponins for inhibition of angiogenesis, and use with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 173 OF 390 USPATFULL on STN
AN 2009:288657 USPATFULL
TI Novel tetrahydropyridothiophenes
IN PEKARI, Klaus, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
SCHMIDT, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
BAR, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
BECKERS, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
GIMMNICH, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20090258873 A1 20091015
AI US 2009-412021 A1 20090326 (12)
RLI Division of Ser. No. US 2007-920572, filed on 4 Dec 2007, PENDING A 371 of International Ser. No. WO 2006-EP62613, filed on 24 May 2006
PRAI EP 2005-104499 20050525
EP 2005-112150 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1-21
DRWN No Drawings
LN.CNT 4159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, BAY43-9006
(preparation of tetrahydropyridothiophene derivs. with display cell cycle dependent, antiproliferative and apoptosis inducing activity useful in treatment of hyperproliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 174 OF 390 USPATFULL on STN
AN 2009:287765 USPATFULL
TI NOVEL TETRAHYDROPYRIDOTHIOPHENES
IN Pekari, Klaus, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20090257977 A1 20091015
AI US 2009-412484 A1 20090327 (12)
RLI Division of Ser. No. US 2007-920501, filed on 14 Dec 2007, PENDING
PRAI EP 2005-104495 20050525
EP 2005-112155 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1-21
DRWN No Drawings
LN.CNT 4908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, BAY43-9006
(preparation of tetrahydropyridothiophene derivs. with display cell cycle dependent, antiproliferative and apoptosis inducing activity useful in treatment of hyperproliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 175 OF 390 USPATFULL on STN
AN 2009:282953 USPATFULL
TI Process for the preparation of sorafenib and salts thereof
IN Rossetto, Pierluigi, Lodi, ITALY
MacDonald, Peter Lindsay, Gentilino, SWITZERLAND
Canavesi, Augusto, Locate Varesino (CO), ITALY
PI US 20090253913 A1 20091008
AI US 2009-381000 A1 20090305 (12)
PRAI US 2008-68478P 20080306 (61)
US 2009-150169P 20090205 (61)
DT Utility
FS APPLICATION
LREP KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 540
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the synthesis of the N-carbamoyl imidazole (I) and its 1:1 adduct with imidazole are provided. Methods for the preparation of these crystalline intermediates in a high state of purity are also provided. These intermediates react cleanly under mild conditions to produce sorafenib in high yield and purity, without generating difficult-to-remove impurities.

##STR1##

IT 284461-73-0P, Sorafenib
(preparation of sorafenib and salts thereof)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1P, Sorafenib tosylate
(preparation of sorafenib and salts thereof)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 176 OF 390 USPATFULL on STN
AN 2009:281751 USPATFULL
TI Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer
IN Pekari, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PI US 20090252706 A1 20091008
AI US 2009-411021 A1 20090325 (12)
RLI Division of Ser. No. US 2007-883624, filed on 18 Sep 2007, PENDING
PRAI EP 2005-101007 20050211
EP 2005-104493 20050525
EP 2005-112159 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-22
DRWN No Drawings
LN.CNT 4961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of formula (I) wherein Ra is --C(O)ORI, in which R1 is 1-7C-alkyl. 3-7C-cycloakyl, 1-7C-alkyl substituted by Raa, or 2-7C-alkyl substituted by Rab and Rac on different carbon atoms, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and Q is substituted by Rba and Rbb and Rbc, and is phenyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer.

##STR1##

IT 284461-73-0, Sorafenib
(preparation of tetrahydropyridothiophenes as antiproliferative and apoptosis-inducing agents useful in treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 177 OF 390 USPATFULL on STN
AN 2009:275772 USPATFULL
TI CUCURBITACIN B AND USES THEREOF
IN Xie, Wei Dong, Hong Kong, CHINA
Li, Kwan, Hong Kong, CHINA
Liu, Edgar Shiu Lam, Hong Kong, CHINA
Chu, Kee Hung, Hong Kong, CHINA
PI US 20090247495 A1 20091001
AI US 2008-334503 A1 20081214 (12)
PRAI WO 2007-GB4775 20071213
US 2007-15565P 20071220 (61)
US 2007-15578P 20071220 (61)
DT Utility
FS APPLICATION
LREP WILKINSON & GRIST, 6TH FLOOR, PRINCE'S BUILDING, CHATER ROAD, CENTRAL,
HONG KONG, CN
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 50 Drawing Page(s)
LN.CNT 3003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.
IT 284461-73-0, Sorafenib
(cucurbitacins, including cucurbitacin B, and therapeutic uses)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 178 OF 390 USPATFULL on STN
AN 2009:274453 USPATFULL
TI INDOLOPYRIDINES AS EG5 KINESIN MODULATORS
IN Vennemann, Matthias, Konstaz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Braunger, Jurgen, Modling, AUSTRIA
Zimmermann, Astrid, Kontanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20090246169 A1 20091001
AI US 2007-280264 A1 20070221 (12)
WO 2007-EP51691 20070221
20090129 PCT 371 date
PRAI EP 2006-110298 20060222
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.
IT 284461-73-0, BAY43-9006 284461-73-0D, Sorafenib, analogs
(indolopyridine compds. as EG5 kinesin modulators with antiproliferative and apoptosis-inducing activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 179 OF 390 USPATFULL on STN
AN 2009:266443 USPATFULL
TI Combinations for the Treatment of Diseases involving Cell Proliferation
IN MUNZERT, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
STEEGMAIER, Martin, Reutlingen, GERMANY, FEDERAL REPUBLIC OF
BAUM, Anke, Vienna, AUSTRIA
PA BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090238828 A1 20090924
AI US 2009-437280 A1 20090507 (12)
RLI Continuation of Ser. No. US 2005-189540, filed on 26 Jul 2005, ABANDONED
PRAI EP 2004-19361 20040814
EP 2004-19448 20040817
DT Utility
FS APPLICATION
LREP MICHAEL P. MORRIS, BOEHRINGER INGELHEIM USA CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I)

##STR1##

wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
IT 284461-73-0, BAY-43-9006
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 180 OF 390 USPATFULL on STN
AN 2009:260796 USPATFULL
TI INDOLOPYRIDINES AS EG5 KINESIN MODULATORS
IN Vennemann, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Braunger, Jurgen, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20090233902 A1 20090917
AI US 2007-280424 A1 20070221 (12)
WO 2007-EP51688 20070221
20081118 PCT 371 date
PRAI EP 2006-110295 20060222
EP 2006-119038 20060816
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.
IT 284461-73-0, BAY43-9006 284461-73-0D, Sorafenib, analogs
(indolopyridine compds. as EG5 kinesin modulators with antiproliferative and apoptosis-inducing activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 181 OF 390 USPATFULL on STN
AN 2009:259708 USPATFULL
TI IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF
IN Kraus, Elmar, Bad Vilbel, GERMANY, FEDERAL REPUBLIC OF
Bruecher, Christoph, Eschborn, GERMANY, FEDERAL REPUBLIC OF
Daelken, Benjamin, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
Zeng, Steffen, Muenster, GERMANY, FEDERAL REPUBLIC OF
Osterroth, Frank, Dietzenbach, GERMANY, FEDERAL REPUBLIC OF
Uherek, Christoph, Seligenstadt, GERMANY, FEDERAL REPUBLIC OF
Aigner, Silke, Frankenthal, GERMANY, FEDERAL REPUBLIC OF
Germer, Matthias, Langen, GERMANY, FEDERAL REPUBLIC OF
PI US 20090232810 A1 20090917
AI US 2008-342407 A1 20081223 (12)
PRAI US 2007-16620P 20071226 (61)
US 2008-87466P 20080808 (61)
US 2008-87590P 20080808 (61)
DT Utility
FS APPLICATION
LREP JOYCE VON NATZMER, PEQUIGNOT + MYERS LLC, 200 Madison Avenue, Suite 1901, New York, NY, 10016, US
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
IT 284461-73-0, Sorafenib
(in combination therapy with immunoconjugates targeting CD138 antigen)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 182 OF 390 USPATFULL on STN
AN 2009:259666 USPATFULL
TI NOVEL COMPOUNDS AND METHODS FOR THERAPY
IN Birkus, Gabriel, San Francisco, CA, UNITED STATES
Ray, Andrian S., Redwood City, CA, UNITED STATES
Tumas, Daniel B., San Carlos, CA, UNITED STATES
Watkins, William J., Saratoga, CA, UNITED STATES
PA Gilead Sciences, Inc., Foster City, CA, UNITED STATES (U.S. corporation)
PI US 20090232768 A1 20090917
AI US 2009-388789 A1 20090219 (12)
PRAI US 2008-30148P 20080220 (61)
DT Utility
FS APPLICATION
LREP GILEAD SCIENCES INC, 333 LAKESIDE DR, FOSTER CITY, CA, 94404, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds having structure (1)

##STR1##

wherein Z, Y, R.sup.1, R.sup.2' and R.sup.2 are defined in the specification, are provided for use in the treatment of tumors and the prophylaxis or treatment of viral infections.

IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(codrug; novel compds. useful in treatment and prophylaxis of tumors and viral infections)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 183 OF 390 USPATFULL on STN
AN 2009:253763 USPATFULL
TI DIARYL UREAS FOR TREATING VIRUS INFECTIONS
IN Weber, Olaf, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PI US 20090227637 A1 20090910
AI US 2006-97350 A1 20061206 (12)
WO 2006-EP11693 20061206
20081103 PCT 371 date
PRAI EP 2005-27451 20051215
JP 2005-5027452 20051215
JP 2005-5027462 20051215
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.
IT 475207-59-1
(.; diaryl ureas for treatment of viral infection and viral infection-related diseases and use with other therapeutic agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0 284461-73-0D, derivs., salts, and metabolites 284461-74-1 284461-74-1D, derivs., salts, and metabolites
(diaryl ureas for treatment of viral infection and viral infection-related diseases and use with other therapeutic agents)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 184 OF 390 USPATFULL on STN
AN 2009:253704 USPATFULL
TI TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER
IN PEKARI, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PI US 20090227577 A1 20090910
AI US 2009-411486 A1 20090326 (12)
RLI Division of Ser. No. US 2007-883596, filed on 17 Sep 2007, PENDING A 371 of International Ser. No. WO 2006-EP50782, filed on 8 Feb 2006
PRAI EP 2005-100895 20050209
EP 2005-104488 20050525
EP 2005-112158 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-20
DRWN No Drawings
LN.CNT 4784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of formula I, wherein Ra is --C(O)ORI, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or Q is optionally substituted by Rca and/or Rcb, and is Has, or Q is optionally substituted by Rda and/or Rdb, and is Het, or Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer.

##STR1##

IT 284461-73-0, Sorafenib
(preparation of tetrahydropyridothiophenes with cell-cycle dependent, antiproliferative and apoptosis-inducing activity useful in treatment of hyperproliferative diseases such as cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 185 OF 390 USPATFULL on STN
AN 2009:252598 USPATFULL
TI MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS
IN Jackson, David Y., Belmont, CA, UNITED STATES
PI US 20090226465 A1 20090910
AI US 2006-92036 A1 20061026 (12)
WO 2006-US60276 20061026
20080918 PCT 371 date
PRAI US 2005-731972P 20051031 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
IT 284461-73-0, Sorafenib
(macrocyclic depsipeptide antibody-drug conjugates and methods for cancer diagnosis and treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 186 OF 390 USPATFULL on STN
AN 2009:252564 USPATFULL
TI Treatment of Cancer and Other Diseases
IN Habib, Nabil, Beirut, LEBANON
PI US 20090226431 A1 20090910
AI US 2006-85892 A1 20061130 (12)
WO 2006-US45665 20061130
20090306 PCT 371 date
PRAI US 2005-741725P 20051202 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.
IT 284461-73-0, BAY-43-9006
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 187 OF 390 USPATFULL on STN
AN 2009:252562 USPATFULL
TI Antibodies That Immunospecifically Bind to TRAIL Receptors
IN Salcedo, Theodora W., East Syracuse, NY, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Pasadena, MD, UNITED STATES
Albert, Vivian R., Palo Alto, CA, UNITED STATES
Dobson, Claire, Cambridge, UNITED KINGDOM
Vaughan, Tristan, Cambridge, UNITED KINGDOM
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 20090226429 A1 20090910
AI US 2008-16372 A1 20080118 (12)
RLI Continuation-in-part of Ser. No. US 2006-391384, filed on 29 Mar 2006, Pat. No. US 7361341 Continuation-in-part of Ser. No. US 2004-986047, filed on 12 Nov 2004, Pat. No. US 7348003 Continuation-in-part of Ser. No. WO 2003-US25457, filed on 15 Aug 2003, PENDING Continuation-in-part of Ser. No. US 2004-986349, filed on 12 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2002-139785, filed on 7 May 2002, Pat. No. US 7064189 Continuation-in-part of Ser. No. US 2002-139785, filed on 7 May 2002, Pat. No. US 7064189
PRAI US 2007-990697P 20071128 (60)
US 2007-885979P 20070122 (60)
US 2005-666161P 20050330 (60)
US 2004-608362P 20040910 (60)
US 2002-403382P 20020815 (60)
US 2002-425730P 20021113 (60)
US 2003-468050P 20030506 (60)
US 2001-293473P 20010525 (60)
US 2001-294981P 20010604 (60)
US 2001-309176P 20010802 (60)
US 2001-323807P 20010921 (60)
US 2001-327364P 20011009 (60)
US 2001-331044P 20011107 (60)
US 2001-331310P 20011114 (60)
US 2001-341237P 20011220 (60)
US 2002-369860P 20020405 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC., INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 14662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related

molecules, that immunospecifically bind to TRAIL receptor TR4.

IT 284461-73-0, BAY 43-9006
(anti-human TRAIL receptor TR4 antibodies and scFvs for diagnosis and treatment of cancer or hyperproliferative disease)

RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 188 OF 390 USPATFULL on STN
AN 2009:246406 USPATFULL
TI Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
IN Elting, James J., Madison, CT, UNITED STATES
Carney, Walter P., North Andover, MA, UNITED STATES
Hamer, Peter J., Reading, MA, UNITED STATES
PI US 20090221010 A1 20090903
AI US 2006-90408 A1 20061020 (12)
WO 2006-US41090 20061020
20080714 PCT 371 date
PRAI US 2005-729410P 20051021 (60)
DT Utility
FS APPLICATION
LREP LEONA L. LAUDER, 235 MONTGOMERY STREET, SUITE 1026, SAN FRANCISCO, CA, 94104-0332, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.
IT 284461-73-0, Sorafenib
(VEGF-165 determination in body fluid by sandwich ELISA for prediction and prognosis of cancer and to monitor efficacy of cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 189 OF 390 USPATFULL on STN
AN 2009:245856 USPATFULL
TI NON-PATHOGENIC AND/OR ATTENUATED BACTERIA CAPABLE OF INDUCING APOPTOSIS IN MACROPHAGES, PROCESS OF MANUFACTURING AND USES THEREOF
IN FENSTERLE, Joachim, Hoechberg, GERMANY, FEDERAL REPUBLIC OF
Galmbacher, Katharina, Muenchen, GERMANY, FEDERAL REPUBLIC OF
Rapp, Ulf, Wuerzburg, GERMANY, FEDERAL REPUBLIC OF
Goebel, Werner, Muenchen, GERMANY, FEDERAL REPUBLIC OF
Hotz, Christian, Muenchen, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090220459 A1 20090903
AI US 2009-361843 A1 20090129 (12)
PRAI EP 2008-101045 20080129
US 2008-24225P 20080129 (61)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 1970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.
IT 284461-73-0, Sorafenib
(non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages process of manufacturing and uses thereof)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 190 OF 390 USPATFULL on STN
AN 2009:240467 USPATFULL
TI TREATMENT OF CANCER WITH SORAFENIB
IN Wilhelm, Scott, Morristown, NJ, UNITED STATES
PI US 20090215835 A1 20090827
AI US 2006-92024 A1 20061031 (12)
WO 2006-US42367 20061031
20081017 PCT 371 date
PRAI US 2005-731597P 20051031 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for treating specific cancers with effective amounts of sorafenib.
IT 284461-73-0, Sorafenib
(treatment of cancer with sorafenib)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1P
(treatment of cancer with sorafenib)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-carbamoyl(4-pyridyloxy)]phenyl]urea
(treatment of cancer with sorafenib)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 191 OF 390 USPATFULL on STN
AN 2009:240465 USPATFULL
TI Thermodynamically stable form of a tosylate salt
IN Grunenberg, Alfons, Dormagen, GERMANY, FEDERAL REPUBLIC OF
Lenz, Jana, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PA Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090215833 A1 20090827
AI US 2005-664363 A1 20050920 (11)
WO 2005-EP10119 20050920
20080620 PCT 371 date
PRAI EP 2004-23130 20040929
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.
IT 284461-73-0, BAY 43-9006
(preparation of a polymorphic crystalline form of the anticancer agent 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide tosylate salt thermodynamically stable at room temperature)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 192 OF 390 USPATFULL on STN
AN 2009:240426 USPATFULL
TI Methods for treating drug resistant cancer
IN Michelson, Glenn C., Emeryville, CA, UNITED STATES
Chan, Vivien W., Emeryville, CA, UNITED STATES
Heise, Carla C., Emeryville, CA, UNITED STATES
Wiesmann, Marion, Emeryville, CA, UNITED STATES
Dawes, Timothy D., Emeryville, CA, UNITED STATES
PA Novartis AG (U.S. corporation)
PI US 20090215793 A1 20090827
AI US 2006-913828 A1 20060510 (11)
WO 2006-US17922 20060510
20080909 PCT 371 date
PRAI US 2005-680722P 20050513 (60)
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER LLP, 150 EAST GILMAN STREET, P.O. BOX 1497, MADISON, WI,
53701-1497, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 3319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.
IT 284461-73-0, BAY43-9006
(methods for treating drug resistant cancer using 4-amino substituted quinolinone benzimidazolyl compds. and combination with other agents in relation to inhibition of protein kinases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 193 OF 390 USPATFULL on STN
AN 2009:239111 USPATFULL
TI Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
IN Jennings, Barbara Brooke, Jupiter, FL, UNITED STATES
PI US 20090214474 A1 20090827
AI US 2009-387239 A1 20090430 (12)
RLI Continuation-in-part of Ser. No. US 2006-591398, filed on 1 Nov 2006, PENDING Continuation-in-part of Ser. No. US 2007-1869, filed on 13 Dec 2007, PENDING
DT Utility
FS APPLICATION
LREP Irving M. Fishman, c/o Cohen, Tauber, Spievak & Wagner, Suite 2400, 420 Lexington Avenue, New York, NY, 10170, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7995
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(inositol compds. and other agents, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 194 OF 390 USPATFULL on STN
AN 2009:233445 USPATFULL
TI 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
IN Gaisser, Sabine, Essex, UNITED KINGDOM
Martin, Christine, Essex, UNITED KINGDOM
Zhang, Ming, Essex, UNITED KINGDOM
Wilkinson, Barrie, Essex, UNITED KINGDOM
Coates, Nigel, Essex, UNITED KINGDOM
Nur-E-Alam, Mohammed, Essex, UNITED KINGDOM
Vousden, William, Essex, UNITED KINGDOM
PI US 20090209507 A1 20090820
AI US 2007-294253 A1 20070330 (12)
WO 2007-EP53131 20070330
20090122 PCT 371 date
PRAI GB 2006-6542 20060331
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 15-O-desmethylmacbecin analogues according to the formula (IA) or (IB) herein, or a pharmaceutically acceptable salt thereof: wherein: R.sub.1 and R.sub.2 either both represent H or together they represent a bond (i.e. C4 to C5 is a double bond); and R.sub.3 represents H or CONH.sub.2 that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.
IT 284461-73-0
(production of 15-desmethylmacbecin analogs from engineered strains of Actinosynnema pretiosum for use in cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 195 OF 390 USPATFULL on STN
AN 2009:233434 USPATFULL
TI METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS
IN Chaplin, David, Oxfordshire, UNITED KINGDOM
Siim, Bronwyn G., Oxford, UNITED KINGDOM
PI US 20090209496 A1 20090820
AI US 2009-372602 A1 20090217 (12)
PRAI US 2008-65898P 20080215 (61)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, LLP, FLOOR 30, SUITE 3000, ONE POST OFFICE SQUARE,
BOSTON, MA, 02109, US
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Receptor Tyrosine Kinase inhibitor (e.g., a small molecule RTK inhibitor, e.g., Sorafenib or Erlotinib) by administering to the subject a Vascular Disrupting Agent (e.g., a Combretastatin or derivative thereof) sequentially or simultaneously in combination with said RTK inhibitor. Pharmaceutical compositions comprising a combination of a RTK inhibitor and a VDA are also provided.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
1181556-90-0 1181556-92-2
(vascular disrupting agent for enhancement of efficacy of receptor tyrosine kinase inhibitor for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 1181556-90-0 USPATFULL
CN Phosphonic acid, P,P'-[3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene]bis-, sodium salt (1:4), mixt. with 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide (CA INDEX NAME)

CM 1

CRN 1181556-89-7
CMF C18 H22 O10 P2 . 4 Na

Double bond geometry as shown.



●4 Na

CM 2

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



RN 1181556-92-2 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mixt. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



L20 ANSWER 196 OF 390 USPATFULL on STN
AN 2009:232890 USPATFULL
TI UTILITY OF RET MUTANT IN DIAGNOSIS AND TREATMENT OF MELANOMA
IN Hoon, Dave S.B., Los Angeles, CA, UNITED STATES
Narita, Norihiko, Fukui, JAPAN
Tanemura, Atsushi, Osaka, JAPAN
PA John Wayne Cancer Institute, Santa Monica Boulevard, CA, UNITED STATES (U.S. corporation)
PI US 20090208952 A1 20090820
US 7943319 B2 20110517
AI US 2008-267541 A1 20081107 (12)
PRAI US 2007-2606P 20071109 (61)
DT Utility
FS APPLICATION
LREP HOGAN & HARTSON L.L.P., 1999 AVENUE OF THE STARS, SUITE 1400, LOS
ANGELES, CA, 90067, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 1131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.
IT 284461-73-0, Sorafenib
(utility of RET mutant in diagnosis and treatment of melanoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 197 OF 390 USPATFULL on STN
AN 2009:232431 USPATFULL
TI Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
IN Larson, Richard S., Albuquerque, NM, UNITED STATES
Sklar, Larry A., Albuquerque, NM, UNITED STATES
Edwards, Bruce S., Albuquerque, NM, UNITED STATES
Ivnitski-Steele, Irena D., Albuquerque, NM, UNITED STATES
Oprea, Tudor I., Albuquerque, NM, UNITED STATES
Lovato, Debbie M., Albuquerque, NM, UNITED STATES
Khawaja, Hadya M., Albuquerque, NM, UNITED STATES
Winter, Stuart S., Albuquerque, NM, UNITED STATES
Young, Susan M., Albuquerque, NM, UNITED STATES
PA STC. UNM, Albuquerque, NM, UNITED STATES (U.S. corporation)
PI US 20090208493 A1 20090820
AI US 2008-315132 A1 20081128 (12)
PRAI US 2007-4342P 20071127 (61)
US 2008-124377P 20080416 (61)
US 2008-131214P 20080606 (61)
DT Utility
FS APPLICATION
LREP COLEMAN SUDOL SAPONE, P.C., 714 COLORADO AVENUE, BRIDGE PORT, CT, 06605-1601, US
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.
IT 284461-73-0, Sorafenib
(compds. and methods for selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 198 OF 390 USPATFULL on STN
AN 2009:226889 USPATFULL
TI Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
IN Steinberg, Joyce L., Northbrook, IL, UNITED STATES
Gupta, Neeraj, Waukegan, IL, UNITED STATES
Pradhan, Rajendra S., Buffalo Grove, IL, UNITED STATES
Enschede, Sari H., River Forest, IL, UNITED STATES
Humerickhouse, Rod A., Highland Park, IL, UNITED STATES
PA ABBOTT LABORATORIES, Abbott Park, IL, UNITED STATES (U.S. corporation)
PI US 20090203709 A1 20090813
AI US 2009-365966 A1 20090205 (12)
PRAI US 2008-26975P 20080207 (61)
DT Utility
FS APPLICATION
LREP PAUL D. YASGER, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.
IT 284461-73-0, Sorafenib 284461-73-0D, Sorafenib, salts, hydrates, solvates
(as tyrosine kinase inhibitor; polymer and solubilizer in pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 199 OF 390 USPATFULL on STN
AN 2009:225726 USPATFULL
TI SUBSTITUTED OXAZAPHOSPHORINES
IN Gant, Thomas G., Carlsbad, CA, UNITED STATES
PA Auspex Pharmaceuticals, Inc., Vista, CA, UNITED STATES (U.S. corporation)
PI US 20090202540 A1 20090813
AI US 2009-368754 A1 20090210 (12)
PRAI US 2008-27775P 20080211 (61)
DT Utility
FS APPLICATION
LREP GLOBAL PATENT GROUP - APX, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##
IT 284461-73-0, Sorafenib
(codrug; preparation of deuterated or tritiated oxazaphosphorine and their biol. activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



```
=> d l20 200-299 bib,ab,hitstr
```

L20 ANSWER 200 OF 390 USPATFULL on STN
AN 2009:220394 USPATFULL
TI COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
IN Maitland, Mardi Gomberg, Chicago, IL, UNITED STATES
Ratain, Mark J., Chicago, IL, UNITED STATES
Garcia, Joe G.N., Chicago, IL, UNITED STATES
Maitland, Michael, Chicago, IL, UNITED STATES
Moreno-Vinasco, Liliana, Chicago, IL, UNITED STATES
PA The University of Chicago, IChicago, IL, UNITED STATES (U.S. corporation)
PI US 20090197922 A1 20090806
AI US 2007-161400 A1 20070124 (12)
WO 2007-US60995 20070124
20081118 PCT 371 date
PRAI US 2006-761612P 20060124 (60)
US 2006-833934P 20060728 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX,
78701, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods of the invention are related to treating pulmonary hypertension using a Raf kinase inhibitor, such as sorafenib. IQ a particular aspect, pulmonary hypertension is pulmonary arterial hypertension.
IT 284461-73-0, Sorafenib
(compns. and methods for treating pulmonary hypertension)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 201 OF 390 USPATFULL on STN
AN 2009:213924 USPATFULL
TI POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF
IN Gavenda, Ales, Ostrava-Lhotka, CZECH REPUBLIC
Jegorov, Alexandr, Dobra Voda, CZECH REPUBLIC
Rossetto, Pierluigi, Lodi, ITALY
MacDonald, Peter Lindsay, Gentilino, SWITZERLAND
Canavesi, Augusto, Locate Varesino (CO), ITALY
PI US 20090192200 A1 20090730
AI US 2009-356004 A1 20090119 (12)
PRAI US 2008-11630P 20080117 (61)
US 2008-131033P 20080604 (61)
US 2008-82723P 20080722 (61)
DT Utility
FS APPLICATION
LREP KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.
IT 284461-73-0, Sorafenib 284461-73-0D, Sorafenib, base derivs
(polymorph form III of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1, Sorafenib tosylate
(polymorph form III of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0DP, Sorafenib, hemitosylate
(polymorph form III of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-73-0P
(polymorph form III of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof)

RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 202 OF 390 USPATFULL on STN
AN 2009:213898 USPATFULL
TI Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action
IN Kato, Tetsuya, Ibaraki, JAPAN
Kawanishi, Nobuhiko, Ibaraki, JAPAN
Mita, Takashi, Ibaraki, JAPAN
Nagai, Keita, Ibaraki, JAPAN
Nonoshita, Katsumasa, Ibaraki, JAPAN
Ohkubo, Mitsuru, Ibaraki, JAPAN
PA BANYU PHARMACEUTICAL CO., LTD., Kudankita, Chiyoda-ku, Tokyo, JAPAN (non-U.S. corporation)
PI US 20090192174 A1 20090730
AI US 2007-226639 A1 20070425 (12)
WO 2007-JP59413 20070425
20081024 PCT 371 date
PRAI JP 2006-124475 20060427
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of general formula I:

##STR1##

wherein:

n.sub.1 and n.sub.2 are the same or different, and are 0 or 1; R is aryl, heteroaryl, etc.; R.sub.e is hydrogen atom or lower alkyl; two groups selected from four groups consisting of (i) either one of R.sub.a1 and R.sub.a1', (ii) either one of R.sub.a2 and R.sub.a2', (iii) either one of R.sub.b1 and R.sub.b1', and (iv) either one of R.sub.b2 and R.sub.b2', are combined to form --(CH.sub.2).sub.n-- where n is 1, 2 or 3; and among R.sub.a1, R.sub.a1', R.sub.a2, R.sub.a2', R.sub.b1, R.sub.b1', R.sub.b2 and R.sub.b2', the groups which do not form --(CH.sub.2).sub.n-- are each independently hydrogen atom, etc.; X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently CH, N, etc.; Y.sub.1, Y.sub.2, Y.sub.3 and Y.sub.4 are the same or different and are CH or N, etc.; W is a 5-membered aromatic heterocyclic group, or a pharmaceutically acceptable salt or ester thereof.
IT 284461-73-0
(preparation of 2,5-diazabicyclo[2.2.1]heptane derivs. as Aurora A inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 203 OF 390 USPATFULL on STN
AN 2009:196394 USPATFULL
TI Diaryl Ureas for Treating Pulmonary Hypertension
IN Sandner, Peter, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Tinel, Hanna, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Hutter, Joachim, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Klein, Martina, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
PA BAYER HEALTHCARE AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090176791 A1 20090709
AI US 2006-84659 A1 20061030 (12)
WO 2006-EP10405 20061030
20090206 PCT 371 date
PRAI EP 2005-24508 20051110
EP 2005-27449 20051215
EP 2006-7775 20060413
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.
IT 284461-73-0, BAY 43-9006 284461-74-1
475207-59-1
(diarylureas in combination with addnl. drugs for treating pulmonary hypertension)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 204 OF 390 USPATFULL on STN
AN 2009:188406 USPATFULL
TI METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS
IN Daelken, Benjamin, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
Uherek, Christoph, Seligenstadt, GERMANY, FEDERAL REPUBLIC OF
Anderson, Kenneth, Wellesley, MA, UNITED STATES
Hideshima, Teru, Brookline, MA, UNITED STATES
Bruecher, Christoph, Eschborn, GERMANY, FEDERAL REPUBLIC OF
PI US 20090169570 A1 20090702
AI US 2008-342815 A1 20081223 (12)
PRAI US 2007-16614P 20071226 (61)
US 2008-87466P 20080808 (61)
US 2008-87590P 20080808 (61)
DT Utility
FS APPLICATION
LREP JOYCE VON NATZMER, PEQUIGNOT + MYERS LLC, 200 Madison Avenue, Suite 1901, New York, NY, 10016, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 3276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.
IT 284461-73-0, Sorafenib
(immunoconjugates targeting of CD138-expressing tumor cells for alleviation of resistance to)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 205 OF 390 USPATFULL on STN
AN 2009:173888 USPATFULL
TI METHODS OF TREATING BLOOD CELL DEPLETION
IN Siegel, Hal, Paradise Valley, AZ, UNITED STATES
Wilhelm, Michael K., Scottsdale, AZ, UNITED STATES
PA ImmuneRegen Biosciences, Inc., Scottsdale, AZ, UNITED STATES (U.S. corporation)
PI US 20090156504 A1 20090618
AI US 2008-179409 A1 20080724 (12)
PRAI US 2007-966948P 20070829 (60)
US 2007-965580P 20070820 (60)
US 2007-952691P 20070730 (60)
US 2008-39866P 20080327 (61)
US 2008-39860P 20080327 (61)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of a substance P analog. In one embodiment, substance P analogs are useful for reducing PARP activity or PARP expression. In one embodiment, substance P analogs are useful for preventing, reducing or ameliorating adverse effects of drugs. In one embodiment, drug induced blood dyscrasias can be ameliorated by the methods and compositions provided herein.
IT 284461-73-0, Sorafenib
(methods of treating blood cell depletion due to drugs or radiation using substance P or its analogs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 206 OF 390 USPATFULL on STN
AN 2009:166090 USPATFULL
TI TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS
IN Ossovskaya, Valeria, San Francisco, CA, UNITED STATES
Bradley, Charles, Half Moon Bay, CA, UNITED STATES
Sherman, Barry, Hillsborough, CA, UNITED STATES
PA BiPar Sciences (U.S. corporation)
PI US 20090149397 A1 20090611
AI US 2008-329503 A1 20081205 (12)
PRAI US 2007-12364P 20071207 (61)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase, as well as providing formulations and modes of administering such compositions.
IT 475207-59-1, Nexavar
(PARP inhibitor for treatment of uterine cancer, endometrial cancer, and ovarian cancer, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 207 OF 390 USPATFULL on STN
AN 2009:159899 USPATFULL
TI Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
IN Yaffe, Michael B., West Roxbury, MA, UNITED STATES
Clapperton, Julie A., London, UNITED KINGDOM
Manke, Isaac A., Cambridge, MA, UNITED STATES
Lowery, Drew M., Cambridge, MA, UNITED STATES
Smerdon, Stephen J., London, UNITED KINGDOM
Haire, Lesley F., London, UNITED KINGDOM
PI US 20090143997 A1 20090604
AI US 2008-229740 A1 20080826 (12)
RLI Division of Ser. No. US 2005-126022, filed on 9 May 2005, ABANDONED
PRAI US 2004-569131P 20040507 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 12647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a human BRCT domain-BACH1 phosphopeptide complex.
IT 284461-73-0, BAY-43-9006
(x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compns. for antitumor drug design)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 208 OF 390 USPATFULL on STN
AN 2009:158245 USPATFULL
TI Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
IN Squires, Matthew Simon, Cambridge, UNITED KINGDOM
PA Astex Therapeutics Limited, Cambridge, UNITED KINGDOM (non-U.S. corporation)
PI US 20090142337 A1 20090604
AI US 2007-300056 A1 20070504 (12)
WO 2007-GB1640 20070504
20090112 PCT 371 date
PRAI US 2006-746694P 20060508 (60)
US 2006-830966P 20060714 (60)
DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-119
DRWN 7 Drawing Page(s)
LN.CNT 8574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a combination comprising (or consisting essentially of) an ancillary compound and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R.sup.1 is 2,6-dichlorophenyl; R.sup.2a and R.sup.2b are both hydrogen; and R.sup.3 is a group: formula (A) where R.sup.4 is C.sub.1-4 alkyl. The combinations have activity as inhibitors of CDK kinases and inhibit the proliferation of cancer cells.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of pyrazole derivs. and their pharmaceutical compns. as CDK kinase inhibitors useful in treatment and prophylaxis of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 209 OF 390 USPATFULL on STN
AN 2009:151659 USPATFULL
TI RAF Inhibitors and Uses Thereof
IN Lapierre, Jean-Marc, Pelham, NH, UNITED STATES
Namdev, Nivedita D., Westford, MA, UNITED STATES
Ashwell, Mark A., Carlisle, MA, UNITED STATES
France, Dennis S., Cambridge, MA, UNITED STATES
Wu, Hui, Malden, MA, UNITED STATES
Hutchins, Patrick M., Denver, CO, UNITED STATES
Tandon, Manish, Framingham, MA, UNITED STATES
Liu, Yanbin, Acton, MA, UNITED STATES
Link, Jeff S., Londonderry, NH, UNITED STATES
Ali, Syed M., North Andover, MA, UNITED STATES
Brassard, Chris J., Somerville, MA, UNITED STATES
Nicewonger, Robb B., Tyngsboro, MA, UNITED STATES
Filikov, Anton, Stoneham, MA, UNITED STATES
Carazza, Rebecca J., Winchester, MA, UNITED STATES
PA ARQULE, INC., Woburn, MA, UNITED STATES (U.S. corporation)
PI US 20090136499 A1 20090528
AI US 2009-356097 A1 20090120 (12)
RLI Continuation of Ser. No. US 2007-785163, filed on 16 Apr 2007, Pat. No. US 7501430
PRAI US 2006-792314P 20060417 (60)
DT Utility
FS APPLICATION
LREP BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-33
DRWN 6 Drawing Page(s)
LN.CNT 4787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAF.sup.V600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
IT 284461-73-0, Sorafenib
(preparation of imidazoloxazole and imidazolothiazole compds. as RAF kinase inhibitors useful in treatment of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 210 OF 390 USPATFULL on STN
AN 2009:145934 USPATFULL
TI TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS
IN Sherman, Barry M., Hillsborough, CA, UNITED STATES
Bradley, Charles, Half Moon Bay, CA, UNITED STATES
Ossovskaya, Valeria, San Francisco, CA, UNITED STATES
PA BiPar Sciences (U.S. corporation)
PI US 20090131529 A1 20090521
US 7732491 B2 20100608
AI US 2008-269024 A1 20081111 (12)
PRAI US 2007-987333P 20071112 (60)
US 2007-12364P 20071207 (61)
US 2008-58528P 20080603 (61)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 121
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
IT 475207-59-1, Nexavar
(PARP inhibitor for treatment of uterine cancer, endometrial cancer, and ovarian cancer, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 211 OF 390 USPATFULL on STN
AN 2009:144526 USPATFULL
TI Substituted Tetrazole Compounds and Uses Thereof
IN Yang, Rui-Yang, Lexington, MA, UNITED STATES
Ali, Syed M., North Andover, MA, UNITED STATES
Ashwell, Mark A., Carlisle, MA, UNITED STATES
Kelleher, Eugene, Wellesley, MA, UNITED STATES
Palma, Rocio, North Andover, MA, UNITED STATES
Westlund, Neil, Groton, MA, UNITED STATES
PA ARQULE, INC., Woburn, MA, UNITED STATES (U.S. corporation)
PI US 20090130117 A1 20090521
US 7932279 B2 20110426
AI US 2008-251093 A1 20081014 (12)
PRAI US 2007-979601P 20071012 (60)
DT Utility
FS APPLICATION
LREP BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.
IT 284461-73-0, Sorafenib
(codrug; preparation of tetrazole compds. as HSP90 inhibitors useful in treatment of cell proliferative disorder, such as cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 212 OF 390 USPATFULL on STN
AN 2009:144510 USPATFULL
TI ANTI-CANCER THERAPY WITH AN EXTRACT OF SCUTELLARIA BARBATA
IN Cohen, Isaac, Piedmont, CA, UNITED STATES
PA BIONOVO, INC., Emeryville, CA, UNITED STATES (U.S. corporation)
PI US 20090130101 A1 20090521
AI US 2008-274251 A1 20081119 (12)
PRAI US 2007-989069P 20071119 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE
MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating cancer with a combination of an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent are provided. Also provided are kits comprising an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent.
IT 284461-73-0, Sorafenib
(Scutellaria barbata extract and combinations for treatment of cancer in relation to levels of estrogen receptors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 213 OF 390 USPATFULL on STN
AN 2009:144507 USPATFULL
TI Specific therapy using integrin ligands for treating cancer
IN Goodman, Simon, Griesheim, GERMANY, FEDERAL REPUBLIC OF
Picard, Martin Andreas, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Mikkelsen, Tom, West Bloomfield, MI, UNITED STATES
Nippgen, Johannes, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Grimm, Ulrike, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF
Stupp, Roger, Lausanne, SWITZERLAND
Weller, Michael, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
Harstrick, Andreas, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF
Grell, Matthias, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
PA Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090130098 A1 20090521
AI US 2007-161195 A1 20070118 (12)
WO 2007-US1446 20070118
20080827 PCT 371 date
PRAI EP 2006-988 20060118
EP 2006-1044 20060118
EP 2006-6003 20060120
EP 2006-15883 20060731
DT Utility
FS APPLICATION
LREP ARENT FOX LLP, 1050 CONNECTICUT AVENUE, N.W., SUITE 400, WASHINGTON, DC, 20036, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(integrin ligand combination with co-therapeutic for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 214 OF 390 USPATFULL on STN
AN 2009:144506 USPATFULL
TI Quinazolinone Compounds and Methods of Use Thereof
IN Liu, Jifeng, Winchester, MA, UNITED STATES
Ali, Syed M., North Andover, MA, UNITED STATES
Ashwell, Mark A., Carlisle, MA, UNITED STATES
Ye, Ping, Lexington, MA, UNITED STATES
Guan, Yousheng, North Billerica, MA, UNITED STATES
Ng, Shi-Chung, San Diego, CA, UNITED STATES
Palma, Rocio, North Andover, MA, UNITED STATES
Yohannes, Dan, Cambridge, MA, UNITED STATES
PA ArQule, Inc., Woburn, MA, UNITED STATES (U.S. corporation)
PI US 20090130097 A1 20090521
AI US 2008-142762 A1 20080619 (12)
PRAI US 2007-945838P 20070622 (60)
DT Utility
FS APPLICATION
LREP BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention
IT 284461-73-0, Sorafenib
(codrug; preparation of quinazolinone derivs. useful in treatment of proliferative diseases and cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 215 OF 390 USPATFULL on STN
AN 2009:137132 USPATFULL
TI COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER
IN Blakey, David Charles, Macclesfield, UNITED KINGDOM
Brown, Jeffrey Lester, Waltham, MA, UNITED STATES
Emery, Stephen Charles, Macclesfield, UNITED KINGDOM
PA ASTRAZENECA AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 20090123474 A1 20090514
AI US 2006-97384 A1 20061212 (12)
WO 2006-GB4611 20061212
20080613 PCT 371 date
PRAI US 2005-750551P 20051215 (60)
DT Utility
FS APPLICATION
LREP ASTRAZENECA R&D BOSTON, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451-1215, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2581
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.
IT 284461-73-0, BAY43-9006
(combination of anti-angiopoietin 2 human monoclonal antibody and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 216 OF 390 USPATFULL on STN
AN 2009:137077 USPATFULL
TI TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS
IN Sherman, Barry M., Hillsborough, CA, UNITED STATES
Bradley, Charles, Half Moon Bay, CA, UNITED STATES
Ossovskaya, Valeria, San Francisco, CA, UNITED STATES
PA BiPar Sciences (U.S. corporation)
PI US 20090123419 A1 20090514
AI US 2008-269833 A1 20081112 (12)
PRAI US 2007-987335P 20071112 (60)
US 2007-12364P 20071207 (61)
US 2008-58528P 20080603 (61)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 147
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5229
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
IT 475207-59-1, Nexavar
(PARP inhibitor for treatment of uterine cancer, endometrial cancer, and ovarian cancer, and use with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 217 OF 390 USPATFULL on STN
AN 2009:131206 USPATFULL
TI OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
IN Riedl, Bernd, Wupperral, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20090118268 A1 20090507
AI US 2008-249386 A1 20081010 (12)
RLI Continuation of Ser. No. US 2007-845597, filed on 27 Aug 2007, PENDING
Division of Ser. No. US 2002-86417, filed on 4 Mar 2002, ABANDONED
Continuation of Ser. No. US 1999-425229, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-38
DRWN No Drawings
LN.CNT 3317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 218 OF 390 USPATFULL on STN
AN 2009:131178 USPATFULL
TI LOCAL TREATMENT OF NEUROFIBROMAS
IN Chen, Ruihong, Foster City, CA, UNITED STATES
Rubenstein, Allan E., New York, NY, UNITED STATES
Shen, Xiaodong, Foster City, CA, UNITED STATES
Stewart, Scott, San Diego, CA, UNITED STATES
Yu, Jin-Chen, Palo Alto, CA, UNITED STATES
PI US 20090118240 A1 20090507
AI US 2006-815443 A1 20060202 (11)
WO 2006-US3588 20060202
20080722 PCT 371 date
PRAI US 2005-649854P 20050202 (60)
US 2005-669813P 20050407 (60)
DT Utility
FS APPLICATION
LREP COOLEY GODWARD KRONISH LLP, ATTN: Patent Group, Suite 1100, 777 - 6th Street, NW, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
IT 284461-73-0, Bay43-9006
(local treatment of neurofibromas including dermal and subdermal and superficial plexiform neurofibromas)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 219 OF 390 USPATFULL on STN
AN 2009:130021 USPATFULL
TI Methods For Treating Tumor Cells
IN Chen, Lei L., Bountiful, UT, UNITED STATES
PI US 20090117076 A1 20090507
AI US 2007-933422 A1 20071101 (11)
DT Utility
FS APPLICATION
LREP THE MCCALLUM LAW FIRM, P. C., 685 BRIGGS STREET, PO BOX 929, ERIE, CO, 80516, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating a disease in a patient are disclosed that include the administration of a targeted therapy in combination with an immunotherapy. Such therapy is useful in the treatment of any disease susceptible to targeted therapy and attack by the immune system.
IT 284461-73-0, Sorafenib
(method for treating tumor cells with immunotherapy and tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 220 OF 390 USPATFULL on STN
AN 2009:130019 USPATFULL
TI Sulfonylpyrroles as Histone Deacetylase Inhibitors
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Dullweber, Frank, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA NYCOMED GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090117074 A1 20090507
AI US 2006-887268 A1 20060407 (11)
WO 2006-EP3171 20060407
20080625 PCT 371 date
PRAI EP 2005-102750 20050407
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of formula (I)

##STR1##

which are effective inhibitors of histone deacetylases.
IT 284461-73-0, BAY43-9006
(preparation of sulfonylpyrroles as histone deacetylase inhibitors useful in disease therapy and prophylaxis)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 221 OF 390 USPATFULL on STN
AN 2009:124116 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111891 A1 20090430
US 7632868 B2 20091215
AI US 2008-235966 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 222 OF 390 USPATFULL on STN
AN 2009:124115 USPATFULL
TI Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111890 A1 20090430
US 7541382 B2 20090602
AI US 2008-235926 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 223 OF 390 USPATFULL on STN
AN 2009:124114 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111889 A1 20090430
US 7635720 B2 20091222
AI US 2008-235887 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 224 OF 390 USPATFULL on STN
AN 2009:124113 USPATFULL
TI Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111888 A1 20090430
US 7553875 B2 20090630
AI US 2008-235807 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 225 OF 390 USPATFULL on STN
AN 2009:124112 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111887 A1 20090430
US 7638557 B2 20091229
AI US 2008-235791 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 226 OF 390 USPATFULL on STN
AN 2009:124111 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111885 A1 20090430
US 7649021 B2 20100119
AI US 2008-235762 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 227 OF 390 USPATFULL on STN
AN 2009:124110 USPATFULL
TI Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111884 A1 20090430
US 7553874 B2 20090630
AI US 2008-235747 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 228 OF 390 USPATFULL on STN
AN 2009:124109 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111883 A1 20090430
US 7632867 B2 20091215
AI US 2008-235736 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 229 OF 390 USPATFULL on STN
AN 2009:124108 USPATFULL
TI Prostaglandin Analog Compositions To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111881 A1 20090430
US 7645800 B2 20100112
AI US 2008-235683 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 230 OF 390 USPATFULL on STN
AN 2009:124107 USPATFULL
TI Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111880 A1 20090430
US 7550508 B2 20090623
AI US 2008-235664 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 231 OF 390 USPATFULL on STN
AN 2009:123988 USPATFULL
TI Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PI US 20090111761 A1 20090430
AI US 2008-236024 A1 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS APPLICATION
LREP Beverly W Lubit, 28 Gravel Hill Road, Kinneion, NJ, 07405, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention further relates to the formulation and delivery of prostaglandin analogs to reduce intraocular pressure.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 232 OF 390 USPATFULL on STN
AN 2009:122890 USPATFULL
TI MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER
IN Breitenkamp, Kurt, Amherst, MA, UNITED STATES
Rios-Doria, Jonathan, Land O Lakes, FL, UNITED STATES
Breitenkamp, Rebecca, Amherst, MA, UNITED STATES
Sill, Kevin N., Tampa, FL, UNITED STATES
Skaff, Habib, Tampa, FL, UNITED STATES
PA Intezyne Technologies, Inc., Tampa, FL, UNITED STATES (U.S. corporation)
PI US 20090110662 A1 20090430
AI US 2008-113101 A1 20080430 (12)
PRAI US 2007-915070P 20070430 (60)
DT Utility
FS APPLICATION
LREP CHOATE, HALL & STEWART LLP, TWO INTERNATIONAL PLACE,
BOSTON, MA, 02110,
US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.
IT 475207-59-1, Nexavar
(modification of peptidyl biol. targeting groups for treatment of cancer)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0, Sorafenib
(modification of peptidyl biol. targeting groups for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 233 OF 390 USPATFULL on STN
AN 2009:116780 USPATFULL
TI PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR
IN Lane, Heidi, Biel-Benken, SWITZERLAND
PA NOVARTIS AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 20090105285 A1 20090423
AI US 2007-299819 A1 20070509 (12)
WO 2007-EP4112 20070509
20081106 PCT 371 date
PRAI GB 2006-9378 20060511
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.
IT 284461-73-0, BAY 43-9006
(pharmaceutical synergistic combinations comprising an mTOR inhibitor and a Raf kinase inhibitor and its use in cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 234 OF 390 USPATFULL on STN
AN 2009:109311 USPATFULL
TI Methods for diagnosis prognosis and methods of treatment
IN Fantl, Wendy J., San Francisco, CA, UNITED STATES
Putta, Santosh K., Foster City, CA, UNITED STATES
Perez, Omar D., San Francisco, CA, UNITED STATES
Francis-Lang, Helen L., San Francisco, CA, UNITED STATES
Cohen, Aileen C., Palo Alto, CA, UNITED STATES
PA Nodality, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20090098594 A1 20090416
AI US 2008-229476 A1 20080821 (12)
PRAI US 2007-957160P 20070821 (60)
US 2008-48920P 20080429 (61)
DT Utility
FS APPLICATION
LREP WILSON, SONSINI, GOODRICH & ROSATI / NODALITY, INC, 650 Page Mill Road, Palo Alto, CA, 94304-1050, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 5355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells.
IT 284461-73-0, Sorafenib
(methods for diagnosis, prognosis and treatment of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 235 OF 390 USPATFULL on STN
AN 2009:108918 USPATFULL
TI COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION
IN Temtsin Krayz, Galia, Ashdod, ISRAEL
Averbuch, Maryana, Ashdod, ISRAEL
Zelkind, Ilya, Ofakim, ISRAEL
Gitis, Larisa, Holon, ISRAEL
PA SOLUBEST LTD., NESS ZIONA, ISRAEL (non-U.S. corporation)
PI US 20090098200 A1 20090416
AI US 2008-238424 A1 20080925 (12)
PRAI US 2007-975066P 20070925 (60)
US 2007-975045P 20070925 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303, US
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.
IT 284461-73-0, Sorafenib
(colloidal nanodispersion compns. comprising lipophilic active compds. and method for their preparation)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 236 OF 390 USPATFULL on STN
AN 2009:108851 USPATFULL
TI Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer
IN Pekari, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, NETHERLANDS
Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PA ALTANA Pharma AG, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090098133 A1 20090416
US 7741488 B2 20100622
AI US 2006-883624 A1 20060210 (11)
WO 2006-EP50859 20060210
20070918 PCT 371 date
PRAI EP 2005-101007 20050211
EP 2005-104493 20050525
EP 2005-112159 20051214
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon
Boulevard, Arlington, VA, 22201, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I),

##STR1##

in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, Sorafenib
(preparation of tetrahydropyridothiophenes as antiproliferative and apoptosis-inducing agents useful in treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 237 OF 390 USPATFULL on STN
AN 2009:105246 USPATFULL
TI Prostaglandin analog compositions and methods to treat epithelial-related conditions
IN Lipkin, Pamela, New York, NY, UNITED STATES
Lubit, Beverly, Kinnelon, NJ, UNITED STATES
PA Meta Cosmetics, LLC, New York, NY, UNITED STATES (U.S. corporation)
PI US 7517912 B1 20090414
US 20090111886 A1 20090430
AI US 2008-235776 20080923 (12)
PRAI US 2007-984198P 20071031 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Padmanabhan, Sreeni; Assistant Examiner: Jean-Louis, Samira
LREP Greenberg, Traurig, LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.
IT 284461-73-0, Sorafenib
(methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 238 OF 390 USPATFULL on STN
AN 2009:90147 USPATFULL
TI Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors
IN Haack, Herbert, Holliston, MA, UNITED STATES
Sullivan, Laura, Beverly, MA, UNITED STATES
PA CELL SIGNALING TECHNOLOGY, INC. (U.S. corporation)
PI US 20090081709 A1 20090326
US 7833736 B2 20101116
AI US 2007-731984 A1 20070402 (11)
PRAI US 2006-788172P 20060331 (60)
DT Utility
FS APPLICATION
LREP Simona Levi-Minzi, Ph.D., General Counsel, CELL SIGNALING TECHNOLOGY, INC., 3 Trask Lane, Danvers, MA, 01923, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided.
IT 284461-73-0, BAY 43-9006
(protein sequence of human cancer protein markers of responsiveness to type III receptor tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 239 OF 390 USPATFULL on STN
AN 2009:89677 USPATFULL
TI Anti-notch1 NRR antibodies and methods using same
IN Siebel, Christian W., Berkeley, CA, UNITED STATES
Wu, Yan, Foster City, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 20090081238 A1 20090326
US 20090258026 A2 20091015
AI US 2008-156590 A1 20080603 (12)
PRAI US 2007-933072P 20070604 (60)
US 2007-994646P 20070920 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 7426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
IT 284461-73-0, Sorafenib
(combination with; anti-Notch1 neg. regulatory region (NRR) antibodies for use in diagnosis and therapy of cancer or proliferative disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 240 OF 390 USPATFULL on STN
AN 2009:83751 USPATFULL
TI METHODS, KITS, AND COMPOUNDS FOR DETERMINING RESPONSIVENESS TO TREATMENT OF A PATHOLOGICAL DISORDER BY EPOTHILONES
IN Hoffmann, Jens, Muhlenbeck, GERMANY, FEDERAL REPUBLIC OF
Hammer, Stefanie, Berlin, GERMANY, FEDERAL REPUBLIC OF
Sommer, Anette, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 20090076098 A1 20090319
AI US 2008-163288 A1 20080627 (12)
PRAI EP 2007-111484 20070629
US 2007-947137P 20070629 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 3380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention further relates to methods, compounds and uses of said compounds for treating subjects suffering from said pathologic disorder, optionally in combination with other therapeutic agents. Also provided are genes and/or proteins encoded by them whose expression level have been determined to differ between epothilone responders and epothilone non-responders.
IT 284461-73-0, Sorafenib
(methods, kits, and compds. for determining responsiveness to treatment of pathol. disorder by epothilones)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 241 OF 390 USPATFULL on STN
AN 2009:76312 USPATFULL
TI DEUTERIUM-ENRICHED SORAFENIB
IN Czarnik, Anthony W., Reno, NV, UNITED STATES
PA PROTIA, LLC, Reno, NV, UNITED STATES (U.S. corporation)
PI US 20090069388 A1 20090312
AI US 2008-196151 A1 20080821 (12)
PRAI US 2007-971566P 20070911 (60)
DT Utility
FS APPLICATION
LREP VANCE INTELLECTUAL PROPERTY, PC, 5467 HILL TOP STREET, CROZET, VA, 22932-3167, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes deuterium-enriched sorafenib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
IT 284461-73-0, Sorafenib 284461-73-0D, Sorafenib, deuterium-enriched 1130115-30-8 1130115-33-1 1130115-36-4 1130115-39-7 1130115-42-2 1130115-44-4
(deuterium-enriched sorafenib for carcinoma treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 1130115-30-8 USPATFULL
CN INDEX NAME NOT YET ASSIGNED



RN 1130115-33-1 USPATFULL
CN INDEX NAME NOT YET ASSIGNED



RN 1130115-36-4 USPATFULL
CN INDEX NAME NOT YET ASSIGNED



RN 1130115-39-7 USPATFULL
CN INDEX NAME NOT YET ASSIGNED



RN 1130115-42-2 USPATFULL
CN 2-Pyridine-3,5,6-d3-carboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 1130115-44-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(methyl-d3)- (CA INDEX NAME)



L20 ANSWER 242 OF 390 USPATFULL on STN
AN 2009:75072 USPATFULL
TI DIARYL UREAS AND COMBINATIONS
IN Wilhelm, Scott, Morristown, NJ, UNITED STATES
PI US 20090068146 A1 20090312
AI US 2006-91983 A1 20061031 (12)
WO 2006-US42368 20061031
20081113 PCT 371 date
PRAI US 2005-731277P 20051031 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2187
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I):

B--NH--C(O)--NH-L-M-L.sup.1-(Q).sub.1-3 (I).

In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group;

M is a bridging group.
each Q is independently C(O)R.sup.4, C(O)OR.sup.4 and C(O)NR.sup.4R.sup.5; and
L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.
IT 284461-73-0P 284461-74-1P 475207-59-1P
(drug candidate; preparation of diaryl ureas as anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 243 OF 390 USPATFULL on STN
AN 2009:75070 USPATFULL
TI TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER
IN Weber, Lutz, Germering, GERMANY, FEDERAL REPUBLIC OF
Khazak, Vladimir, Brooklyn, NY, UNITED STATES
Ross, Gunther, Munchen, GERMANY, FEDERAL REPUBLIC OF
Kalinski, Cotic, Munchen, GERMANY, FEDERAL REPUBLIC OF
Burdack, Chritoph, Munchen, GERMANY, FEDERAL REPUBLIC OF
PI US 20090068144 A1 20090312
AI US 2006-909014 A1 20060317 (11)
WO 2006-EP2471 20060317
20080623 PCT 371 date
PRAI DE 2005-102005012680 20050318
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of tetrahydroisoquinolinones as HDM2 ligands for the treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 244 OF 390 USPATFULL on STN
AN 2009:59894 USPATFULL
TI Flt3 inhibitors for immune suppression
IN Small, Donald, Baltimore, MD, UNITED STATES
Whartenby, Katharine A., Baltimore, MD, UNITED STATES
Pardoll, Drew, Brookeville, MD, UNITED STATES
PA THE JOHN HOPKINS UNIVERSITY, Baltimore, MD, UNITED STATES (U.S. corporation)
PI US 20090054358 A1 20090226
AI US 2005-632924 A1 20050714 (11)
WO 2005-US25318 20050714
20081016 PCT 371 date
PRAI US 2004-589511P 20040719 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
IT 284461-73-0, BAY43-9006
(Flt3 inhibitors for immune suppression by treating cells for therapy of immune or neurol. disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 245 OF 390 USPATFULL on STN
AN 2009:58787 USPATFULL
TI Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood
IN Mutz, Mitchell W., La Jolla, CA, UNITED STATES
Marquis, Andre L., San Carlos, CA, UNITED STATES
PI US 20090053245 A1 20090226
AI US 2008-129487 A1 20080529 (12)
PRAI US 2007-932359P 20070529 (60)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C, 5 Palo Alto Square - 6th Floor, 3000 El Camino Real, PALO ALTO, CA, 94306-2155, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood disease or steroid therapeutic or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the anticancer therapeutic as well as enhanced efficacy not due to compound degradation. It is preferred that the pharmacokinetic modulating moiety has a mass of less than 1100 Daltons.
IT 284461-73-0D, Sorafenib, conjugates with pharmacokinetic modulating moieties
(improvement of pharmacokinetics and efficacy of anti-angiogenic drugs and drugs for blood diseases using bifunctional compds. with pharmacokinetic modulating moiety)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 246 OF 390 USPATFULL on STN
AN 2009:58778 USPATFULL
TI USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
IN Yamamoto, Yuji, Ibaraki, JAPAN
PA EISAI R & D MANAGEMENT CO., LTD., Tokyo, JAPAN (non-U.S. corporation)
PI US 20090053236 A1 20090226
AI US 2006-92539 A1 20061107 (12)
WO 2006-JP322514 20061107
20080502 PCT 371 date
PRAI JP 2005-322946 20051107
DT Utility
FS APPLICATION
LREP DICKSTEIN SHAPIRO LLP, 1177 AVENUE OF THE AMERICAS (6TH AVENUE), NEW YORK, NY, 10036-2714, US
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity.
IT 284461-73-0, Sorafenib
(use of combination of anti-angiogenic substance and c-kit kinase inhibitor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 247 OF 390 USPATFULL on STN
AN 2009:58711 USPATFULL
TI TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
IN Rickles, Richard, Arlington, MA, UNITED STATES
Lee, Margaret S., Middleton, MA, UNITED STATES
PI US 20090053168 A1 20090226
AI US 2008-175219 A1 20080717 (12)
PRAI US 2007-950307P 20070717 (60)
US 2007-965587P 20070821 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2409
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
IT 475207-59-1, Nexavar
(adenosine A2A receptor agonists and phosphodiesterase inhibitors for treatment of B-cell proliferative disorders, and combinations with other agents)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 248 OF 390 USPATFULL on STN
AN 2009:53138 USPATFULL
TI METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
IN Erickson-Miller, Connie, Collegeville, PA, UNITED STATES
Jenkins, Julian, Collegeville, PA, UNITED STATES
PI US 20090048318 A1 20090219
AI US 2008-256669 A1 20081023 (12)
RLI Continuation-in-part of Ser. No. US 2006-554811, filed on 10 Nov 2006, PENDING A 371 of International Ser. No. WO 2004-US13468, filed on 29 Apr 2004
PRAI US 2003-466540P 20030429 (60)
US 2003-471554P 20030519 (60)
US 2003-495034P 20030814 (60)
US 2004-549977P 20040304 (60)
US 2004-554581P 20040319 (60)
US 2004-556390P 20040325 (60)
DT Utility
FS APPLICATION
LREP GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939, US
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
IT 475207-59-1, Nexavar
(non-peptide TPO receptor agonists for treatment of cardiovascular diseases/injuries)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 249 OF 390 USPATFULL on STN
AN 2009:53112 USPATFULL
TI SYNERGISTIC COMBINATION
IN HESS-STUMP, Holger, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 20090048292 A1 20090219
AI US 2008-163125 A1 20080627 (12)
PRAI EP 2007-75536 20070628
US 2007-947122P 20070629 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical combinations comprising as compound A at least one compound from the group of angiogenesis inhibitors of general formula I

##STR1##

and as compound B at least one compound from the group of histone deacetylase inhibitors (HDAC) of general formula II

##STR2##

and their use for the treatment of different diseases resulting by persistent angiogenesis, are described.
IT 284461-73-0, BAY 43-9006
(synergistic combination of anthranilamide pyridinureas and benzamide derivs. for treatment of angiogenesis-associated diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 250 OF 390 USPATFULL on STN
AN 2009:52065 USPATFULL
TI COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
IN Rickles, Richard, Arlington, MA, UNITED STATES
Pierce, Laura, San Diego, CA, UNITED STATES
Lee, Margaret S., Middleton, MA, UNITED STATES
PI US 20090047243 A1 20090219
AI US 2008-175121 A1 20080717 (12)
PRAI US 2007-959877P 20070717 (60)
US 2007-965595P 20070821 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
IT 475207-59-1, Nexavar
(combinations for treatment of B-cell proliferative disorders using PDE inhibitors and A2A receptor agonists and antiproliferative compds.)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 251 OF 390 USPATFULL on STN
AN 2009:45800 USPATFULL
TI PHARMACEUTICAL COMBINATIONS
IN Ramakrishnan, Vanitha, Belmont, CA, UNITED STATES
Bhaskar, Vinay, San Francisco, CA, UNITED STATES
PI US 20090041767 A1 20090212
AI US 2008-181201 A1 20080728 (12)
PRAI US 2007-952328P 20070727 (60)
DT Utility
FS APPLICATION
LREP HOWREY LLP-CA, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DRIVE, SUITE 200, FALLS CHURCH, VA, 22042-2924, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical combinations comprising an α5β1 antagonist in combination with a tyrosine kinase inhibitor. In some embodiments, the α5β1 antagonist is volociximab. In some embodiments, the tyrosine kinase inhibitor is sunitinib or a pharmaceutically acceptable salt thereof. The invention also relates to methods for treating cancer by administering the pharmaceutical combinations to a subject.
IT 284461-73-0, Sorafenib 475207-59-1, Sorafenib tosylate (pharmaceutical combinations comprising α5β1 integrin antagonist with tyrosine kinase inhibitor and use thereof in cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 252 OF 390 USPATFULL on STN
AN 2009:39142 USPATFULL
TI DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS
IN Singh, Sharat, Los Altos Hills, CA, UNITED STATES
Harvey, Jeanne, Livermore, CA, UNITED STATES
PA Prometheus Laboratories Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20090035792 A1 20090205
AI US 2008-172100 A1 20080711 (12)
PRAI US 2007-949820P 20070713 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
IT 284461-73-0, Sorafenib
(drug selection for lung cancer therapy using antibody-based arrays for detecting activation of signal transduction pathways in isolated cells)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 253 OF 390 USPATFULL on STN
AN 2009:38624 USPATFULL
TI PARAPOXVIRUSES IN COMBINATION WITH CLASSICAL CYTOTOXIC CHEMOTHERAPEUTIC AGENTS AS BIOCHEMOTHERAPY FOR THE TREATMENT OF CANCER
IN WEBER, Olaf, Wuelfrath, GERMANY, FEDERAL REPUBLIC OF
PI US 20090035269 A1 20090205
US 7897159 B2 20110301
AI US 2008-123360 A1 20080519 (12)
RLI Continuation of Ser. No. WO 2006-EP9855, filed on 12 Oct 2006, PENDING
PRAI EP 2005-25600 20051124
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 12531 HIGH BLUFF DRIVE, SUITE 100, SAN DIEGO,
CA, 92130-2040, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for the production of a pharmaceutical composition for treating cancer by combining Parapoxvirus ovis with at least one anticancer agent. The invention furthermore relates to a method for treating a patient afflicted with cancer comprising the administration of Parapoxvirus ovis in combination with at least one anticancer agent.
IT 284461-73-0, Soraf-enib
(parapoxvirus combination with cytotoxic chemotherapeutic agents for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 254 OF 390 USPATFULL on STN
AN 2009:31582 USPATFULL
TI Hydroxy sulfonate of quinone compounds and their uses
IN Bartis, Judit, Westford, MA, UNITED STATES
Volckova, Erika, Concord, MA, UNITED STATES
Tandon, Manish, Framingham, MA, UNITED STATES
Lowe, Deirdre, Salem, MA, UNITED STATES
Redmon, Martin P., Oxford, MA, UNITED STATES
PI US 20090028952 A1 20090129
US 7790765 B2 20100907
AI US 2008-150914 A1 20080430 (12)
PRAI US 2007-914971P 20070430 (60)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C, ONE FINANCIAL CENTER, BOSTON, MA, 02111, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.
IT 284461-73-0, Sorafenib
(combination chemotherapy addnl. antitumor agent; preparation of hydroxy sulfonate of quinone compds. and their uses in the treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 255 OF 390 USPATFULL on STN
AN 2009:31499 USPATFULL
TI Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
IN Fujiwara, Kosaku, Tokyo, JAPAN
Shimazaki, Naomi, Kawasaki-shi, JAPAN
PA DAIICHI SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)
PI US 20090028868 A1 20090129
AI US 2008-221019 A1 20080730 (12)
RLI Continuation-in-part of Ser. No. WO 2007-JP52178, filed on 8 Feb 2007, PENDING
PRAI JP 2006-31791 20060209
DT Utility
FS APPLICATION
LREP FRISHAUF, HOLTZ, GOODMAN & CHICK, PC, 220 Fifth Avenue, 16TH Floor, NEW YORK, NY, 10001-7708, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I)

##STR1##

and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).
IT 284461-73-0, Sorafenib
(anti-cancer pharmaceutical compns. containing benzimidazole thiazolidinedione derivs. - PPARγ agonists and RXR agonists and methods for treating patients with cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 256 OF 390 USPATFULL on STN
AN 2009:11653 USPATFULL
TI Methods for treating HIV
IN Stevenson, Mario, Worcester, MA, UNITED STATES
Swingler, Simon, Worcester, MA, UNITED STATES
PA University of Massachusetts, Boston, MA, UNITED STATES (U.S. corporation)
PI US 20090010941 A1 20090108
AI US 2008-2092 A1 20080408 (12)
PRAI US 2007-922483P 20070409 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 2875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods of treating HIV by administering a TRAIL receptor activator. The invention also relates to methods for inducing apoptosis in an HIV reservoir cell by contacting the cell with TRAIL receptor activator such as an M-CSF effector kinase inhibitor.
IT 284461-73-0, Sorafenib
(methods for treating HIV)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 257 OF 390 USPATFULL on STN
AN 2009:4201 USPATFULL
TI COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY
IN Singh, Harpreet, Tubingen, GERMANY, FEDERAL REPUBLIC OF
Emmerich, Niels, Tubingen, GERMANY, FEDERAL REPUBLIC OF
Hilf, Norbert, Kirchentellinsfurt, GERMANY, FEDERAL REPUBLIC OF
Walter, Steffen, Dusslingen, GERMANY, FEDERAL REPUBLIC OF
Weinschenk, Toni, Aichwald, GERMANY, FEDERAL REPUBLIC OF
PA Immatics Biotechnologies GmbH, Tubingen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20090004213 A1 20090101
AI US 2008-55151 A1 20080325 (12)
PRAI US 2007-908012P 20070326 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, ATTN: PATENT DOCKETING 32ND FLOOR, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 77 Drawing Page(s)
LN.CNT 5789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof.
IT 475207-59-1, Sorafenib tosylate
(in cancer therapy; combination therapy of cancer using tumor antigens and protein kinase inhibitors)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 258 OF 390 USPATFULL on STN
AN 2008:355430 USPATFULL
TI Biological markers predictive of anti-cancer response to kinase inhibitors
IN Haley, John D., Sea Cliff, NY, UNITED STATES
Thomson, Stuart, Port Washington, NY, UNITED STATES
PI US 20080312260 A1 20081218
AI US 2008-2762 A1 20080414 (12)
PRAI US 2007-923463P 20070412 (60)
DT Utility
FS APPLICATION
LREP OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE, NY, 11747, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 3347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such "hybrid" tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided.
IT 284461-73-0, Sorafenib
(biol. markers predictive of anti-cancer response to receptor protein-tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 259 OF 390 USPATFULL on STN
AN 2008:354775 USPATFULL
TI Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
IN Elting, James J., Madison, CT, UNITED STATES
Carney, Walter P., North Andover, MA, UNITED STATES
Hamer, Peter J., Reading, MA, UNITED STATES
Bigwood, Douglas, Madison, CT, UNITED STATES
PI US 20080311604 A1 20081218
AI US 2006-91899 A1 20061101 (12)
WO 2006-US42661 20061101
20080801 PCT 371 date
PRAI US 2005-733098P 20051102 (60)
DT Utility
FS APPLICATION
LREP LEONA L. LAUDER, 235 MONTGOMERY STREET, SUITE 1026, SAN FRANCISCO, CA, 94104-0332, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.
IT 284461-73-0, Sorafenib
(ELISA determination of VEGF-R2 for prediction and prognosis of cancer and therapy monitoring)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 260 OF 390 USPATFULL on STN
AN 2008:354772 USPATFULL
TI Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
IN Elting, James J., Madison, CT, UNITED STATES
Carney, Walter P., North Andover, MA, UNITED STATES
Hamer, Peter J., Reading, MA, UNITED STATES
Bigwood, Douglas, Madison, CT, UNITED STATES
PI US 20080311601 A1 20081218
AI US 2006-91889 A1 20061101 (12)
WO 2006-US42660 20061101
20080801 PCT 371 date
PRAI US 2005-733100P 20051102 (60)
DT Utility
FS APPLICATION
LREP LEONA L. LAUDER, 235 MONTGOMERY STREET, SUITE 1026, SAN FRANCISCO, CA, 94104-0332, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.
IT 284461-73-0, Sorafenib
(immunoassay determination of biomarkers for prediction and prognosis of cancer
and therapy monitoring)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 261 OF 390 USPATFULL on STN
AN 2008:348362 USPATFULL
TI Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
IN Wirtz, Ralph Markus, Cologne, GERMANY, FEDERAL REPUBLIC OF
PI US 20080305962 A1 20081211
AI US 2006-996680 A1 20060720 (11)
WO 2006-US28230 20060720
20080627 PCT 371 date
PRAI US 2005-703682P 20050729 (60)
DT Utility
FS APPLICATION
LREP CHOATE, HALL & STEWART LLP, TWO INTERNATIONAL PLACE, BOSTON, MA, 02110, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 5081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal "healthy" tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well.
IT 284461-73-0, Sorafenib
(methods and kits for the prognosis of therapeutic success, recurrence free and overall survival in cancer therapies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 262 OF 390 USPATFULL on STN
AN 2008:340749 USPATFULL
TI Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
IN Arnold, Lee D., East Islip, NY, UNITED STATES
Ji, Qun-Sheng, Farmingdale, NY, UNITED STATES
Mulvihill, Mark Joseph, Farmingdale, NY, UNITED STATES
PI US 20080299113 A1 20081204
AI US 2006-641346 A1 20061218 (11)
PRAI US 2005-752243P 20051219 (60)
DT Utility
FS APPLICATION
LREP OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE, NY, 11747, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IGF1R inhibitor compound of Formula I combination with a pharmaceutically acceptable carrier. The IGF1R inhibitor is represented by Formula I:

##STR1##

wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein.
IT 284461-73-0, Sorafenib
(combined treatment with bicyclic ring substituted heterobicyclic protein kinase inhibitor and anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 263 OF 390 USPATFULL on STN
AN 2008:326287 USPATFULL
TI Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
IN Semba, Taro, Ibaraki, JAPAN
Hata, Naoko, Ibaraki, JAPAN
Ozawa, Yoichi, Ibaraki, JAPAN
Owa, Takashi, Ibaraki, JAPAN
PA Eisai R & D Management Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20080286282 A1 20081120
AI US 2006-886214 A1 20060228 (11)
WO 2006-JP4208 20060228
20070827 PCT 371 date
PRAI JP 2005-54150 20050228
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.
IT 284461-73-0, BAY 43-9006
(sulfonamide-containing compds. and angiogenesis inhibitors for combination chemotherapy of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 264 OF 390 USPATFULL on STN
AN 2008:305473 USPATFULL
TI Combination cancer therapy
IN Arnold, Lee D., East Islip, NY, UNITED STATES
Ji, Qun-Sheng, Babylon, NY, UNITED STATES
Buck, Elizabeth, Farmingdale, NY, UNITED STATES
Haley, John D., Farmingdale, NY, UNITED STATES
Mulvihill, Mark J., Farmingdale, NY, UNITED STATES
PI US 20080267957 A1 20081030
AI US 2008-72269 A1 20080225 (12)
RLI Continuation-in-part of Ser. No. US 2007-787236, filed on 13 Apr 2007, PENDING Continuation-in-part of Ser. No. US 2006-641346, filed on 18 Dec 2006, PENDING
PRAI US 2005-752243P 20051219 (60)
DT Utility
FS APPLICATION
LREP OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE, NY, 11747, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 6780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I:

##STR1##

wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein.
IT 284461-73-0, Sorafenib
(IGFR inhibitor antitumor combination for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 265 OF 390 USPATFULL on STN
AN 2008:299009 USPATFULL
TI Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide
IN Logers, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Gehring, Reinhold, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Kuhn, Oliver, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Matthaus, Mike, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Mohrs, Klaus, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Muller-Gliemann, Matthias, Solingen, GERMANY, FEDERAL REPUBLIC OF
Stiehl, Jurgen, Sprockhovel, GERMANY, FEDERAL REPUBLIC OF
Berwe, Mathias, Sprockhovel, GERMANY, FEDERAL REPUBLIC OF
Lenz, Jana, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Heilmann, Werner, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PA Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080262236 A1 20081023
AI US 2005-664332 A1 20050920 (11)
WO 2005-EP10118 20050920
20080521 PCT 371 date
PRAI EP 2004-23131 20040929
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoro-methyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide and its tosylate salt.
IT 284461-73-0P
(in a process for the preparation of 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide and its tosylate salt)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1P
(process for the preparation of 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide and its tosylate salt)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 266 OF 390 USPATFULL on STN
AN 2008:298603 USPATFULL
TI ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS
IN Harvey, Jeanne, Livermore, CA, UNITED STATES
Singh, Sharat, Los Altos Hills, CA, UNITED STATES
Kim, Phillip, Irvine, CA, UNITED STATES
Liu, Xinjun, San Diego, CA, UNITED STATES
Barham, Robert, San Macos, CA, UNITED STATES
Liu, Limin, San Diego, CA, UNITED STATES
PA Prometheus Laboratories Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20080261829 A1 20081023
AI US 2008-46381 A1 20080311 (12)
RLI Continuation of Ser. No. WO 2007-US79002, filed on 20 Sep 2007, PENDING
PRAI US 2007-913087P 20070420 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2869
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
IT 475207-59-1, Nexavar
(cell stimulation with drug treatment; antibody-based arrays for detecting multiple signal transducers in rare circulating cells and use in diagnosis and treatment of cancer)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 267 OF 390 USPATFULL on STN
AN 2008:297526 USPATFULL
TI Novel Tetrahydropyridothiophenes
IN Pekari, Klaus, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA NYCOMED GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080260749 A1 20081023
US 7763728 B2 20100727
AI US 2006-920501 A1 20060524 (11)
WO 2006-EP62617 20060524
20071214 PCT 371 date
PRAI EP 2005-104495 20050525
EP 2005-112155 20051214
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I)

##STR1##

in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, BAY43-9006
(preparation of tetrahydropyridothiophene derivs. with display cell cycle dependent, antiproliferative and apoptosis inducing activity useful in treatment of hyperproliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 268 OF 390 USPATFULL on STN
AN 2008:291179 USPATFULL
TI THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS
IN Miller, Duane D., Germantown, TN, UNITED STATES
Dalton, James T., Columbus, OH, UNITED STATES
Li, Wei, Germantown, TN, UNITED STATES
Yan, Lu, Bartlett, TN, UNITED STATES
PA University of Tennessee Research Foundation, Knoxville, TN, UNITED STATES (U.S. corporation)
Ohio State University Research Foundation, Columbus, OH, UNITED STATES (U.S. corporation)
PI US 20080255213 A1 20081016
AI US 2008-102575 A1 20080414 (12)
PRAI US 2007-911882P 20070414 (60)
DT Utility
FS APPLICATION
LREP NIXON PEABODY LLP - PATENT GROUP, 1100 CLINTON SQUARE, ROCHESTER, NY, 14604, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides having a structure

##STR1##

where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.
IT 284461-73-0, Sorafenib
(thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides as selective anti-cancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 269 OF 390 USPATFULL on STN
AN 2008:291099 USPATFULL
TI Inhibitors of MEK
IN Vernier, Jean-Michel, Laguna Niguel, CA, UNITED STATES
Maderna, Andreas, Stony Point, NY, UNITED STATES
Koh, Yung-hyo, Irvine, CA, UNITED STATES
Hong, Zhi, Chapel Hill, NC, UNITED STATES
PA ARDEA BIOSCIENCES, INC., Costa Mesa, CA, UNITED STATES (U.S. corporation)
PI US 20080255133 A1 20081016
US 7820664 B2 20101026
AI US 2008-16897 A1 20080118 (12)
PRAI US 2007-885849P 20070119 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(preparation of substituted cyclopropanesulfonamides as MEK kinase and Raf protein kinase inhibitors useful in prevention and combination therapy of cancer and hyperproliferative disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 270 OF 390 USPATFULL on STN
AN 2008:291001 USPATFULL
TI SPARC AND METHODS OF USE THEREOF
IN Trieu, Vuong, Calabasas, CA, UNITED STATES
Desai, Neil P., Los Angeles, CA, UNITED STATES
PA Abraxis BioScience, Inc., Los Angeles, CA, UNITED STATES (U.S. corporation)
PI US 20080255035 A1 20081016
AI US 2008-102383 A1 20080414 (12)
PRAI US 2007-923340P 20070413 (60)
DT Utility
FS APPLICATION
LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH
STETSON AVENUE, CHICAGO, IL, 60601-6731, US
CLMN Number of Claims: 85
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides, an angiogenesis inhibitor and paclitaxel. The invention provides also methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides and paclitaxel. Further, the invention produces kits and methods to predict therapy responses.
IT 284461-73-0, Sorafenib
(in cancer therapy; antitumor formulations including SPARC proteins, antitumor agents, and angiogenesis inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 271 OF 390 USPATFULL on STN
AN 2008:283186 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte-MG, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 20080248046 A1 20081009
AI US 2008-10106 A1 20080118 (12)
RLI Continuation-in-part of Ser. No. US 2004-979831, filed on 3 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2003-648825, filed on 27 Aug 2003, PENDING Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000, Pat. No. US 6872568 Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000, Pat. No. US 6872568 Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
PRAI US 2007-990701P 20071128 (60)
US 2007-885944P 20070122 (60)
US 2004-551811P 20040311 (60)
US 2004-608429P 20040910 (60)
US 2002-413747P 20020927 (60)
US 2002-406307P 20020828 (60)
US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-40846P 19970317 (60)
US 1997-54021P 19970729 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.,
1100 NEW YORK AVENUE, N.W.,
WASHINGTON, DC, 20005, US
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 13328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity.
IT 284461-73-0, BAY 43-9006
(combination chemotherapy with; DR5-binding agonist antibodies for induction of apoptosis in DR5 expressing cells and for treatment of cancer and hepatitis C virus infections)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 272 OF 390 USPATFULL on STN
AN 2008:277094 USPATFULL
TI Pharmaceutical Composition for the Treatment of Cancer
IN Schuckler, Fritz, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
Wollenschlager, Axel, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
PA Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080242707 A1 20081002
AI US 2006-885930 A1 20060222 (11)
WO 2006-EP1574 20060222
20080609 PCT 371 date
PRAI US 2005-658827P 20050307 (60)
DT Utility
FS APPLICATION
LREP Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.
IT 284461-73-0 475207-59-1
(pharmaceutical composition comprising omega-carboxyaryl substituted di-Ph urea for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0

CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 273 OF 390 USPATFULL on STN
AN 2008:277036 USPATFULL
TI COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
IN Ordentlich, Peter, San Diego, CA, UNITED STATES
Horobin, Joanna, Wellesley, MA, UNITED STATES
Whitehouse, Martha Jo, San Francisco, CA, UNITED STATES
Rees, Miranda, Mill Valley, CA, UNITED STATES
PA Syndax Pharmaceuticals, Inc., a California Corporation, San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20080242648 A1 20081002
AI US 2007-938130 A1 20071109 (11)
PRAI US 2006-865357P 20061110 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
IT 284461-73-0, Sorafenib
(estrogen receptor α+ ligand-histone deacetylase inhibitor combination for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 274 OF 390 USPATFULL on STN
AN 2008:275548 USPATFULL
TI Death domain containing receptor 4
IN Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Pan, James G., Toronto, CANADA
Gentz, Reiner L., Belo Horizonte-MG, BRAZIL
Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
The Regents of the University of Michigan (U.S. corporation)
PI US 20080241155 A1 20081002
AI US 2008-10108 A1 20080118 (12)
RLI Continuation-in-part of Ser. No. US 2005-76187, filed on 10 Mar 2005, PENDING Continuation-in-part of Ser. No. US 2003-648786, filed on 27 Aug 2003, PENDING Continuation-in-part of Ser. No. US 2000-565918, filed on 5 May 2000, Pat. No. US 6433147 Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998, Pat. No. US 6342363
PRAI US 2007-990687P 20071128 (60)
US 2007-885971P 20070122 (60)
US 2004-551768P 20040311 (60)
US 2004-608469P 20040910 (60)
US 2002-413861P 20020927 (60)
US 2002-406922P 20020830 (60)
US 1999-132922P 19990506 (60)
US 1997-35722P 19970128 (60)
US 1997-37829P 19970205 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.,
1100 NEW YORK AVENUE, N.W.,
WASHINGTON, DC, 20005, US
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
IT 284461-73-0, BAY 43-9006
(combination chemotherapy with; death domain containing receptor DR4 and methods for inducing apoptosis and treating cancer with DR4 agonist antibodies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
O
MeNH
C
O

L20 ANSWER 275 OF 390 USPATFULL on STN
AN 2008:275525 USPATFULL
TI BRAF Mutation T1796A in Thyroid Cancers
IN Sidransky, David, Baltimore, MD, UNITED STATES
Cohen, Yoram, Baltimore, MD, UNITED STATES
Zhao, Ming, Baltimore, MD, UNITED STATES
PA The Johns Hopkins University, Baltimore, MD, UNITED STATES (U.S. corporation)
PI US 20080241132 A1 20081002
US 7923460 B2 20110412
AI US 2008-124504 A1 20080521 (12)
RLI Division of Ser. No. US 2004-821203, filed on 9 Apr 2004, Pat. No. US 7378233
PRAI US 2003-462046P 20030412 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, LTD., 1100 13th STREET, N.W., SUITE 1200, WASHINGTON,
DC, 20005-4051, US
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggested that activating BGRAF mutations may be an important even in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas.
IT 284461-73-0, BAY 43-9006
(detection of BRAF transversion mutation for diagnosis of malignant thyroid cancer and uses of Ras-Raf-MAPK or Raf/MEK/ERK signaling pathway inhibitor in treating thyroid cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 276 OF 390 USPATFULL on STN
AN 2008:268164 USPATFULL
TI RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY
IN Cai, Xiong, Belmont, MA, UNITED STATES
Qian, Changgeng, Wayland, MA, UNITED STATES
Gould, Stephen, San Carlos, CA, UNITED STATES
Zhai, Haixiao, Bedford, MA, UNITED STATES
PI US 20080234332 A1 20080925
AI US 2007-852463 A1 20070910 (11)
PRAI US 2007-895910P 20070320 (60)
DT Utility
FS APPLICATION
LREP ELMORE PATENT LAW GROUP, PC, 515 Groton Road, Unit 1R, Westford, MA, 01886, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
IT 284461-74-1P
(preparation of pyridine derivs. as Raf kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 277 OF 390 USPATFULL on STN
AN 2008:268077 USPATFULL
TI CUCURBITACIN B AND USES THEREOF
IN Xie, Wei Dong, Hong Kong, CHINA
Li, Kwan, Hong Kong, CHINA
Liu, Edgar Shiu Lam, Hong Kong, CHINA
Chu, Kee Hung, Hong Kong, CHINA
PI US 20080234244 A1 20080925
AI US 2008-51461 A1 20080319 (12)
PRAI US 2007-919088P 20070319 (60)
DT Utility
FS APPLICATION
LREP EVAN LAW GROUP LLC, 600 WEST JACKSON BLVD., SUITE 625, CHICAGO, IL, 60661, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2184
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.
IT 284461-73-0, Sorafenib
(combination; cucurbitacins and therapeutic uses)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 278 OF 390 USPATFULL on STN
AN 2008:266975 USPATFULL
TI Cobalamin taxane bioconjugates
IN Gebhard, John R., Salt Lake City, UT, UNITED STATES
Vollmer, David, West Jordan, UT, UNITED STATES
Daugherty, Claire, Salt Lake City, UT, UNITED STATES
Patel, Dinesh, Salt Lake City, UT, UNITED STATES
PI US 20080233135 A1 20080925
AI US 2008-77060 A1 20080314 (12)
PRAI US 2007-919121P 20070319 (60)
DT Utility
FS APPLICATION
LREP THORPE NORTH & WESTERN, LLP., P.O. Box 1219, SANDY, UT, 84091-1219, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.
IT 284461-73-0, Sorafenib
(cobalamin taxane bioconjugates useful as oral anti-cancer or anti-angiogenic drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 279 OF 390 USPATFULL on STN
AN 2008:261182 USPATFULL
TI Aryl Ureas With Angiogenisis Inhibiting Activity
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
Hatoum-Makdad, Holia, Hamden, CT, UNITED STATES
PI US 20080227828 A1 20080918
AI US 2007-932626 A1 20071031 (11)
RLI Division of Ser. No. US 2003-361858, filed on 11 Feb 2003, PENDING
PRAI US 2002-354950P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
IT 284461-73-0P 284461-74-1P
(preparation of aryl ureas with angiogenesis inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 280 OF 390 USPATFULL on STN
AN 2008:259949 USPATFULL
TI Treating melanoma with bis(thiohydrazide amides)
IN McLeod, Matthew, Boston, MA, UNITED STATES
PI US 20080226588 A1 20080918
AI US 2007-894270 A1 20070820 (11)
PRAI US 2006-838977P 20060821 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
IT 284461-73-0, Sorafenib
(treating melanoma with (thiohydrazide amides) and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 281 OF 390 USPATFULL on STN
AN 2008:253871 USPATFULL
TI Multi-Functional Small Molecules as Anti-Proliferative Agents
IN Cai, Xiong, Belmont, MA, UNITED STATES
Qian, Changgeng, Wayland, MA, UNITED STATES
Gould, Stephen, San Carlos, CA, UNITED STATES
Zhai, Haixiao, Bedford, MA, UNITED STATES
PI US 20080221132 A1 20080911
AI US 2007-852458 A1 20070910 (11)
PRAI US 2006-843590P 20060911 (60)
US 2007-895889P 20070320 (60)
DT Utility
FS APPLICATION
LREP ELMORE PATENT LAW GROUP, PC, 515 Groton Road, Westford, MA, 01886, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 14242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.
IT 284461-74-1P
(intermediate; preparation of multi-functional small mols. as antiproliferative agents)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 282 OF 390 USPATFULL on STN
AN 2008:246577 USPATFULL
TI Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer
IN Lee, Wendy, South San Francisco, CA, UNITED STATES
Ladouceur, Gaetan, Guilford, CT, UNITED STATES
Dumas, Jacques, Waltham, MA, UNITED STATES
Smith, Roger, Madison, CT, UNITED STATES
Ying, Shihong, Orange, CT, UNITED STATES
Wang, Gan, Wallingord, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Liu, Qingjie, Orange, CT, UNITED STATES
Mokdad, Holia Hatoum, Hamden, CT, UNITED STATES
PI US 20080214545 A1 20080904
US 7838524 B2 20101123
AI US 2005-579093 A1 20050502 (11)
WO 2005-US15106 20050502
20080115 PCT 371 date
PRAI US 2004-566445P 20040430 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

##STR1##
IT 284461-73-0, BAY 43-9006
(substituted pyrazolylurea derivs. useful for cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 283 OF 390 USPATFULL on STN
AN 2008:245410 USPATFULL
TI NANOPARTICULATE SORAFENIB FORMULATIONS
IN Carty, Sarah, Bray, IRELAND
Jenkins, Scott, Downingtown, PA, UNITED STATES
Liversidge, Gary, West Chester, PA, UNITED STATES
PA Elan Pharma International Limited (non-U.S. corporation)
PI US 20080213374 A1 20080904
AI US 2007-775002 A1 20070709 (11)
PRAI US 2006-819367P 20060710 (60)
DT Utility
FS APPLICATION
LREP Elan Drug Delivery, Inc. c/o Foley & Lardner, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases.
IT 284461-73-0D, Sorafenib, salts
(nanoparticulate sorafenib formulations)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1, Sorafenib tosylate
(nanoparticulate sorafenib formulations)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 284 OF 390 USPATFULL on STN
AN 2008:245304 USPATFULL
TI NEUROPILIN ANTAGONISTS
IN Watts, Ryan J., San Mateo, CA, UNITED STATES
Wu, Yan, Foster City, CA, UNITED STATES
PI US 20080213268 A1 20080904
AI US 2008-107544 A1 20080422 (12)
RLI Continuation of Ser. No. WO 2006-US43516, filed on 8 Nov 2006, PENDING
PRAI US 2005-734798P 20051108 (60)
US 2006-820561P 20060727 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 4089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
IT 284461-73-0, Sorafenib
(anti-neuropilin 1 antagonistic antibodies for research, diagnosis and therapy of cancer and angiogenesis-associated disease)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 285 OF 390 USPATFULL on STN
AN 2008:238890 USPATFULL
TI METHOD OF INDUCING APOPTOSIS IN CANCER TREATMENT BY USING CUCURBITACINS
IN Chu, Kee Hung, Hong Kong, CHINA
Xing, Hongtao, Hong Kong, CHINA
PI US 20080207578 A1 20080828
AI US 2007-954805 A1 20071212 (11)
PRAI US 2006-870381P 20061215 (60)
DT Utility
FS APPLICATION
LREP EVAN LAW GROUP LLC, 600 WEST JACKSON BLVD., SUITE 625, CHICAGO, IL, 60661, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the preparation and use of anti-cancer compounds/formulation containing cucurbitacins. Said formulation comprises active ingredients, particularly cucurbitacin B and cucurbitacin D, with the efficacy of anti-proliferation and inducing cellular apoptosis. Said formulation owns the anticancer activity. This invention also provides a method of isolating and purifying the active ingredients in lab-scale and in industrial-scale.
IT 284461-73-0, Sorafenib
(combination; cucurbitacins and therapeutic uses)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 286 OF 390 USPATFULL on STN
AN 2008:237575 USPATFULL
TI Novel Tetrahydropyridothiophenes
IN Pekari, Klaus, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20080206258 A1 20080828
US 7714136 B2 20100511
AI US 2006-920572 A1 20060524 (11)
WO 2006-EP62613 20060524
20071204 PCT 371 date
PRAI EP 2005-104499 20050525
EP 2005-112150 20051214
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I)

##STR1##

in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, BAY43-9006
(preparation of tetrahydropyridothiophene derivs. with display cell cycle dependent, antiproliferative and apoptosis inducing activity useful in treatment of hyperproliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 287 OF 390 USPATFULL on STN
AN 2008:221571 USPATFULL
TI CANCER TREATMENT METHODS USING CADHERIN ANTAGONISTS IN COMBINATION WITH ANTICANCER AGENTS
IN Peters, William Paul, Fernandina Beach, FL, UNITED STATES
Huber, Brian, Durham, NC, UNITED STATES
Tyler, Douglas Scott, Hillsborough, NC, UNITED STATES
PA ADHEREX TECHNOLOGIES, INC., Ottawa, CANADA (non-U.S. corporation)
DEPARTMENT OF VETERANS AFFAIRS, Washington, DC, UNITED STATES (U.S. corporation)
PI US 20080194467 A1 20080814
AI US 2007-863127 A1 20070927 (11)
PRAI US 2006-848624P 20060927 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved methods for treating cancer which employ combinations comprising cadherin antagonists with certain anticancer agents or treatments are provided. The methods of the invention involve the administration of cadherin antagonist before, concurrent with, or after, administration of an anticancer agent or treatment and provide unexpectedly improved therapeutic benefit in the treatment of tumors growing in vivo.
IT 284461-73-0, Sorafenib
(as anticancer agent; cancer treatment with cadherin antagonists in combination with anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 288 OF 390 USPATFULL on STN
AN 2008:208468 USPATFULL
TI HISTONE DEACETYLASE INHIBITORS SENSITIZE CANCER CELLS TO EPIDERMAL GROWTH FACTOR INHIBITORS
IN Witta, Samir E., Greenwood Village, CO, UNITED STATES
Bunn, Paul A., Steamboat Springs, CO, UNITED STATES
Drabkin, Harry A., Charleston, SC, UNITED STATES
Gemmill, Robert M., Charleston, SC, UNITED STATES
Chan, Daniel Chuen-Fong, Denver, CO, UNITED STATES
PI US 20080182865 A1 20080731
AI US 2007-861033 A1 20070925 (11)
RLI Continuation-in-part of Ser. No. US 2007-908388, PENDING A 371 of International Ser. No. WO 2006-US9078, filed on 13 Mar 2006
PRAI US 2007-951445P 20070723 (60)
US 2005-660893P 20050311 (60)
US 2007-951445P 20070723 (60)
DT Utility
FS APPLICATION
LREP SHERIDAN ROSS PC, 1560 BROADWAY, SUITE 1200, DENVER, CO, 80202, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.
IT 284461-73-0, Sorafenib
(histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 289 OF 390 USPATFULL on STN
AN 2008:201886 USPATFULL
TI N-Sulphonylpyrroles and Their Use as Histone Deacetylase Inhibitors
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Zimmermann, Astrid, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Schneider, Siegfried, Rodolfzell, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA Nycomed GmbH, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080176848 A1 20080724
US 7666868 B2 20100223
AI US 2006-885832 A1 20060314 (11)
WO 2006-EP60712 20060314
20070907 PCT 371 date
PRAI EP 2005-102019 20050315
EP 2005-108735 20050921
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I)

##STR1##

in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
IT 284461-73-0, Sorafenib
(preparation of sulfonylpyrrole derivs. as histone deacetylase inhibitors useful in treatment and prevention of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 290 OF 390 USPATFULL on STN
AN 2008:201866 USPATFULL
TI Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
IN Williams, Martin, Cambridge, MA, UNITED STATES
McLeod, Matthew, Boston, MA, UNITED STATES
Koya, Keizo, Chestnut Hill, MA, UNITED STATES
PI US 20080176828 A1 20080724
AI US 2007-894261 A1 20070820 (11)
PRAI US 2006-838986P 20060821 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
IT 284461-73-0, Sorafenib
(treating melanoma with (thiohydrazide amides) and combination with other agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 291 OF 390 USPATFULL on STN
AN 2008:196063 USPATFULL
TI Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
IN Brown, Bob D., Millington, NJ, UNITED STATES
PI US 20080171718 A1 20080717
AI US 2007-935654 A1 20071106 (11)
PRAI US 2006-864859P 20061108 (60)
DT Utility
FS APPLICATION
LREP DIEHL SERVILLA LLC, 77 BRANT AVE, SUITE 210, CLARK, NJ, 07066, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 610
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are provided for treating cell-proliferative related disorders such as cancer. Methods of inhibiting the growth of cancer cells comprise contacting the cancer cells with a Bcl-2 antisense oligomer; contacting the cancer cells with a tyrosine kinase inhibitor; and contacting the cancer cells with a cytotoxic chemotherapeutic agent. Methods of treating cancer in a human comprise administering to the human a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. Kits containing compositions in amounts sufficient for at least one cycle of treatment comprise a triplet combination therapy of a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. In selected embodiments, the tyrosine kinase inhibitor is one that targets cell surface kinase receptors, such as VEGFR (e.g., VEGFR1, VEGFR2, VEGFR3), PDGFR, KIT, and FLT-3.
IT 284461-73-0 475207-59-1
(Bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents for cancer treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 292 OF 390 USPATFULL on STN
AN 2008:189961 USPATFULL
TI Methods of using MEK inhibitors
IN Lamb, Peter, Oakland, CA, UNITED STATES
PI US 20080166359 A1 20080710
AI US 2007-2340 A1 20071214 (12)
PRAI US 2006-875412P 20061214 (60)
DT Utility
FS APPLICATION
LREP PATENT DEPT, EXELIXIS, INC., 170 HARBOR WAY, P.O. BOX 511, SOUTH SAN FRANCISCO, CA, 94083-0511, US
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

##STR1##
IT 284461-73-0, Sorafenib
(preparation of N-acylazetidine derivs. as MEK inhibitors useful in the mono- and combination therapy of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 293 OF 390 USPATFULL on STN
AN 2008:189960 USPATFULL
TI QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
IN Tung, Roger, Lexington, MA, UNITED STATES
PA Concert Pharmaceuticals Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 20080166358 A1 20080710
AI US 2007-957442 A1 20071215 (11)
PRAI US 2006-875320P 20061215 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.
IT 284461-73-0, Sorafenib
(quinazoline derivs. and methods of treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 294 OF 390 USPATFULL on STN
AN 2008:184228 USPATFULL
TI USE OF PYRIDONE DERIVATIVES IN THE PREVENTION OR TREATMENT OF TISSUE OR ORGAN TOXICITY INDUCED BY CYTOTOXIC AGENTS AND RADIATION
IN Wu, Jun, Shanghai, CHINA
Luo, Ying, Shanghai, CHINA
Zhou, Tieling, Shanghai, CHINA
PI US 20080161361 A1 20080703
AI US 2007-958353 A1 20071217 (11)
RLI Continuation-in-part of Ser. No. WO 2006-CN2504, filed on 25 Sep 2006, PENDING
PRAI US 2006-804914P 20060615 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a novel use of pyridone derivatives such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and/or therapeutic effects of the pyridone derivatives make it possible to increase therapeutic dosages of the cytotoxic agent, thereby enhancing the therapeutic efficacy of the cytotoxic agent and radiation therapy.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(pyridone derivs. in prevention or treatment of tissue or organ toxicity induced by cytotoxic agents and radiation)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 295 OF 390 USPATFULL on STN
AN 2008:184118 USPATFULL
TI Pharmaceutical Compounds
IN Curry, Jayne Elizabeth, Cambridge, UNITED KINGDOM
Lyons, John Francis, Cambridge, UNITED KINGDOM
Squires, Matthew Simon, Cambridge, UNITED KINGDOM
Thompson, Neil Thomas, Cambridge, UNITED KINGDOM
Thompson, Kyla Merriom, Cambridge, UNITED KINGDOM
Wyatt, Paul Graham, Perth, UNITED KINGDOM
PA ASTEX THERAPEUTICS LIMITED, Cambridge, UK (non-U.S. corporation)
PI US 20080161251 A1 20080703
AI US 2006-814456 A1 20060120 (11)
WO 2006-GB204 20060120
20080124 PCT 371 date
PRAI US 2005-645987P 20050121 (60)
US 2005-645986P 20050121 (60)
US 2005-646113P 20050121 (60)
US 2005-645976P 20050121 (60)
US 2005-645975P 20050121 (60)
DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5
COLUMBIA CIRCLE, ALBANY, NY,
12203, US
CLMN Number of Claims: 42
ECL Exemplary Claim: 1-99
DRWN 11 Drawing Page(s)
LN.CNT 8689
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a combination of a cytotoxic compound or signalling inhibitor and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R.sup.1-A-NR.sup.4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO.sub.2, C.dbd.O, NR.sup.g(C.dbd.O) or 0(C.dbd.O) wherein R.sup.g is hydrogen or C.sub.1-4 hydrocarbyl optionally substituted by hydroxy or C.sub.1-4alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R.sup.1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C.sub.1-8hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C.sub.1-4 hydrocarbyloxy, amino, mono- or di-C.sub.1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO.sub.2; R.sup.2 is hydrogen; halogen; C.sub.1-4alkoxy (e.g. methoxy); or a C.sub.1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C.sub.1-4alkoxy (e.g. methoxy); R.sup.3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R.sup.4 is hydrogen or a C.sub.1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C.sub.1-4 alkoxy (e.g. methoxy).

##STR1##
IT 284461-73-0, Sorafenib
(preparation of pyrazolecarboxamides for use in combination with cytotoxic compound or signaling inhibitor for treating and preventing diseases)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 296 OF 390 USPATFULL on STN
AN 2008:182892 USPATFULL
TI SEQUENTIAL COMBINATION THERAPY
IN Wood, Clive R., Boston, MA, UNITED STATES
Dransfield, Daniel T., Hanson, MA, UNITED STATES
Arulanandam, Antonio, Winchester, MA, UNITED STATES
Jain, Rakesh K., Wellesley, MA, UNITED STATES
PA DYAX CORP., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20080160019 A1 20080703
AI US 2007-873856 A1 20071017 (11)
PRAI US 2006-852263P 20061017 (60)
US 2006-875736P 20061219 (60)
DT Utility
FS APPLICATION
LREP LOWRIE, LANDO & ANASTASI, LLP, ONE MAIN STREET, SUITE 1100, CAMBRIDGE,
MA, 02142, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a VEGF antagonist agent.
IT 284461-73-0, Sorafenib
(treatment of angiogenesis-related disorders by sequential administration of Tie1 ectodomain-binding agent and VEGF antagonist)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 297 OF 390 USPATFULL on STN
AN 2008:175939 USPATFULL
TI Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Hyogo, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill, North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert, North Haven, CT, UNITED STATES
PI US 20080153823 A1 20080626
AI US 2007-956111 A1 20071213 (11)
RLI Continuation of Ser. No. US 2002-889227, filed on 8 Jan 2002, Pat. No. US 7351834 A 371 of International Ser. No. WO 2000-US648, filed on 12 Jan 2000
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 298 OF 390 USPATFULL on STN
AN 2008:158988 USPATFULL
TI Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs
IN KIM, Meehyein, Yongin-si, KOREA, REPUBLIC OF
Kim, Soo In, Yongin-si, KOREA, REPUBLIC OF
Shin, Duckhyang, Yongin-si, KOREA, REPUBLIC OF
Park, Mahnhoon, Yongin-si, KOREA, REPUBLIC OF
PA MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, Yongin-si, KOREA, REPUBLIC OF (non-U.S. corporation)
PI US 20080138394 A1 20080612
AI US 2007-741287 A1 20070427 (11)
PRAI KR 2006-110402 20061109
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
IT 284461-73-0, Sorafenib
(apolipoprotein A-I conjugates with liposomes for delivering nucleic acids and drugs to liver)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 299 OF 390 USPATFULL on STN
AN 2008:158973 USPATFULL
TI Methods, treatments, and compositions for modulating Hedgehog pathways
IN Jennings-Spring, Barbara L., Jupiter, FL, UNITED STATES
PI US 20080138379 A1 20080612
AI US 2007-1869 A1 20071213 (12)
RLI Continuation-in-part of Ser. No. US 2006-591398, filed on 1 Nov 2006, PENDING
DT Utility
FS APPLICATION
LREP Irving M. Fishman, c/o Cohen Tauber Spievack and Wagner, Suite 2400, 420 Lexington Avenue, New York, NY, 10170, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to prevention of congenital deformations The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events gene expression during prenatal development, post-natal development and during development in the adult organism.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
(methods, treatments, and compns. for modulating hedgehog pathways using inositols, folates, and other drugs to prevent congenital malformations, cancer, and other diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



```
=> d l20 300-390 bib,ab,hitstr
```

L20 ANSWER 300 OF 390 USPATFULL on STN
AN 2008:151589 USPATFULL
TI Biomarkers for cancer treatment
IN Pratilas, Christine, New York, NY, UNITED STATES
Rosen, Neal, New York, NY, UNITED STATES
PA Memorial Sloan Kettering Cancer Center (U.S. corporation)
PI US 20080131885 A1 20080605
US 7812143 B2 20101012
AI US 2007-732362 A1 20070402 (11)
PRAI US 2006-788014P 20060331 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 45 Drawing Page(s)
LN.CNT 5909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides identification of a thirty-five gene set that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway, methods of qualifying cancer status in a subject, methods of identifying an anti-tumor response in a subject, methods of monitoring the efficacy of a therapeutic drug in a subject, and methods of identifying an agent useful in the treatment of a cancer based on expression of the thirty-five gene set.
IT 284461-73-0, Bay 43-9006
(predicting tumor response to; marker genes responding to antineoplastic drug therapy and their use in selection of chemotherapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 301 OF 390 USPATFULL on STN
AN 2008:144215 USPATFULL
TI Indolopyridines,Benzofuranopyridines and Benzothienopyridines
IN Vennemann, Matthias, Kontanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Braunger, Jurgen, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Ciossek, Thomas, Ravensburg, GERMANY, FEDERAL REPUBLIC OF
Nappe, Sandra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA ALTANA PHARMA AG, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080125452 A1 20080529
AI US 2006-795762 A1 20060126 (11)
WO 2006-EP50465 20060126
20070831 PCT 371 date
PRAI EP 2005-100594 20050128
EP 2005-100913 20050209
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I),

##STR1##

in which R1, R2, R3, R4, R5 and X have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.
IT 284461-73-0
(preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 302 OF 390 USPATFULL on STN
AN 2008:143099 USPATFULL
TI METHODS AND COMPOSITIONS FOR TREATING MELANOMA
IN Goydos, James S., East Brunswick, NJ, UNITED STATES
Chen, Suzie, Highland Park, NJ, UNITED STATES
PA UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, New Brunswick, NJ, UNITED STATES (U.S. corporation)
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ, UNITED STATES (U.S. corporation)
PI US 20080124333 A1 20080529
US 7691377 B2 20100406
AI US 2007-855890 A1 20070914 (11)
RLI Continuation-in-part of Ser. No. US 2005-91076, filed on 28 Mar 2005, PENDING
PRAI US 2005-649022P 20050201 (60)
US 2004-563131P 20040416 (60)
DT Utility
FS APPLICATION
LREP SYNNESTVEDT LECHNER & WOODBRIDGE LLP, P O BOX 592, 112 NASSAU STREET,
PRINCETON, NJ, 08542-0592, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM 1 antagonist, or a combination thereof
IT 284461-73-0, Sorafenib
(compns. for treating melanoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 303 OF 390 USPATFULL on STN
AN 2008:131049 USPATFULL
TI Novel Indolopyridines, Benzofuranopyridines and Benzothienopyridines
IN Vennemann, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenaus, GERMANY, FEDERAL REPUBLIC OF
Braunger, Jurgen, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PI US 20080114017 A1 20080515
AI US 2006-795763 A1 20060126 (11)
WO 2006-EP50467 20060126
20070720 PCT 371 date
PRAI EP 2005-100526 20050127
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I),

##STR1##

in which R1, R2, R3, R4, R5, R6 and X have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.

IT 284461-73-0, Sorafenib
(preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 304 OF 390 USPATFULL on STN
AN 2008:129997 USPATFULL
TI MN/CA IX and EGFR Pathway Inhibition
IN DORAI, Thambi, Nanuet, NY, UNITED STATES
PI US 20080112960 A1 20080515
US 7820159 B2 20101026
AI US 2007-927150 A1 20071029 (11)
PRAI US 2006-855507P 20061031 (60)
DT Utility
FS APPLICATION
LREP Leona L. Lauder, Attorney at Law, Suite 1026, 235 Montgomery Street, San Francisco, CA, 94104-3008, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2562
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.
IT 284461-73-0, Sorafenib
(MN gene-encoded carbonic anhydrase IX and EGFR pathway inhibition in treating preneoplastic/neoplastic diseases in relation to therapy selection and combination chemotherapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 305 OF 390 USPATFULL on STN
AN 2008:124874 USPATFULL
TI Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Siego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20080108672 A1 20080508
AI US 2007-768104 A1 20070625 (11)
RLI Continuation of Ser. No. US 2002-42203, filed on 11 Jan 2002, Pat. No. US 7235576
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 475207-59-1P 943024-27-9P
(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 943024-27-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-74-1
CMF C20 H14 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0P 284461-74-1P
(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 306 OF 390 USPATFULL on STN
AN 2008:111364 USPATFULL
TI Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer
IN Pekari, Klaus, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bartels, Bjorn, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
PA ALTANA Pharma AG, Konstanz, GERMANY, FEDERAL REPUBLIC OF, 78467 (non-U.S. corporation)
PI US 20080096914 A1 20080424
US 7714135 B2 20100511
AI US 2006-883596 A1 20060208 (11)
WO 2006-EP50782 20060208
20070917 PCT 371 date
PRAI EP 2005-100895 20050209
EP 2005-104488 20050525
EP 2005-112158 20051214
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula (I), ##STR1## in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
IT 284461-73-0, Sorafenib
(preparation of tetrahydropyridothiophenes with cell-cycle dependent, antiproliferative and apoptosis-inducing activity useful in treatment of hyperproliferative diseases such as cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 307 OF 390 USPATFULL on STN
AN 2008:104285 USPATFULL
TI CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF
IN Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schaefer, Olaf, Biberach an der Riss, GERMANY, FEDERAL REPUBLIC OF
Teifel, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Paulini, Klaus, Maintal, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF, 60314 (non-U.S. corporation)
PI US 20080090758 A1 20080417
US 7741277 B2 20100622
AI US 2007-850747 A1 20070906 (11)
PRAI EP 2006-18750 20060907
US 2006-842357P 20060906 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
IT 284461-73-0, Sorafenib
(combination chemotherapy; manufacturing process for conjugates of disorazoles and their derivs. with cell-binding mols.)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 308 OF 390 USPATFULL on STN
AN 2008:98551 USPATFULL
TI Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
IN Bold, Guido, Gipf-Oberfrick, SWITZERLAND
Brueggen, Josef Bernhard, Riehen, GERMANY, FEDERAL REPUBLIC OF
Huang, Jerry Min-Jian, Florham Park, NJ, UNITED STATES
Kinder, Frederick Ray, Morristown, NJ, UNITED STATES
Lane, Heidi, Biel-Benken, SWITZERLAND
Latour, Elisabeth Jeanne, Bartenheim-La Chaussee, FRANCE
Manley, Paul W., Arlesheim, UNITED KINGDOM
Wood, Jeanette Marjorie, Biel-Benken, SWITZERLAND
PI US 20080085902 A1 20080410
AI US 2004-573163 A1 20040923 (10)
WO 2004-EP10686 20040923
20070228 PCT 371 date
PRAI US 2003-505250P 20030923 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2274
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with a VEGF inhibitor compound; and one or more chemotherapeutic agents.
IT 284461-73-0, BAY43-9006
(combination of vegf receptor inhibitor with chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 309 OF 390 USPATFULL on STN
AN 2008:97978 USPATFULL
TI Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kemnitzer, William E., San Diego, CA, UNITED STATES
Tseng, Ben Y., San Diego, CA, UNITED STATES
Blais, Charles, Beaconsfield, CANADA
Labrecque, Denis, Laval, CANADA
Gourdeau, Henriette, Montreal, CANADA
PI US 20080085328 A1 20080410
AI US 2007-822535 A1 20070706 (11)
PRAI US 2006-806674P 20060706 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.,
1100 NEW YORK AVENUE, N.W.,
WASHINGTON, DC, 20005, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer:

##STR1##

The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
IT 284461-73-0, Sorafenib
(substituted 4-aryl-chromene as caspase activator and apoptosis inducer, and as antivascular agent for treatment of diseases due to vasculature overgrowth, such as solid tumors and ocular neovascularization)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 310 OF 390 USPATFULL on STN
AN 2008:89565 USPATFULL
TI ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy, Hyogo, JAPAN
Scott, William, Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert, North Haven, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 7351834 B1 20080401
WO 2000042012 20000720
AI US 2000-889227 20000112 (9)
WO 2000-US648 20000112
20020108 PCT 371 date
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Desai, Rita
LREP Millen, White, Zelano & Branigan, P.C.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 311 OF 390 USPATFULL on STN
AN 2008:86940 USPATFULL
TI Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
IN Singh, Sharat, Los Altos, CA, UNITED STATES
PI US 20080076139 A1 20080327
AI US 2006-525598 A1 20060921 (11)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and kits for detecting the activation states of a plurality of signal transducers of circulating cells of a solid tumor in a specific, multiplex, high-throughput assay are described. The methods comprise: contacting the signal transducers extracted from the cells with first, second, and third binding partners specific for each of the signal transducers to produce signal transducer-binding partner complexes. The second binding partners bind the corresponding signal transducers independent of their activation state and are labeled with a first moiety, and the third binding partners bind the corresponding signal transducers dependent of their activation state and are labeled with a second moiety. The first and second moieties are detected as an indication of the activation states of the plurality of signal transducers.
IT 475207-59-1, Nexavar
(cell stimulation with drug treatment; antibody-based arrays for detecting multiple signal transducers in rare circulating cells and use in diagnosis and treatment of cancer)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 312 OF 390 USPATFULL on STN
AN 2008:73679 USPATFULL
TI Novel Pyrrolodihydroisoquinolines
IN Vennemann, Matthias, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Bar, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Braunger, Juergen, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gekeler, Volker, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Gimmnich, Petra, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Ciapetti, Paola, Altdorf, FRANCE
Contreras, Jean-Marie, Benfeld, FRANCE
Wermuth, Camille Georges, Strasbourg, FRANCE
PA NYCOMED GMBH, Konstanz, GERMANY, FEDERAL REPUBLIC OF, 78467 (non-U.S. corporation)
PI US 20080064714 A1 20080313
AI US 2006-794494 A1 20060111 (11)
WO 2006-EP50165 20060111
20070816 PCT 371 date
PRAI EP 2005-100155 20050112
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel pyrrolodihydroisoquinoline derivatives which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells.
IT 284461-73-0, BAY43-9006
(preparation of novel pyrrolodihydroisoquinolines as inhibitors of cellular proliferation and inducers of apoptosis in cancer cells)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 313 OF 390 USPATFULL on STN
AN 2008:66427 USPATFULL
TI Novel aminopyridine derivatives having aurora a selective inhibitory action
IN Iwasawa, Yoshikuzu, Tsukuba-shi, JAPAN
Kato, Tetsuya, Tsukuba-shi, JAPAN
Kawanishi, Nobuhiko, Moriya-shi, JAPAN
Masutani, Kouta, Tsukuba-shi, JAPAN
Mita, Takashi, Tsukuba-shi, JAPAN
Nonoshita, Katsumasa, Tsukuba-shi, JAPAN
Ohkubo, Mitsuru, Ushiku-shi, JAPAN
PI US 20080058347 A1 20080306
US 7915263 B2 20110329
AI US 2007-897272 A1 20070829 (11)
PRAI JP 2006-236472 20060831
US 2007-926086P 20070425 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a compound of formula I: ##STR1## wherein: R.sub.1 is a hydrogen atom, F, CN, etc.; R.sub.1' is a hydrogen atom or lower alkyl which may be substituted; R.sub.2 is O, S, SO, SO.sub.2, etc.; R.sub.3 is a phenyl which may be substituted; X.sub.1, X.sub.2, and X.sub.3 each independently CH, N, etc. provided, however, that among X.sub.1, X.sub.2 and X.sub.3, the number of nitrogen is 0 or 1; W is the following residue: ##STR2## wherein: W.sub.1, W.sub.2, and W.sub.3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.
IT 284461-73-0, Sorafenib
(preparation of 2-(azolylamino)pyridine derivs. having Aurora A kinase selective inhibitory action)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 314 OF 390 USPATFULL on STN
AN 2008:58618 USPATFULL
TI ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS
IN Gerlach, Matthias, Brachttal, GERMANY, FEDERAL REPUBLIC OF
Gunther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Peter, Schoeneck, GERMANY, FEDERAL REPUBLIC OF
Prinz, Helge, Havixbeck, GERMANY, FEDERAL REPUBLIC OF
Bohm, Konrad, Jena, GERMANY, FEDERAL REPUBLIC OF
Unger, Eberhard, Jena, GERMANY, FEDERAL REPUBLIC OF
PA AETERNA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20080051463 A1 20080228
AI US 2007-833254 A1 20070803 (11)
PRAI EP 2006-16401 20060807
US 2007-894935P 20070315 (60)
US 2006-835431P 20060804 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER &
NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions which can be treated by inhibiting tubulin polymerization and/or by inhibiting microtubuli-based motor proteins, in particular various tumor disorders.
IT 284461-73-0, Sorafenib
(medicaments with; preparation of phenacylidenylanthrones and related compds. for treatment of benign and malignant tumorous diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 315 OF 390 USPATFULL on STN
AN 2008:58565 USPATFULL
TI Protein Kinase Targeted Therapeutics
IN Watterson, D. Martin, Chicago, IL, UNITED STATES
Van Eldik, Linda J., Chicago, IL, UNITED STATES
PA Northwestern University, Evanston, IL, UNITED STATES, 60208 (U.S. corporation)
PI US 20080051410 A1 20080228
AI US 2007-833152 A1 20070802 (11)
PRAI US 2006-834962P 20060802 (60)
DT Utility
FS APPLICATION
LREP Casimir Jones, S.C., 440 Science Drive, Suite 203, Madison, WI, 53711, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
IT 284461-73-0, Sorafenib
(preparation of phenyl(pyridinyl)pyridazinamines for protein kinase targeted therapeutics)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 316 OF 390 USPATFULL on STN
AN 2008:51833 USPATFULL
TI Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
IN Kelley, Susan, Woodbridge, CT, UNITED STATES
PI US 20080045589 A1 20080221
AI US 2007-754082 A1 20070525 (11)
PRAI US 2006-808555P 20060526 (60)
US 2006-859241P 20061116 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to drug combinations and pharmaceutical compositions for treating cancer such as non-small cell lung carcinoma, said combination comprising (1) at least one substituted-diaryl urea such as BAY 43-9006, (2) at least one taxane such as Paclitaxel (Taxol®), Docetaxel (Taxotere®) and Abraxane.TM. and (3) at least one platinum complex antineoplastic nucleic acid binding agent such as carboplatin (Paraplatin®), oxaplatin (Eloxatin®) and cisplatin (Platinol®), where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof.
IT 284461-73-0, BAY 43-9006 475207-59-1, Nexavar
(drug combinations with substituted diaryl ureas for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0

CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0D, polymorph, solvate, hydrate, metabolite, prodrug, or salt
(kits; drug combinations with substituted diaryl ureas for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 317 OF 390 USPATFULL on STN
AN 2008:43696 USPATFULL
TI Conveniently implantable sustained release drug compositions
IN Wong, Vernon G., Menlo Park, CA, UNITED STATES
Wood, Louis L., Potomac, MD, UNITED STATES
PI US 20080038316 A1 20080214
AI US 2007-826833 A1 20070718 (11)
RLI Continuation-in-part of Ser. No. US 2005-236426, filed on 27 Sep 2005, PENDING
PRAI US 2005-709665P 20050819 (60)
US 2004-614484P 20041001 (60)
US 2006-831991P 20060719 (60)
DT Utility
FS APPLICATION
LREP NIXON PEABODY, LLP, 401 9TH STREET, NW, SUITE 900, WASHINGTON, DC, 20004-2128, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 3606
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.
IT 284461-73-0, Sorafenib
(injectable biocompatible and biodegradable implantable sustained-release drug compns.)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 318 OF 390 USPATFULL on STN
AN 2008:43631 USPATFULL
TI MN/CA IX and MAPK inhibition
IN Pastorekova, Silvia, Stupava, SLOVAKIA
Pastorek, Jaromir, Stupava, SLOVAKIA
PI US 20080038251 A1 20080214
AI US 2007-726065 A1 20070320 (11)
PRAI US 2006-784284P 20060320 (60)
DT Utility
FS APPLICATION
LREP Leona L. Lauder, Attorney at Law, Suite 1026, 235 Montgomery Street, San Francisco, CA, 94104-3008, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is based upon the discovery that the mitogen-activated protein kinase (MAPK) pathway can increase CA9 expression independently of HIF-1, as well as increasing CA9 expression under HIF-1-dependent pathways initiated by hypoxia or high cell density. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using MAPK pathway inhibitors. Preferably, the MAPK pathway inhibitors are raf kinase inhibitors, particularly the raf kinase inhibitor Sorafenib. Further disclosed are methods for patient therapy selection for MAPK pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.
IT 284461-73-0, Sorafenib
(methods for MN gene-encoded carbonic anhydrase IX and MAP kinase inhibition for treatment of preneoplasm and neoplasm)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 319 OF 390 USPATFULL on STN
AN 2008:37550 USPATFULL
TI Method of treating inflammatory diseases using tyroskine kinase inhibitors
IN Robinson, William H., Palo Alto, CA, UNITED STATES
Paniagua, Ricardo T., Redwood City, CA, UNITED STATES
PI US 20080032989 A1 20080207
AI US 2007-809515 A1 20070531 (11)
PRAI US 2006-810030P 20060531 (60)
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 2368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating and preventing inflammatory diseases using tyrosine kinase inhibitors are described. The inhibitors inhibit, e.g., T lymphocyte and/or B lymphocyte function, fibroblast proliferation, mast cells activation, and/or monocyte differentiation.
IT 284461-73-0, Sorafenib
(treating inflammatory diseases using tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 320 OF 390 USPATFULL on STN
AN 2008:37540 USPATFULL
TI Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishnomiya City, JAPAN
William, Scott J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reink, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20080032979 A1 20080207
AI US 2007-845595 A1 20070827 (11)
RLI Division of Ser. No. US 2001-948915, filed on 10 Sep 2001, ABANDONED
Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-67
DRWN No Drawings
LN.CNT 3088
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 321 OF 390 USPATFULL on STN
AN 2008:30765 USPATFULL
TI omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors
IN Riedl, Bernd, Wupperral, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20080027061 A1 20080131
US 7897623 B2 20110301
AI US 2007-845597 A1 20070827 (11)
RLI Division of Ser. No. US 2002-86417, filed on 4 Mar 2002, ABANDONED
Continuation of Ser. No. US 1999-425229, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1-38
DRWN No Drawings
LN.CNT 3640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 322 OF 390 USPATFULL on STN
AN 2008:29659 USPATFULL
TI INTERLEUKIN 21 AND TYROSINE KINASE INHIBITOR COMBINATION THERAPY
IN Sivakumar, Pallavur V., Seattle, WA, UNITED STATES
Hausman, Diana F., Seattle, WA, UNITED STATES
Hughes, Steven D., Kenmore, WA, UNITED STATES
Sievers, Eric, Seattle, WA, UNITED STATES
Miller, Dennis M., Woodinville, WA, UNITED STATES
PI US 20080025946 A1 20080131
AI US 2007-777852 A1 20070713 (11)
PRAI US 2006-807256P 20060713 (60)
DT Utility
FS APPLICATION
LREP ZYMOGENETICS, INC., INTELLECTUAL PROPERTY DEPARTMENT, 1201 EASTLAKE AVENUE EAST, SEATTLE, WA, 98102-3702, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for use of IL-21 in combination with a tyrosine kinase inhibitor (TKI) in treatment of diseases in which inhibition of phosphorylation via TK inhibition and modulation of immune function play a clinically beneficial role. These diseases include, but are not limited to, cancers, such as renal cell carcinoma and metastatic melanoma.
IT 284461-73-0, Sorafenib
(interleukin 21 combination with tyrosine kinase inhibitor for cancer therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 323 OF 390 USPATFULL on STN
AN 2008:16545 USPATFULL
TI Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
IN Arnold, Lee D., East Islip, NY, UNITED STATES
Ji, Qun-Sheng, Farmingdale, NY, UNITED STATES
Mulvihill, Mark Joseph, Farmingdale, NY, UNITED STATES
PI US 20080014200 A1 20080117
AI US 2007-787236 A1 20070413 (11)
RLI Continuation-in-part of Ser. No. US 2005-641346, ABANDONED
PRAI US 2005-752243P 20051219 (60)
DT Utility
FS APPLICATION
LREP OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE, NY, 11747, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 9149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The IGF1R inhibitor is represented by Formula I: ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein.
IT 284461-73-0, Sorafenib
(combined treatment with bicyclic ring substituted heterobicyclic protein kinase inhibitor and anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 324 OF 390 USPATFULL on STN
AN 2008:5109 USPATFULL
TI Substituted Piperidines that Increase P53 Activity and the Uses Thereof
IN Ma, Yao, Westwood, MA, UNITED STATES
Lahue, Brian Robert, Millbury, MA, UNITED STATES
Shipps, Gerald W. JR., Stoneham, MA, UNITED STATES
Wang, Yaolin, Edison, NJ, UNITED STATES
Bogen, Stephane L., Somerset, NJ, UNITED STATES
Voss, Matthew Ernst, Nassau, NY, UNITED STATES
Nair, Latha G., Edison, NJ, UNITED STATES
Tian, Yuan, Newton, MA, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Guo, Zhuyan, Scotch Plains, NJ, UNITED STATES
Strickland, Corey O., Martinsville, NJ, UNITED STATES
Zhang, Rumin, Edison, NJ, UNITED STATES
McCoy, Mark A., Acton, MA, UNITED STATES
Pan, Weidong, Somerset, NJ, UNITED STATES
Siegel, Elise M., Jersey City, NJ, UNITED STATES
Gibeau, Craig R., Arlington, MA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20080004287 A1 20080103
US 7884107 B2 20110208
AI US 2007-769030 A1 20070627 (11)
PRAI US 2006-817753P 20060630 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein, methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.
IT 284461-73-0
(novel substituted piperidines useful in treatment and prevention of P53- and HDM2 protein-related diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 325 OF 390 USPATFULL on STN
AN 2008:5108 USPATFULL
TI Method of Using Substituted Piperidines that Increase P53 Activity
IN Wang, Yaolin, Edison, NJ, UNITED STATES
Zhang, Rumin, Edison, NJ, UNITED STATES
Ma, Yao, Westwood, MA, UNITED STATES
Lahue, Brian Robert, Millbury, MA, UNITED STATES
Shipps, Gerald W., Stoneham, MA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20080004286 A1 20080103
AI US 2007-769003 A1 20070627 (11)
PRAI US 2006-818128P 20060630 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses a method of using compounds, which have HDM2 protein antagonist activity, to treat or prevent cancer, other diseases caused by abnormal cell proliferation, diseases associated with HDM2, or diseases caused by inadequate P53 activity.
IT 284461-73-0
(antitumor substituted piperidines that increase p53 activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 326 OF 390 USPATFULL on STN
AN 2007:334519 USPATFULL
TI Novel genes and markers in type 2 diabetes and obesity
IN Salonen, Jukka T., Kuopio, FINLAND
Hypponen, Jelena, Kuopio, FINLAND
Kaikkonen, Jari, Kuopio, FINLAND
Pirskanen, Mia, Kuopio, FINLAND
Uimari, Pekka, Kuopio, FINLAND
Aalto, Juha-Matti, Siilinjarvi, FINLAND
PA Oy Jurilab Ltd, Kuopio, FINLAND (non-U.S. corporation)
PI US 20070292412 A1 20071220
US 7901885 B2 20110308
AI US 2007-798002 A1 20070509 (11)
PRAI US 2006-798706P 20060509 (60)
US 2006-798774P 20060509 (60)
US 2006-805522P 20060622 (60)
US 2006-819015P 20060707 (60)
US 2006-827306P 20060928 (60)
US 2006-863438P 20061030 (60)
US 2006-864681P 20061107 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747,
FALLS CHURCH, VA, 22040-0747,
US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.
IT 284461-73-0
(target for, in treatment of diabetes; alleles and polymorphisms associated with type 2 diabetes and obesity and their diagnostic use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 327 OF 390 USPATFULL on STN
AN 2007:322623 USPATFULL
TI RAF inhibitors and their uses
IN Lapierre, Jean-Marc, Pelham, NH, UNITED STATES
Namdev, Nivedita D., Westford, MA, UNITED STATES
Ashwell, Mark A., Carlisle, MA, UNITED STATES
France, Dennis S., Cambridge, MA, UNITED STATES
Wu, Hui, Malden, MA, UNITED STATES
Hutchins, Patrick M., Denver, CO, UNITED STATES
Tandon, Manish, Framingham, MA, UNITED STATES
Liu, Yanbin, Acton, MA, UNITED STATES
Link, Jeff S., Londonderry, NH, UNITED STATES
Ali, Syed M., North Andover, MA, UNITED STATES
Brassard, Chris J., Somerville, MA, UNITED STATES
Nicewonger, Robb B., Tyngsboro, MA, UNITED STATES
Filikov, Anton, Stoneham, MA, UNITED STATES
Carazza, Rebecca J., Winchester, MA, UNITED STATES
PI US 20070281955 A1 20071206
US 7501430 B2 20090310
AI US 2007-785163 A1 20070416 (11)
PRAI US 2006-792314P 20060417 (60)
DT Utility
FS APPLICATION
LREP ARNOLD & PORTER LLP, ATTN: IP DOCKETING DEPT., 555 TWELFTH STREET, N.W.,
WASHINGTON, DC, 20004-1206, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAF.sup.V600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
IT 284461-73-0, Sorafenib
(preparation of imidazoloxazole and imidazolothiazole compds. as RAF kinase inhibitors useful in treatment of diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 328 OF 390 USPATFULL on STN
AN 2007:322602 USPATFULL
TI INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE
IN Buggy, Joseph J., Mountain View, CA, UNITED STATES
Balasubramanian, Sriram, San Carlos, CA, UNITED STATES
Verner, Erik, San Mateo, CA, UNITED STATES
Tai, Vincent W.F., San Mateo, CA, UNITED STATES
Lee, Chang-Sun, Belle Mead, NJ, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 20070281934 A1 20071206
AI US 2007-687565 A1 20070316 (11)
PRAI US 2006-783287P 20060316 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE
MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 7284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
IT 475207-59-1, Nexavar
(indole derivs. as inhibitors of histone deacetylase)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L20 ANSWER 329 OF 390 USPATFULL on STN
AN 2007:303318 USPATFULL
TI PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PI US 20070265315 A1 20071115
US 7678811 B2 20100316
AI US 2007-775457 A1 20070710 (11)
RLI Continuation of Ser. No. US 2003-361850, filed on 11 Feb 2003, ABANDONED
PRAI US 2002-354935P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angogenesis disorders.
IT 284461-73-0
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-74-1P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-03-3P 583840-04-4P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



L20 ANSWER 330 OF 390 USPATFULL on STN
AN 2007:296186 USPATFULL
TI COMPOSITIONS AND METHODS FOR CONVECTION ENHANCED DELIVERY OF HIGH MOLECULAR WEIGHT NEUROTHERAPEUTICS
IN Bankiewicz, Krystof S., Oakland, CA, UNITED STATES
Kunwar, Sandeep, Hillsborough, CA, UNITED STATES
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA, UNITED STATES, 94607 (U.S. corporation)
PI US 20070259031 A1 20071108
AI US 2007-740508 A1 20070426 (11)
PRAI US 2006-795371P 20060426 (60)
US 2007-900492P 20070209 (60)
DT Utility
FS APPLICATION
LREP JOHN P. O'BANION, O'BANION & RITCHEY LLP,
400 CAPITOL MALL SUITE 1550,
SACRAMENTO, CA, 95814, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 1749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.
IT 284461-73-0, Sorafenib
(convection-enhanced local delivery of high mol. weight neurotherapeutics for treatment of CNS disorders)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 331 OF 390 USPATFULL on STN
AN 2007:290599 USPATFULL
TI METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY
IN Harvey, Jeanne, Livermore, CA, UNITED STATES
Neri, Bruce, Carlsbad, CA, UNITED STATES
Singh, Sharat, Los Altos Hills, CA, UNITED STATES
PA Prometheus Laboratories Inc., San Diego, CA, UNITED STATES, 92121-5201 (U.S. corporation)
PI US 20070254295 A1 20071101
US 7908091 B2 20110315
AI US 2007-687254 A1 20070316 (11)
PRAI US 2006-829812P 20061017 (60)
US 2006-783743P 20060317 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 75
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 3601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.
IT 284461-73-0, Sorafenib
(methods of predicting and monitoring tyrosine kinase inhibitor cancer therapy using gene and protein expression profiling)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 332 OF 390 USPATFULL on STN
AN 2007:290351 USPATFULL
TI Novel Pyrazolopyrimidines
IN Maier, Thomas, Stockach, GERMANY, FEDERAL REPUBLIC OF
Zuelch, Armin, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Ciossek, Thomas, Ravensburg, GERMANY, FEDERAL REPUBLIC OF
Baer, Thomas, Reichenau, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Konstanz, GERMANY, FEDERAL REPUBLIC OF
PA Altana Pharma AG, Konstanz, GERMANY, FEDERAL REPUBLIC OF, 78467 (non-U.S. corporation)
PI US 20070254046 A1 20071101
US 7745446 B2 20100629
AI US 2005-661111 A1 20050905 (11)
WO 2005-EP54366 20050905
20070226 PCT 371 date
PRAI EP 2004-104283 20040906
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of a certain formula I ##STR1## in which R1, R2, R3 and R4 have the meanings indicated in the description are novel compounds expected to be useful in the therapy of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis.
IT 284461-73-0, BAY43-9006
(novel pyrazolopyrimidine compds. useful in therapy of hyper-proliferative diseases and disorders responsive to induction of apoptosis)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 333 OF 390 USPATFULL on STN
AN 2007:284051 USPATFULL
TI ANTI-FGF19 ANTIBODIES AND METHODS USING SAME
IN Desnoyers, Luc, San Francisco, CA, UNITED STATES
French, Dorothy, San Carlos, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES, 94080 (U.S. corporation)
PI US 20070248604 A1 20071025
US 7678373 B2 20100316
AI US 2007-673411 A1 20070209 (11)
PRAI US 2007-885866P 20070119 (60)
US 2006-780608P 20060309 (60)
US 2006-772310P 20060210 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 6563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
IT 284461-73-0, Sorafenib
(in combination therapy with antibody to human fibroblast growth factor 19)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 334 OF 390 USPATFULL on STN
AN 2007:211261 USPATFULL
TI Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
IN Plum, Stacy M., Arlington, VA, UNITED STATES
Strawn, Steven J., Arlington, VA, UNITED STATES
LaVallee, Theresa M., Rockville, MD, UNITED STATES
Sidor, Carolyn F., Chapel Hill, NC, UNITED STATES
Fogler, William E., Rockville, MD, UNITED STATES
Treston, Anthony M., Rockville, MD, UNITED STATES
PI US 20070185069 A1 20070809
AI US 2006-599997 A1 20061114 (11)
PRAI US 2005-736220P 20051114 (60)
US 2006-788354P 20060331 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING LLP, 1180 PEACHTREE STREET, ATLANTA, GA, 30309-3521, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods and compositions of treating disease characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with chemotherapeutic agents. More specifically, the present invention relates to a methods and compositions of treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol, in combination with chemotherapeutic agents.
IT 284461-73-0, Sorafenib
(anti-angiogenic activity of 2-methoxyestradiol and other estradiols in combination with anti-cancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 335 OF 390 USPATFULL on STN
AN 2007:203840 USPATFULL
TI Methods for prediction and prognosis of cancer, and monitoring cancer therapy
IN Elting, James, Madison, CT, UNITED STATES
Wilhelm, Scott, Orange, CT, UNITED STATES
PI US 20070178494 A1 20070802
AI US 2006-598824 A1 20061114 (11)
PRAI US 2005-735854P 20051114 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF and sVEGFR as a biomarker for subjects treated with sorafenib.
IT 284461-73-0, Sorafenib 284461-73-0D, salt, polymorph, hydrate, or solvate
(biomarkers for prediction and prognosis of cancer and monitoring chemotherapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 336 OF 390 USPATFULL on STN
AN 2007:170797 USPATFULL
TI NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
IN Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Seipelt, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20070149484 A1 20070628
AI US 2006-558503 A1 20061110 (11)
PRAI US 2006-849761P 20061006 (60)
US 2005-735698P 20051111 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
IT 284461-73-0
(medicaments with; preparation of pyridopyrazines as kinase modulators)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 337 OF 390 USPATFULL on STN
AN 2007:170029 USPATFULL
TI Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alpha
IN Rikova, Klarisa, Reading, MA, UNITED STATES
Polakiewicz, Roberto, Lexington, MA, UNITED STATES
Guo, Ailan, Burlington, MA, UNITED STATES
Crosby, Katherine, Middleton, MA, UNITED STATES
Zeng, Qingfu, Hamilton, MA, UNITED STATES
Lee, Kimberly, Boston, MA, UNITED STATES
PI US 20070148711 A1 20070628
US 7932044 B2 20110426
AI US 2005-174051 A1 20050701 (11)
DT Utility
FS APPLICATION
LREP James Gregory Cullem, Esq., Intellectual Property Counsel, CELL SIGNALING TECHNOLOGY, INC., 3 Trask Lane, Danvers, MA, 01923, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor.
IT 284461-73-0, BAY 43-9006
(for inhibition of growth of PDGFRα-dependent NSCLC; subtype of NSCLC tumors dependent on PDGFRα and its diagnosis and treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 338 OF 390 USPATFULL on STN
AN 2007:164998 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 7235576 B1 20070626
AI US 2002-42203 20020111 (10)
PRAI US 2001-367380P 20010112 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Millen, White, Zelano & Branigan, P.C.
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 475207-59-1P 943024-27-9P
(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 943024-27-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-74-1
CMF C20 H14 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-73-0P 284461-74-1P
(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 339 OF 390 USPATFULL on STN
AN 2007:141503 USPATFULL
TI PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
IN SEIPELT, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20070123494 A1 20070531
AI US 2006-558493 A1 20061110 (11)
PRAI US 2005-735707P 20051111 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER &
NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
IT 284461-73-0
(medicaments with; preparation of pyridopyrazines as kinase modulators)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 340 OF 390 USPATFULL on STN
AN 2007:120940 USPATFULL
TI Methods for prognosis and monitoring cancer therapy
IN Wilhelm, Scott, Milford, CT, UNITED STATES
PI US 20070105142 A1 20070510
AI US 2006-589295 A1 20061030 (11)
PRAI US 2005-731278P 20051031 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of HER-2, EGFR, VEGF, u-PA, p-PAI-1, and soluble forms thereof, as biomarkers for cancer, especially for subjects treated with sorafenib.
IT 284461-73-0, Sorafenib
(biomarker-based methods for prognosis and monitoring cancer therapy with sorafenib)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 475207-59-1P
(biomarker-based methods for prognosis and monitoring cancer therapy with sorafenib)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 284461-74-1P
(biomarker-based methods for prognosis and monitoring cancer therapy with sorafenib)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 341 OF 390 USPATFULL on STN
AN 2007:42528 USPATFULL
TI Quantitative assays for PDGFR-beta in body fluids
IN Hamer, Peter J., Reading, MA, UNITED STATES
Carney, Walter P., North Andover, MA, UNITED STATES
Morris, Leticia, Chestnut Hill, MA, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
PI US 20070037224 A1 20070215
AI US 2006-502013 A1 20060810 (11)
PRAI US 2005-707806P 20050811 (60)
DT Utility
FS APPLICATION
LREP LEONA L. LAUDER, 235 MONTGOMERY STREET, SUITE 1026, SAN FRANCISCO, CA, 94104-0332, US
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the detection and quantification of total PDGFR-β in body fluids, particularly serial changes of total PDGFR-β levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-β in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.
IT 284461-73-0, BAY 43-9006
(quant. immunoassays to measure serial changes in PGDFR-β protein in human body fluids for disease diagnosis, prognosis and to monitor how a patient is responding to a therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 342 OF 390 USPATFULL on STN
AN 2007:35800 USPATFULL
TI Embolized cryoablation for treatment of tumors
IN Zabinski, Peter P., Melbourne, FL, UNITED STATES
PI US 20070031338 A1 20070208
AI US 2006-496265 A1 20060731 (11)
PRAI US 2005-704938P 20050802 (60)
DT Utility
FS APPLICATION
LREP MELVIN K. SILVERMAN, 500 WEST CYPRESS CREEK ROAD, SUITE 500, FT. LAUDERDALE, FL, 33309, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An embolized-cryoablation method for treating a tumor of an organ is provided. The method includes inserting a catheter in a vascular pathway connected to a target region adjacent the tumor, and advancing the catheter through the vascular pathway to place a distal end portion of the catheter in the target region; injecting a liquid embolization material through the catheter into the target region; removing the catheter through the vascular pathway from the organ; inserting a cryoprobe laparoscopically into the target region, and placing a distal end portion of the cryoprobe within the target region; delivering a cryogen into and circulating the cryogen inside the cryoprobe for a period of time, thereby providing a cryotreatment to the target region of the organ. The combined embolization-cryoablation treatment reduces bleeding and enhances cell death, necrosis, or apoptosis in the tumor tissue.
IT 284461-73-0, Sorafenib
(embolized cryoablation for treatment of tumors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 343 OF 390 USPATFULL on STN
AN 2007:30875 USPATFULL
TI 2-Amino-quinazolin-5-ones
IN Bellamacina, Cornelia R., Castro Valley, CA, UNITED STATES
Costales, Abran, El Cerrito, CA, UNITED STATES
Doughan, Brandon M., Eugene, OR, UNITED STATES
Fong, Susan, Richmond, CA, UNITED STATES
Gao, Zhenhai, Hercules, CA, UNITED STATES
Hendrickson, Thomas, Encinitas, CA, UNITED STATES
Levine, Barry H., Lafayette, CA, UNITED STATES
Lin, Xiaodong, Walnut Creek, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Antonios-McCrea, William R., Berkeley, CA, UNITED STATES
McKenna, Maureen, Pinole, CA, UNITED STATES
Mendenhall, Kris G., Concord, CA, UNITED STATES
Rico, Alice C., Castro Valley, CA, UNITED STATES
Shafer, Cynthia M., Moraga, CA, UNITED STATES
Wang, X. Michael, Livermore, CA, UNITED STATES
Xia, Yi, Foster City, CA, UNITED STATES
Zhou, Yasheen, Moraga, CA, UNITED STATES
PI US 20070027150 A1 20070201
AI US 2006-404372 A1 20060414 (11)
PRAI US 2005-671662P 20050414 (60)
DT Utility
FS APPLICATION
LREP NOVARTIS VACCINES AND DIAGNOSTICS INC., CORPORATE INTELLECTUAL PROPERTY R338, P.O. BOX 8097, Emeryville, CA, 94662-8097, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.
IT 284461-73-0, Sorafenib
(preparation of aminoquinazolinone compds. useful in treatment and prophylaxis of cell proliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 344 OF 390 USPATFULL on STN
AN 2007:23660 USPATFULL
TI Diaryl ureas with kinase inhibiting activity
IN Wilhelm, Scott, Orange, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Ladouceur, Gaetan, Guilford, CT, UNITED STATES
Lynch, Mark, Madison, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
PI US 20070020704 A1 20070125
AI US 2004-571100 A1 20040519 (10)
WO 2004-US15655 20040519
20060728 PCT 371 date
PRAI US 2003-471735P 20030520 (60)
US 2003-520399P 20031117 (60)
US 2004-556062P 20040325 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3724
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.
IT 284461-73-0P 284461-74-1P
(preparation of diaryl ureas with kinase inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 345 OF 390 USPATFULL on STN
AN 2006:308860 USPATFULL
TI Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
IN Khazak, Vladimir, Brooklyn, NY, UNITED STATES
Golemis, Erica A., Oreland, PA, UNITED STATES
Menon, Sanjay R., Danbury, CT, UNITED STATES
Weber, Lutz, Germering, GERMANY, FEDERAL REPUBLIC OF
PI US 20060264473 A1 20061123
US 7705021 B2 20100427
AI US 2006-412367 A1 20060427 (11)
PRAI US 2005-676864P 20050502 (60)
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400,
PHILADELPHIA, PA, 19103-2307, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isoindolone derivatives, compositions containing the same, and methods of use thereof for the treatment or prophylaxis of viral infection are disclosed.
IT 284461-73-0, Bay43-9006
(co-drug; preparation of isoindolone compds. as MAPK inhibitors for the treatment of viral infections)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 346 OF 390 USPATFULL on STN
AN 2006:289192 USPATFULL
TI Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
IN Carter, Christopher A., Guilford, CT, UNITED STATES
Gibson, Neil, East Northport, NY, UNITED STATES
Hibner, Barbara, Madison, CT, UNITED STATES
Humphrey, Rachel W., Woodbridge, CT, UNITED STATES
Trail, Pamela, Madison, CT, UNITED STATES
Vincent, Patrick W., Cheshire, CT, UNITED STATES
Zhai, Yifan, Guilford, CT, UNITED STATES
PI US 20060247186 A1 20061102
AI US 2006-480360 A1 20060705 (11)
RLI Continuation of Ser. No. US 2002-308187, filed on 3 Dec 2002, ABANDONED
PRAI US 2001-334609P 20011203 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1-9
DRWN 5 Drawing Page(s)
LN.CNT 1055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.
IT 475207-59-1
(aryl urea compds. in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 347 OF 390 USPATFULL on STN
AN 2006:275134 USPATFULL
TI Treatment of diseases with kinase inhibitors
IN Biggs, William H. III, San Clemente, CA, UNITED STATES
Carter, Todd, San Diego, CA, UNITED STATES
Fabian, Miles A., La Jolla, CA, UNITED STATES
Lockhart, David J., Del Mar, CA, UNITED STATES
Zarrinkar, Patrick Parvis, San Diego, CA, UNITED STATES
Treiber, Daniel Kelly, San Diego, CA, UNITED STATES
Edeen, Phillip, Poway, CA, UNITED STATES
PI US 20060234931 A1 20061019
AI US 2004-894877 A1 20040719 (10)
PRAI US 2003-488513P 20030717 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE
MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to the identification and use of additional targets of BIRB 796, imatinib mesylate, and BAY 43-9006. The new targets of BIRB 796, imatinib mesylate, and BAY 43-9006 can be used to screen for suitable therapeutic compounds. Also, novel therapeutic and prophylactic uses for BIRB 796, imatinib mesylate, and BAY 43-9006 are disclosed herein.
IT 284461-73-0, BAY 43-9006
(novel targets of protein kinase-inhibiting drugs for novel disease therapies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 348 OF 390 USPATFULL on STN
AN 2006:273912 USPATFULL
TI Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways
IN Schuller, Hildegard M., Knoxville, TN, UNITED STATES
Kabalka, George W., Knoxville, TN, UNITED STATES
PI US 20060233705 A1 20061019
AI US 2005-109428 A1 20050419 (11)
DT Utility
FS APPLICATION
LREP HOWARD EISENBERG, ESQ., 2206 APPLEWOOD COURT, PERKASIE, PA, 18944, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A non-invasive method for determining the presence or severity of a bodily disorder associated with hyperactivity or increased expression of a signal transduction protein, transcription factor, or protein kinase that is a member of the MAPK or GPCR pathways. A reagent that binds to such a signal transduction protein, transcription factor, or protein kinase is non-invasively contacted to a tissue or fluid within the body of a subject or to a fluid removed from a subject, the reagent is permitted to bind to the signal transduction protein, transcription factor, or protein kinase in the tissue or fluid, the presence of binding of the reagent to the signal transduction protein, transcription factor, or protein kinase in said tissue or fluid is determined, and the binding is correlated with the presence or severity of said bodily disorder within the subject.
IT 284461-73-0D, Bay 43-9006, radiolabeled analogs
912469-65-9 912469-69-3
(radiol. cancer diagnosis based on hyperactivity or increased expression of members of cell signaling pathways)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 912469-65-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-6-(fluoro-18F)-N-methyl- (9CI) (CA INDEX NAME)



RN 912469-69-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-6-(iodo-124I)-N-methyl- (9CI) (CA INDEX NAME)



L20 ANSWER 349 OF 390 USPATFULL on STN
AN 2006:253838 USPATFULL
TI Combinations for the treatment of cancer
IN Chang, David, Calabasas, CA, UNITED STATES
PA Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)
PI US 20060216288 A1 20060928
AI US 2006-386271 A1 20060321 (11)
PRAI US 2005-664381P 20050322 (60)
DT Utility
FS APPLICATION
LREP AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
IT 284461-73-0 475207-59-1, Nexavar
(combinations for the treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 350 OF 390 USPATFULL on STN
AN 2006:241361 USPATFULL
TI Platinum therapeutic combinations
IN Zong, Chen, Metuchen, NJ, UNITED STATES
Kirschmeier, Paul, Basking Ridge, NJ, UNITED STATES
Medeiros, Paul T., Easton, PA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060205810 A1 20060914
AI US 2005-284016 A1 20051121 (11)
PRAI US 2004-630581P 20041124 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2086
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides combination compositions comprising Pt based compounds, including satraplatin, along with another chemotherapeutic agent such as temozolomide or lonafarnib. The combinations are useful for the prevention or treatment of cancer. Method of using the combinations to treat or prevent cancer are also provided
IT 284461-73-0, BAY43-9006
(binary antitumor compns. comprising platinum(IV) derivs. with other chemotherapeutic agents including monoclonal antibody specific for insulin-like growth factor receptor 1)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 351 OF 390 USPATFULL on STN
AN 2006:241306 USPATFULL
TI Novel farnesyl protein transferase inhibitors as antitumor agents
IN Cooper, Alan B., West Caldwell, NJ, UNITED STATES
Zhu, Hugh, Scotch Plains, NJ, UNITED STATES
Wang, James J-S, Westfield, NJ, UNITED STATES
Desai, Jagdish A., Monroe Township, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060205755 A1 20060914
AI US 2005-311052 A1 20051219 (11)
PRAI US 2004-638008P 20041221 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 102
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel tricyclic compounds of the formula: ##STR1## and the pharmaceutically acceptable salts thereof. Y is C or CH. When Y is C then Z is not present and the optional bond from Y to the C-11 carbon of the tricyclic nucleus is present. When Y is CH then Z is present and Z is H or --OH. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
IT 284461-73-0, BAY 43-9006
(preparation of benzopyridinocycoheptenyl-piperidine compds. as farnesyl protein transferase inhibitors and their use in treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 352 OF 390 USPATFULL on STN
AN 2006:166966 USPATFULL
TI Medical use of ras antagonists for the treatment of capillary malformation
IN Vikkula, Miikka, Kraainem, BELGIUM
Boon, Laurence, Kraainem, BELGIUM
Eerola, Liro, Brussels, BELGIUM
PI US 20060141472 A1 20060629
AI US 2003-546692 A1 20030320 (10)
WO 2003-EP2913 20030320
20050928 PCT 371 date
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 1479
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the field of vascular anomalies and methods for diagnosing and treating them. The invention provides for the causative gene (RASA1) and mutations therein which are useful for diagnosis of inherited capillary malformations. The invention further provides RASA1 antagonists for use in treatment of capillary malformations.
IT 284461-73-0, BAY 43-9006
(Raf protein inhibitor; diagnosis and treatment of vascular anomalies using primers to detect RASA1 gene mutations and ras protein antagonists)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 353 OF 390 USPATFULL on STN
AN 2006:159951 USPATFULL
TI Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
IN Owa, Takashi, Tsukuba-shi, JAPAN
Ozawa, Yoichi, Tsukuba-shi, JAPAN
Semba, Taro, Tsukuba-shi, JAPAN
PA Eisai Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 20060135486 A1 20060622
AI US 2005-226655 A1 20050913 (11)
PRAI JP 2005-54150 20050228
JP 2005-54475 20050228
US 2004-609452P 20040913 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.
IT 284461-73-0, BAY 43-9006
(sulfonamide-containing compds. and angiogenesis inhibitors for combination chemotherapy of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 354 OF 390 USPATFULL on STN
AN 2006:93363 USPATFULL
TI Specific kinase inhibitors
IN Santi, Daniel V., San Francisco, CA, UNITED STATES
Reid, Ralph C., San Rafael, CA, UNITED STATES
Hutchinson, C. Richard, Cross Plains, WI, UNITED STATES
Sundermann, Kurt F., Burlingame, CA, UNITED STATES
Lau, Janice, San Mateo, CA, UNITED STATES
PI US 20060079494 A1 20060413
AI US 2005-236244 A1 20050926 (11)
PRAI US 2004-613680P 20040927 (60)
US 2004-629575P 20041118 (60)
US 2005-698520P 20050711 (60)
DT Utility
FS APPLICATION
LREP KOSAN BIOSCIENCES, INC, 3832 BAY CENTER PLACE, HAYWARD, CA, 94588, US
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site.
IT 284461-73-0, BAY 43-9006
(resorcylic acid lactone kinase inhibitors, and therapeutic use)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 355 OF 390 USPATFULL on STN
AN 2006:92490 USPATFULL
TI Pharmaceutical compositions for the treatment of cancer
IN Schueckler, Fritz, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
PI US 20060078617 A1 20060413
AI US 2005-212907 A1 20050829 (11)
PRAI US 2004-604753P 20040827 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 613
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I is as follows: ##STR1##
IT 284461-73-0, BAY 43-9006
(pharmaceutical compns. for treatment of cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 356 OF 390 USPATFULL on STN
AN 2006:68089 USPATFULL
TI Combinations for the treatment of diseases involving cell proliferation
IN Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Steegmaier, Martin, Wien, AUSTRIA
Baum, Anke, Vienna, AUSTRIA
PA Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 20060058311 A1 20060316
AI US 2005-189540 A1 20050726 (11)
PRAI EP 2004-19361 20040814
EP 2004-19448 20040817
DT Utility
FS APPLICATION
LREP MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
IT 284461-73-0, BAY-43-9006
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 357 OF 390 USPATFULL on STN
AN 2005:306417 USPATFULL
TI Combinatorial methods and compositions for treatment of melanoma
IN Robertson, Gavin P., Harrisburg, PA, UNITED STATES
Sandirasegarane, Lakshman, Hershey, PA, UNITED STATES
Kester, Mark, Harrisburg, PA, UNITED STATES
Sharma, Arati, Hummelstown, PA, UNITED STATES
PA The Penn State Research Foundation, University Park, PA, UNITED STATES, 16802 (U.S. corporation)
PI US 20050267060 A1 20051201
AI US 2005-83583 A1 20050318 (11)
PRAI US 2004-554509P 20040319 (60)
DT Utility
FS APPLICATION
LREP MCKEE, VOORHEES & SEASE, P.L.C., ATTN: PENNSYLVANIA STATE UNIVERSITY,
801 GRAND AVENUE, SUITE 3200, DES MOINES, IA, 50309-2721, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 4679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a rational basis for combining targeted therapies together with selected chemotherapeutics, which does not currently exist for the treatment of melanoma. The present invention is based on the present inventors' discovery that Akt3 regulates apoptosis and V599E B-Raf regulates growth and vascular development in melanoma. Inventors are the first to recognize an effective combined targeted therapeutic for treating melanoma. In one embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity. In yet another embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity. Consequently, the method provided restores normal apoptotic sensitivity to a melanoma tumor cell, thereby allowing the administration of a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. The present inventors' contemplate a method for treating a melanoma tumor in a mammal comprising: administering to a melanoma tumor an effective amount of an agent to induce apoptosis; and administering to a melanoma tumor an effective amount of an agent to reduce angiogenesis and cell proliferation. Also disclosed herein is a method for treating a melanoma in a mammal comprising: administering to a melanoma tumor in a mammal an effective amount of an agent that reduces Akt3 activity; administering to a melanoma tumor in a mammal an effective amount of an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor. In another aspect, the invention provides a pharmaceutical composition for treating a melanoma tumor comprising: an agent that reduces Akt3 activity; and a carrier.
IT 284461-73-0, BAY 43-9006
(combination methods and compns. including Akt3 inhibitors for treatment of melanoma)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 358 OF 390 USPATFULL on STN
AN 2005:261902 USPATFULL
TI Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
IN Masferrer, Jaime L., Baldwin, MO, UNITED STATES
PI US 20050227929 A1 20051013
AI US 2004-989192 A1 20041115 (10)
PRAI US 2003-519701P 20031113 (60)
DT Utility
FS APPLICATION
LREP Harness, Dickey & Pierce, P.L.C., Suite 400, 7700 Bonhomme, St. Louis, MO, 63105, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.
IT 284461-73-0, BAY 439006
(cyclooxygenase 2 inhibitor-antineoplastic agent combination for treatment or prevention of neoplasia)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 359 OF 390 USPATFULL on STN
AN 2005:255665 USPATFULL
TI Combinations of signal transduction inhibitors
IN Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES
Fry, David William, Ypsilanti, MI, UNITED STATES
Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES
PA PFIZER INC (U.S. corporation)
PI US 20050222163 A1 20051006
AI US 2005-95442 A1 20050330 (11)
PRAI US 2004-557623P 20040330 (60)
DT Utility
FS APPLICATION
LREP AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
IT 284461-73-0, BAY 43-9006
(combinations of signal transduction inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 360 OF 390 USPATFULL on STN
AN 2005:247130 USPATFULL
TI Compositions and methods to increase the effect of a neurotoxin treatment
IN David, Nathaniel E., San Francisco, CA, UNITED STATES
PA VVII NewCo 2003, Inc., Menlo Park, CA, UNITED STATES (U.S. corporation)
PI US 20050214325 A1 20050929
AI US 2004-810391 A1 20040326 (10)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses compositions and methods for enhancing the effect (e.g., duration) of a neurotoxin treatment. The compositions herein include neurotoxins and neuron growth inhibitors. Such compositions are administered locally to treat or prevent conditions, such as dermatological conditions, urological conditions, thyroid conditions, optical conditions, and neurological conditions.
IT 284461-73-0, BAY-43-9006
(compns. and methods to increase effect of neurotoxin treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 361 OF 390 USPATFULL on STN
AN 2005:183990 USPATFULL
TI JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
IN Mohapatra, Shyam S., Tampa, FL, UNITED STATES
PI US 20050159385 A1 20050721
AI US 2004-18954 A1 20041220 (11)
PRAI US 2003-531052P 20031219 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX
142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection
IT 284461-73-0, BAY 43-9006
(JAK/STAT inhibitors and MAPK/ERK inhibitors for respiratory syncytial virus infection treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 362 OF 390 USPATFULL on STN
AN 2005:171786 USPATFULL
TI IAP nucleobase oligomers and oligomeric complexes and uses thereof
IN LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
PI US 20050148535 A1 20050707
AI US 2004-975974 A1 20041028 (10)
PRAI US 2003-516192P 20031030 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.
IT 284461-73-0, BAY-43-9006
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 363 OF 390 USPATFULL on STN
AN 2005:138567 USPATFULL
TI Methods and reagents for the treatment of proliferative diseases
IN LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
Durkin, Jon P., Montreal, CANADA
PI US 20050119217 A1 20050602
AI US 2004-975790 A1 20041028 (10)
PRAI US 2003-516263P 20031030 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 5896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods, compositions, and kits for treating a patient having a proliferative disease.
IT 284461-73-0, BAY-43-9006
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 364 OF 390 USPATFULL on STN
AN 2005:137954 USPATFULL
TI Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
IN Aoki, Yuko, Kanagawa, JAPAN
Hasegawa, Kiyoshi, Kanagawa, JAPAN
Ishii, Nobuya, Kanagawa, JAPAN
Mori, Kazushige, Kanagawa, JAPAN
PI US 20050118600 A1 20050602
AI US 2003-507389 A1 20020313 (10)
WO 2002-JP2354 20020313
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate analysis with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the respective genes to drug sensitivity was determined to select genes with a high degree of contribution. In addition, the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values determined experimentally. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens associated with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).
IT 284461-73-0, BAY 439006
(method for selecting antitumor drug sensitivity-determining factors and predicting antitumor drug sensitivity using the selected factors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 365 OF 390 USPATFULL on STN
AN 2005:69562 USPATFULL
TI Diaryl ureas for diseases mediated by PDGFR
IN Wilhelm, Scott, Orange, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Ladouceur, Gaetan, Guilford, CT, UNITED STATES
Lynch, Mark, Madison, CT, UNITED STATES
Scott, William, Guilford, CT, UNITED STATES
PI US 20050059703 A1 20050317
AI US 2004-848567 A1 20040519 (10) pending
PRAI US 2004-556062P 20040325 (60)
US 2003-520399P 20031117 (60)
US 2003-471735P 20030520 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
IT 284461-73-0P 284461-74-1P
(preparation of diaryl ureas with kinase inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 366 OF 390 USPATFULL on STN
AN 2005:69531 USPATFULL
TI Novel farnesyl protein transferase inhibitors as antitumor agents
IN Zhu, Hugh Y., Scotch Plains, NJ, UNITED STATES
Cooper, Alan B., West Caldwell, NJ, UNITED STATES
Desai, Jagdish A., Monroe Township, NJ, UNITED STATES
Wang, James J-S, Westfield, NJ, UNITED STATES
Rane, Dinanath F., Morganville, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Njoroge, F. George, Warren, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsipanny, NJ, UNITED STATES
PA SCHERING CORPORATION (U.S. corporation)
PI US 20050059672 A1 20050317
US 7557107 B2 20090707
AI US 2004-911340 A1 20040804 (10)
PRAI US 2003-493269P 20030807 (60)
US 2003-498509P 20030828 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
CLMN Number of Claims: 120
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel tricyclic compounds of the formula: ##STR1##

and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of piperazinylbenzocycloheptapyridines as farnesyl protein transferase inhibitors useful as antitumor agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 367 OF 390 USPATFULL on STN
AN 2005:56618 USPATFULL
TI BRAF mutation T1796A in thyroid cancers
IN Sidransky, David, Baltimore, MD, UNITED STATES
Cohen, Yoram, Baltimore, MD, UNITED STATES
Zhao, Ming, Clarksville, MD, UNITED STATES
PA The Johns Hopkins University, Baltimore, MD, UNITED STATES, 21218 (U.S. corporation)
PI US 20050048533 A1 20050303
US 7378233 B2 20080527 no odp
AI US 2004-821203 A1 20040409 (10)
PRAI US 2003-462046P 20030412 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas.
IT 284461-73-0, BAY 43-9006
(detection of BRAF transversion mutation for diagnosis of malignant thyroid cancer and uses of Ras-Raf-MAPK or Raf/MEK/ERK signaling pathway inhibitor in treating thyroid cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 368 OF 390 USPATFULL on STN
AN 2005:44298 USPATFULL
TI Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Boyer, Stephen, Fairfield, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Scott, William J., Guildford, CT, UNITED STATES
Burke, Jennifer, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Miranda, Karl, North Haven, CT, UNITED STATES
Raudenbush, Brian, Charlton, MA, UNITED STATES
Redman, Aniko, Derby, CT, UNITED STATES
Shao, Jianxing, Acton, MA, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
Zhu, Qingming, West Haven, CT, UNITED STATES
PI US 20050038031 A1 20050217
AI US 2004-788426 A1 20040301 (10) no odp
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 369 OF 390 USPATFULL on STN
AN 2005:38118 USPATFULL
TI 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders
IN Boyer, Stephen, Fairfield, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Scott, William J., Guildford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Jones, Benjamin, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
PI US 20050032798 A1 20050210
US 7928227 B2 20110419 no ODP
AI US 2004-788405 A1 20040301 (10)
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 370 OF 390 USPATFULL on STN
AN 2004:299960 USPATFULL
TI Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
IN Scott, William J., Guilford, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Lee, Wendy, Hamden, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Raudenbush, Brian, Charlton, MA, UNITED STATES
Redman, Aniko, Derby, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
Zhu, Qingming, West Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
PI US 20040235829 A1 20041125
US 7557129 B2 20090707 no ABN
AI US 2004-788029 A1 20040227 (10)
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L20 ANSWER 371 OF 390 USPATFULL on STN
AN 2004:292848 USPATFULL
TI Substituted pyridine derivatives useful in the treatment of cancer and other disorders
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
PI US 20040229937 A1 20041118
AI US 2004-789446 A1 20040301 (10) ABN
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 372 OF 390 USPATFULL on STN
AN 2004:165963 USPATFULL
TI Method for treating diseases associated with abnormal kinase activity
IN Lyons, John, Moraga, CA, UNITED STATES
Rubinfeld, Joseph, Danville, CA, UNITED STATES
PI US 20040127453 A1 20040701
US 6998391 B2 20060214 no ODP
AI US 2002-206854 A1 20020726 (10)
RLI Continuation-in-part of Ser. No. US 2002-71849, filed on 7 Feb 2002, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.
IT 284461-73-0, BAY 43-9006
(Raf kinase inhibitor; treating diseases associated with abnormal tyrosine kinase activity by administering DNA methylation inhibitors and tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 373 OF 390 USPATFULL on STN
AN 2003:330550 USPATFULL
TI Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
IN Carter, Christopher A., Guilford, CT, UNITED STATES
Gibson, Neil, East Northport, NY, UNITED STATES
Hibner, Barbara, Madison, CT, UNITED STATES
Humphrey, Rachel W., Woodbridge, CT, UNITED STATES
Trail, Pamela, Madison, CT, UNITED STATES
Vincent, Patrick W., Cheshire, CT, UNITED STATES
Zhai, Yifan, Guilford, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, UNITED STATES (U.S. corporation)
PI US 20030232765 A1 20031218
AI US 2002-308187 A1 20021203 (10) ABN
PRAI US 2001-334609P 20011203 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.
IT 475207-59-1
(aryl urea compds. in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L20 ANSWER 374 OF 390 USPATFULL on STN
AN 2003:307010 USPATFULL
TI Aryl ureas as kinase inhibitors
IN Dumas, Jacques, Orange, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Chien, Du-Shieng, Guilford, CT, UNITED STATES
Nassar, Ala, Milford, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Bjorge, Susan, Milford, CT, UNITED STATES
Musza, Laszlo L., Guilford, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, UNITED STATES (U.S. corporation)
PI US 20030216446 A1 20031120
AI US 2003-361859 A1 20030211 (10)
PRAI US 2002-354937P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-carbamoyl(4-pyridyloxy)phenyl]urea 583840-03-3P 583840-04-4P
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

now allowed
method of inhibiting RAF



RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



IT 284461-73-0P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)(4-pyridyloxy)phenyl]urea
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 375 OF 390 USPATFULL on STN
AN 2003:306960 USPATFULL
TI Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PA BAYER CORPORATION, Pittsburgh, PA (U.S. corporation)
PI US 20030216396 A1 20031120
AI US 2003-361850 A1 20030211 (10) ABN
PRAI US 2002-354935P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
IT 284461-73-0
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-74-1P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-03-3P 583840-04-4P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



L20 ANSWER 376 OF 390 USPATFULL on STN
AN 2003:294854 USPATFULL
TI OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 20030207872 A1 20031106
AI US 2002-42226 A1 20020111 (10) ABN
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P
(preparation of ω-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 377 OF 390 USPATFULL on STN
AN 2003:294852 USPATFULL
TI Aryl ureas with angiogenisis inhibiting activity
IN Dumas, Jacques, Orange, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
Hatoum-Makdad, Holia, Hamden, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (U.S. corporation)
PI US 20030207870 A1 20031106
US 7838541 B2 20101123
AI US 2003-361858 A1 20030211 (10)
PRAI US 2002-354950P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
IT 284461-73-0P 284461-74-1P
(preparation of aryl ureas with angiogenesis inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

no ODP ... Claims are drawn to method of treating retinopathy



L20 ANSWER 378 OF 390 USPATFULL on STN
AN 2003:258389 USPATFULL
TI omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Piittsburgh, PA (non-U.S. corporation)
PI US 20030181442 A1 20030925
AI US 2001-993647 A1 20011127 (9) Applicant's
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P,
N-(4-Chloro-3-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl)oxy]phenyl]urea
(preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 379 OF 390 USPATFULL on STN
AN 2003:207917 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (non-U.S. corporation)
PI US 20030144278 A1 20030731
AI US 2002-283248 A1 20021030 (10) abn
RLI Continuation of Ser. No. US 2002-42203, filed on 11 Jan 2002, PENDING
PRAI US 2001-367380P 20010112 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of diphenylureas as RAF kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 380 OF 390 USPATFULL on STN
AN 2003:201617 USPATFULL
TI Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., North Haven, CT, UNITED STATES
PI US 20030139605 A1 20030724
US 7528255 B2 20090505 no ODP. All compound claims
AI US 2002-71248 A1 20020211 (10)
RLI Continuation of Ser. No. US 2001-948915, filed on 10 Sep 2001, PENDING
Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy of the formula

A--D--B wherein

D is --NH--C(O)--NH--

A is a substituted moiety of the formula: --L--(M--L.sup.1).sub.q, and

B is a substituted or unsubstituted up to tricyclic aryl or heteroaryl moiety with a t least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen oxygen and sulfur.

L is a 5-6 membered cyclic structure bound directly to D,

L.sup.1 comprises a substituted cyclic moiety having at least 5 members

M is a bridging group having at least one atom and q is an integer of from 1-3.
IT 284461-73-0P 284461-74-1P
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA

INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 381 OF 390 USPATFULL on STN
AN 2003:181526 USPATFULL
TI RAF-MEK-ERK pathway inhibitors to treat cancer
IN Lyons, John F., Moraga, CA, UNITED STATES
Bollag, Gideon, Hercules, CA, UNITED STATES
PI US 20030125359 A1 20030703
US 7307071 B2 20071211 no ODP
AI US 2002-308721 A1 20021203 (10)
PRAI US 2001-336886P 20011204 (60)
DT Utility
FS APPLICATION
LREP Gregory Giotta, Ph.D., Vice President and Chief Legal Counsel, ONYX Pharmaceuticals, Inc., 3031 Research Drive, Richmond, CA, 94806
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
IT 284461-73-0, BAY 43-9006
(BAY 43-9006; RAF-MEK-ERK pathway inhibitors to treat cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 382 OF 390 USPATFULL on STN
AN 2003:153423 USPATFULL
TI Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Handen, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya, JAPAN
William, Scott J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Naero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20030105091 A1 20030605
AI US 2002-86417 A1 20020304 (10) abn
RLI Continuation of Ser. No. US 1999-425229, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 383 OF 390 USPATFULL on STN
AN 2002:295343 USPATFULL
TI Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IN Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Khire, Uday, Hamden, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Robert, Sibley N., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Gunn, David E., Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 20020165394 A1 20021107
US 7928239 B2 20110419 no ODP
AI US 2001-777920 A1 20010207 (9)
RLI Continuation-in-part of Ser. No. US 2001-758548, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
IT 284461-73-0P 284461-74-1P
(drug candidate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L20 ANSWER 384 OF 390 USPATFULL on STN
AN 2002:251820 USPATFULL
TI Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, CANADA
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 20020137774 A1 20020926
AI US 2001-907970 A1 20010719 (9) ABN
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200
CLARENDON BLVD., SUITE
1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA

INDEX NAME)



L20 ANSWER 385 OF 390 USPATFULL on STN
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 20020042517 A1 20020411
AI US 2001-948915 A1 20010910 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 386 OF 390 USPATFULL on STN
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010034447 A1 20011025
AI US 2001-773604 A1 20010202 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 387 OF 390 USPATFULL on STN
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 20010027202 A1 20011004
AI US 2001-773658 A1 20010202 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C.,
Arlington Courthouse Plaza I,
Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 388 OF 390 USPATFULL on STN
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010016659 A1 20010823
AI US 2001-773672 A1 20010202 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 389 OF 390 USPATFULL on STN
AN 2001:123628 USPATFULL
TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010011136 A1 20010802
AI US 2001-773675 A1 20010202 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon
Blvd., Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L20 ANSWER 390 OF 390 USPATFULL on STN
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010011135 A1 20010802
AI US 2001-773659 A1 20010202 (9) ABN
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse
Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  2592.83    2886.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.57

STN INTERNATIONAL LOGOFF AT 21:56:11 ON 16 JUN 2011
```